<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id><journal-id journal-id-type="publisher-id">CN</journal-id><journal-title>Current Neuropharmacology</journal-title><issn pub-type="ppub">1570-159X</issn><issn pub-type="epub">1875-6190</issn><publisher><publisher-name>Bentham Science Publishers Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19305788</article-id><article-id pub-id-type="pmc">2645549</article-id><article-id pub-id-type="publisher-id">CN-6-55</article-id><article-id pub-id-type="doi">10.2174/157015908783769671</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pharmacodynamics of Memantine: An Update</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rammes</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Danysz</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Parsons</surname><given-names>C.G</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Clinical Neuropharmacology, Max Planck Institute of Psychiatry, 80804 Munich, Germany;</aff><aff id="aff2"><label>2</label>Preclinical R &#x00026; D, Merz Pharmaceuticals, Eckenheimer Landstrasse 100, 60318 Frankfurt am Main, Germany;</aff><aff id="aff3"><label>3</label>Clinic rechts der Isar, Department of Anaesthesiology, Technical University, 81675 Munich, Germany</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at Preclinical R &#x00026; D, Merz Pharmaceuticals, Eckenheimer Landstrasse 100, 60318 Frankfurt am Main, Germany; Tel: +49 69 1503368; E-mail: <email xlink:href="christopher.parsons@merz.de">christopher.parsons@merz.de</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2008</year></pub-date><volume>6</volume><issue>1</issue><fpage>55</fpage><lpage>78</lpage><history><date date-type="received"><day>19</day><month>3</month><year>2007</year></date><date date-type="rev-recd"><day>10</day><month>5</month><year>2007</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9;2008 Bentham Science Publishers Ltd.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>) which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimer&#x000b4;s disease (AD) in Europe on 17<sup>th</sup> May 2002 and shortly thereafter was also approved by the FDA for use in the same indication in the USA. Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with strong voltage-dependency and fast kinetics. Due to this mechanism of action (MOA), there is a wealth of other possible therapeutic indications for memantine and numerous preclinical data in animal models support this assumption. This review is intended to provide an update on preclinical studies on the pharmacodynamics of memantine, with an additional focus on animal models of diseases aside from the approved indication. For most studies prior to 1999, the reader is referred to a previous review [<xref ref-type="bibr" rid="R196">196</xref>].</p><p>In general, since 1999, considerable additional preclinical evidence has accumulated supporting the use of memantine in AD (both symptomatic and neuroprotective). In addition, there has been further confirmation of the MOA of memantine as an uncompetitive NMDA receptor antagonist and essentially no data contradicting our understanding of the benign side effect profile of memantine.</p></abstract></article-meta></front><body><sec><title>THERAPEUTIC TARGET</title><p>The maximal therapeutically-relevant plasma concentration of memantine is around 1 &#x000b5;M (see [<xref ref-type="bibr" rid="R55">55</xref>,<xref ref-type="bibr" rid="R203">203</xref>]). Brain extracellular fluid (ECF) concentration of around 0.8 &#x000b5;M can be anticipated [<xref ref-type="bibr" rid="R102">102</xref>] and any receptor that expresses an affinity at, or below, the very low &#x000b5;M range should be considered as a potential therapeutic target. Given this assumption, there are only four plausible known target types to date: the most likely is the NMDA receptor channel, but 5-hydroxy-trypta-mine (5-HT<sub>3</sub>) receptors [<xref ref-type="bibr" rid="R220">220</xref>] and &#x003b1;7 and/or &#x003b1;4&#x003b2;2 nicotinic receptors [<xref ref-type="bibr" rid="R11">11</xref>] should also be taken into consideration [<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R37"> 37</xref>,<xref ref-type="bibr" rid="R165"> 165</xref>].</p><p>The &#x003b1;7 and &#x003b1;4&#x003b2;2 nicotinic acetylcholine receptor and the 5-HT<sub>3</sub> receptor systems have been suggested to play a role in modulating CNS functions, including learning and memory. These receptors are structurally related, containing large extracellular ligand-binding domains and four transmembrane domains that are largely conserved. They exhibit considerable cross-pharmacology, e.g. high concentrations of the &#x003b1;7 nAChR agonist nicotine inhibit 5-HT<sub>3</sub> receptor-mediated responses, and high concentrations of the 5-HT<sub>3</sub> receptor agonist serotonin inhibit &#x003b1;7 nAChR-mediated responses. Based on this knowledge, it seems reasonable to investigate whether ligands specific for either receptor, might have affinity for both. </p></sec><sec><title>NMDA RECEPTORS</title><sec><title>Fast Kinetics and Strong Voltage-Dependency</title><p>Memantine blocks the NMDA receptor channel in an use-dependent manner, meaning that it can only gain access to the channel in the presence of agonist and remains largely trapped in the channel following removal of agonist [<xref ref-type="bibr" rid="R113">113</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R198"> 198</xref>]. Both the clinical tolerability and symptomatic effects of memantine have been attributed to its moderate affinity (IC<sub>50</sub> around 1&#x000b5;M at &#x02013;70 mV) and associated fast blocking / unblocking kinetics and strong voltage-depen-dency [<xref ref-type="bibr" rid="R113">113</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R198"> 198</xref>,<xref ref-type="bibr" rid="R229"> 229</xref>]. These properties have been characterized and confirmed by numerous groups using whole cell patch clamp recordings from primary cultures of hippocampal and cortical neurons as well as for NMDA receptors expressed heterologously in HEK-293 cells [<xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R34"> 34</xref>,<xref ref-type="bibr" rid="R43"> 43</xref>,<xref ref-type="bibr" rid="R154"> 154</xref>,<xref ref-type="bibr" rid="R198"> 198</xref>-<xref ref-type="bibr" rid="R201">201</xref>,<xref ref-type="bibr" rid="R259"> 259</xref>,<xref ref-type="bibr" rid="R260"> 260</xref>]. How these biophysical properties account for the better therapeutic safety of memantine compared to other channel blockers such as (+)MK-801 and phencyclidine has been a matter of considerable debate and there are several theories.</p><p>Memantine and other well tolerated open channel blockers show much faster open channel blocking / unblocking kinetics than compounds burdened with negative psychotropic effects such as (+)MK-801 or phencyclidine [<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R28"> 28</xref>,<xref ref-type="bibr" rid="R44"> 44</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R198"> 198</xref>,<xref ref-type="bibr" rid="R229"> 229</xref>,<xref ref-type="bibr" rid="R231"> 231</xref>]. The kinetics of (+)MK-801 and phencyclidine are too slow to allow them to leave the channel upon depolarization, which is often reflected in apparently weaker functional voltage-dependency. These two parameters are directly related to affinity, with lower affinity compounds such as memantine showing faster kinetics and apparently stronger voltage-dependency, as reflected in an estimated &#x003b4; value of around 0.8 [<xref ref-type="bibr" rid="R201">201</xref>]. The &#x003b4; value describes the percentage of the trans-membrane field the drug experiences when blocking the NMDA receptor channel [<xref ref-type="bibr" rid="R196">196</xref>]. The unblocking rate of memantine in the continuous presence of this antagonist following depolarizing voltage-steps is very rapid and well within the time course of NMDA receptor-mediated EPSP. </p><p>Memantine blocks and unblocks open NMDA receptor channels with double exponential kinetics. The amplitude and speed of the fast component of block increases with memantine concentration. In contrast, the speed of fast unblock remains constant but its weight (relative to the slow component) decreases with memantine concentration [<xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R34"> 34</xref>,<xref ref-type="bibr" rid="R77"> 77</xref>,<xref ref-type="bibr" rid="R259"> 259</xref>,<xref ref-type="bibr" rid="R260"> 260</xref>]. Moreover, the predominant effect of depolarization is to increase dramatically the weight of the faster recovery time-constant [<xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R77"> 77</xref>,<xref ref-type="bibr" rid="R199"> 199</xref>]. These data indicate that memantine binds to at least two sites within the channel [<xref ref-type="bibr" rid="R259">259</xref>,<xref ref-type="bibr" rid="R260"> 260</xref>].</p></sec><sec><title>Fast Agonist Concentration-Dependent Access to the Open Channel During Pathological Activation</title><p>It has been proposed that the ability of low affinity open channel blockers to gain rapid access to the NMDA receptor channel is important in determining their therapeutic safety in ischemia and epilepsy [<xref ref-type="bibr" rid="R44">44</xref>,<xref ref-type="bibr" rid="R229"> 229</xref>,<xref ref-type="bibr" rid="R231"> 231</xref>]. However, this hypothesis alone cannot explain the better therapeutic profile of memantine in AD as, even if receptors were only blocked following pathological activation, most would then remain blocked in the continuous presence of memantine and therefore be unavailable for subsequent physiological activation - in the therapy of AD, memantine is continuously present at very stable steady-state concentrations due to its very long half life in humans.</p><p>It has further been suggested that memantine blocks NMDA receptor channels in an agonist concentration-depen-dent manner i.e. the more agonist, the more equilibrium blockade [<xref ref-type="bibr" rid="R152">152</xref>]. This assumption is supported neither by the blocking model proposed by [<xref ref-type="bibr" rid="R29">29</xref>] nor by our own recent unpublished data which highlight, for us, the technical problems in performing such studies [<xref ref-type="bibr" rid="R86">86</xref>]. At very low agonist concentrations, the open channel probability is very much reduced and open channel blockers take much longer to access and to leave the open channel. As such, it seems most likely that memantine blockade only appeared to be less efficacious at lower agonist concentrations in previous publications because it had not really reached equilibrium blockade.</p></sec><sec><title>Fast, Voltage-Dependent Unblock from the Open Channel During Synaptic Activation&#x02013;Basis for the Signal-to-Noise Hypothesis</title><p>Physiologically, NMDA receptors are transiently activated by mM concentrations of glutamate [<xref ref-type="bibr" rid="R48">48</xref>] following strong depolarization of the postsynaptic membrane, which rapidly relieves their voltage-dependent blockade by Mg<sup>2+</sup> [<xref ref-type="bibr" rid="R189">189</xref>] whereas, during pathological activation, NMDA receptors are activated by lower concentrations of glutamate but for a much longer time [<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R19"> 19</xref>,<xref ref-type="bibr" rid="R36"> 36</xref>,<xref ref-type="bibr" rid="R87"> 87</xref>,<xref ref-type="bibr" rid="R88"> 88</xref>,<xref ref-type="bibr" rid="R177"> 177</xref>]. The voltage-dependency of the divalent cation Mg<sup>2+</sup> is so pronounced that it also leaves the NMDA channel upon moderate depolarization under pathological conditions, i.e. in the presence of tonically mildly elevated glutamate levels and moderate membrane depolarization due to energy deficits. Although uncompetitive antagonists also block the NMDA receptor channel, high affinity compounds such as (+)MK-801 have much slower unblocking kinetics than Mg<sup>2+</sup> and less pronounced functional voltage-dependency and are therefore unable to leave the channel within the time course of a normal NMDA receptor-mediated excitatory post-synaptic potential. As a result, (+)MK-801 blocks both the pathological and physiological activation of NMDA receptors [<xref ref-type="bibr" rid="R196">196</xref>].</p><p>We were the first to suggest that the combination of fast offset kinetics and strong voltage-dependency allows memantine to rapidly leave the NMDA channel upon transient physiological activation by mM concentrations of synaptic glutamate, but block the sustained activation by &#x000b5;M concentrations of glutamate under moderate pathological conditions [<xref ref-type="bibr" rid="R198">198</xref>,<xref ref-type="bibr" rid="R200"> 200</xref>,<xref ref-type="bibr" rid="R201"> 201</xref>]. This hypothesis is further supported by the fact that, although the slower component of offset kinetic at near resting membrane potentials and room temperature is still too slow to allow synaptic activation - i.e., around 5 seconds, the relief of blockade in the continuous presence of memantine upon depolarization is much faster due to an increase in the weight of the faster recovery time-constant [<xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R77"> 77</xref>,<xref ref-type="bibr" rid="R259"> 259</xref>,<xref ref-type="bibr" rid="R260"> 260</xref>]. These kinetics are almost certainly even faster <italic>in vivo</italic> due to higher temperatures [<xref ref-type="bibr" rid="R57">57</xref>]. Furthermore, the rate of recovery from memantine blockade is dependent on the open probability of NMDA channels [<xref ref-type="bibr" rid="R43">43</xref>,<xref ref-type="bibr" rid="R197"> 197</xref>] and therefore would be faster in the presence of higher, synaptic concentrations of glutamate [<xref ref-type="bibr" rid="R48">48</xref>].</p><p>Given the crucial role of NMDA receptor synaptic activation in neuronal plasticity, simplistic interpretation of the observation that a NMDA receptor antagonist such as memantine can improve cognition and neuronal plasticity under pathological conditions might seem to be paradoxical. It should, however, be stressed that divalent cation Mg<sup>2+</sup> is an endogenous NMDA receptor channel blocker and its absence leads both to an impairment in neuronal plasticity [<xref ref-type="bibr" rid="R49">49</xref>,<xref ref-type="bibr" rid="R74"> 74</xref>] and neuronal death [<xref ref-type="bibr" rid="R81">81</xref>]. Any dysfunction of postsynaptic neurons leading to weakened blockade by Mg<sup>2+</sup>, e.g. due to partial depolarization as a consequence of an energy deficit, may also trigger prolonged Ca<sup>2+</sup> influx and structural (neuronal loss) deficits [<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R230"> 230</xref>]. Because memantine is more potent and slightly less voltage-dependent than Mg<sup>2+</sup> due to its simple monovalent charge, it may thus serve as a more effective surrogate for Mg<sup>2+</sup> [<xref ref-type="bibr" rid="R198">198</xref>]. As a result of its somewhat less pronounced functional voltage-dependency, memantine is more effective than Mg<sup>2+</sup> in blocking tonic pathological activation of NMDA receptors at moderately depolarized membrane potentials. However, following strong synaptic activation, memantine, like Mg<sup>2+</sup>, can leave the NMDA receptor channel with voltage-dependent, fast unblocking kinetics. In turn, memantine not only suppresses tonic pathological synaptic &#x0201c;noise&#x0201d; but also allows the relevant physiological synaptic signal to be detected. This provides both neuroprotection and symptomatic restoration of synaptic plasticity by one and the same mechanism [<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>]. Antagonists that have &#x0201c;too high&#x0201d; affinity for the channel or &#x0201c;too little&#x0201d; functional voltage-dependence, such as dizocilpine ((+)MK-801), thus produce numerous side effects, since they essentially act as an irreversible plug of the NMDA receptor channel and block both pathological and physiological function. </p></sec><sec><title>Partial Untrapping</title><p>Another theory to explain the better therapeutic tolerability of memantine was proposed in a seminal paper by [<xref ref-type="bibr" rid="R29">29</xref>] and supported by data from [<xref ref-type="bibr" rid="R169">169</xref>,<xref ref-type="bibr" rid="R259"> 259</xref>] (see [<xref ref-type="bibr" rid="R113">113</xref>] for review). Their data indicate that memantine and amantadine appear to have a lesser tendency to be trapped in NMDA receptor channels than do phencyclidine or (+)MK-801. This difference was attributed to the ability of channel blockers to increase the affinity of NMDA receptors for agonist and the faster kinetics of the amino-adamantanes. Receptors blocked by memantine retain agonist and thereby open and release memantine following removal of both agonist and memantine from the extracellular solution - see also [<xref ref-type="bibr" rid="R43">43</xref>]. This partial untrapping was reported to be less pronounced for higher affinity compounds as their slower unblocking kinetics do not allow them to leave the channel quickly enough following agonist removal.</p><p>Recently, Dr. Johnson&#x02019;s group provided more data characterizing the mechanism underlying partial trapping of memantine but not ketamine in the NMDA receptor channel [<xref ref-type="bibr" rid="R113">113</xref>,<xref ref-type="bibr" rid="R129"> 129</xref>]. Their most recent data are also consistent with a model in which there are two binding sites for memantine, a deep site inside of the external gate that allows trapping and a shallow site outside the gate that does not (see also [<xref ref-type="bibr" rid="R32">32</xref>]. Ketamine only binds to the deep site [<xref ref-type="bibr" rid="R113">113</xref>,<xref ref-type="bibr" rid="R129"> 129</xref>]).</p><p>This same group [<xref ref-type="bibr" rid="R29">29</xref>] proposed that partial trapping may underlie the better therapeutic profile of memantine, as a proportion of channels - around 15 to 20% - would always unblock in the absence of agonist and thereby be available for subsequent physiological activation. In other words, the antagonism by memantine is like that of a low intrinsic activity partial agonist in that it does not cause 100% blockade of NMDA receptors. However, although this theory can be used to explain the therapeutic tolerability of memantine, it provides no MOA for the symptomatic effects on cognition observed in AD patients.</p></sec><sec><title>Channel Blocking Site</title><p>Several studies indicate that memantine and Mg<sup>2+</sup> block at the same or similar channel site as they are mutually exclusive - as evidenced by the kinetics of unblock in the presence of both [<xref ref-type="bibr" rid="R44">44</xref>,<xref ref-type="bibr" rid="R259"> 259</xref>]. Moreover, the potency of memantine was observed to be reduced 20 fold by mutations at the N-site (N598Q) of the M2 trans-membrane segment in NR1 subunits and 30- to 100- fold by double mutations (W593L/ N598Q) within the channel-forming domain. Double mutations at the equivalent L- (L577W) and Q/R-sites (Q582T) in GluR1 receptors permitted open channel blockade of AMPA receptors by memantine (IC<sub>50</sub> at -70 mV = 1.3 &#x000b5;M, &#x003b4;=0.75) [<xref ref-type="bibr" rid="R71">71</xref>]. In this study on human NR1/NR2A receptors expressed in <italic>Xenopus</italic> oocytes, memantine blocked normal receptors in a strongly voltage-dependent manner (IC<sub>50 </sub>at -80 mV= 0.3 &#x000b5;M, &#x003b4; = 0.77; [<xref ref-type="bibr" rid="R71">71</xref>]). </p><p>In a more recent study in <italic>Xenopus </italic>oocytes, memantine blocked rat NR1a/2B receptors with an IC<sub>50</sub> of 0.46 &#x000b5;M at &#x02013;70 mV. The effects of memantine were strongly voltage-dependent with a &#x003b4; value of 0.89 and a Kd(0) value of 7.1 &#x000b5;M. Mutations at the critical asparagine residues in the M2 loop of NR1 and NR2B and at a tryptophan residue in M2 of NR2B reduced blocking by MK-801, memantine and TB-3-4. In contrast, many mutations at residues in the pre-M1, M1, M3, post-M3 and post-M4 regions reduced blocking by MK-801 and TB-3-4, but had no effect on the block by memantine [<xref ref-type="bibr" rid="R116">116</xref>].</p><p>We attempted to verify the common channel blocking locus proposed for memantine and Mg<sup>2+</sup> using channel mutations at the N-sites of NR1 and NR2 receptor subunits [<xref ref-type="bibr" rid="R202">202</xref>]. N598G mutations at the N-site of the M2 trans-membrane segment in NR1a subunits and N595G or N596G mutations in the NR2A subunit had little or no effect on the potency of memantine. These same mutations had pronounced effects on the potency of Mg<sup>2+ </sup>and double mutations may have even apparently permitted permeation of this divalent cation[<xref ref-type="bibr" rid="R117">117</xref>,<xref ref-type="bibr" rid="R299"> 299</xref>,<xref ref-type="bibr" rid="R300"> 300</xref>]. This contrasts with the N598Q mutation data [<xref ref-type="bibr" rid="R71">71</xref>] which decreased the potency of memantine but had little or no effect on Mg<sup>2+</sup> voltage-dependent block [<xref ref-type="bibr" rid="R237">237</xref>,<xref ref-type="bibr" rid="R299"> 299</xref>]. These differences gave important insights into differences in the mechanism of channel blockade by memantine and Mg<sup>2+</sup>.</p><p>All mutations in our own internal study replaced asparagine residues with short &#x0201c;naked&#x0201d; residues. These sites are known to act as channel binding sites for Mg<sup>2+</sup> and these mutations, as expected, reduced the potency of Mg<sup>2+</sup> [<xref ref-type="bibr" rid="R299">299</xref>]. In contrast, they did not have any effect on the potency of memantine, indicating that memantine can still plug the widened pore (from 0.55 to 0.7 nm). The N598Q mutation used by [<xref ref-type="bibr" rid="R71">71</xref>] replaces an asparagine with a longer glutamine residue. This could reduce the pore diameter and thereby prevent memantine from penetrating so deeply whilst having little effect on the Mg<sup>2+</sup> binding site. This difference indicates that, in contrast to Mg<sup>2+</sup>, the channel block by memantine is determined largely by the size of the channel pore. </p><p>In contrast to glycine site NMDA receptor antagonists, memantine (12 &#x000b5;M) did not inhibit NR1/NR3 &#x0201c;excitatory glycine&#x0201d; receptors expressed in <italic>Xenopus</italic> oocytes [<xref ref-type="bibr" rid="R42">42</xref>].</p></sec><sec><title><italic>In Vivo</italic> NMDA Receptor Antagonism</title><p>Memantine selectively reduced responses of single spinal neurones to micro-iontophoretic application of NMDA with an ID<sub>50</sub> of around 2 mg/kg i.v. in anaesthetised rats [<xref ref-type="bibr" rid="R184">184</xref>] and inhibited NMDA-induced convulsions in mice with an ID<sub>50</sub> of 4.6 mg/kg i.p. [<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R201"> 201</xref>]. In a more recent study, memantine protected against NMDA-induced convulsions (ED<sub>50</sub> 2.9 mg/kg) at doses that were 7-, 8- to 18-fold lower than those producing effects on MK-801 discrimination, ataxia or locomotion respectively [<xref ref-type="bibr" rid="R85">85</xref>]. In rats, convulsions produced by i.c.v. injection of NMDA were inhibited by memantine with an IC<sub>50</sub> of 9.7 mg/kg [<xref ref-type="bibr" rid="R27">27</xref>]. Memantine was also potent with an ID<sub>50</sub> of 2.7 mg/kg against NMDA-induced damage of cholinergic neurons in the Nucleus Basalis of Meynert (NBM) [<xref ref-type="bibr" rid="R288">288</xref>].</p><p>Initial data indicated that much higher doses of memantine were required to block responses of spinal neurones to micro-iontopho-retic NMDA (ID<sub>50</sub> of 26 mg/kg i.v.) [<xref ref-type="bibr" rid="R100">100</xref>]. However, more recent data from the same group [<xref ref-type="bibr" rid="R114">114</xref>,<xref ref-type="bibr" rid="R167"> 167</xref>], showed memantine to be more potent when the control NMDA responses were of low intensity. Memantine (10&#x000a0;mg/kg), ketamine (2&#x000a0;mg/kg) and (+)MK-801 (0.1&#x000a0;mg/kg i.v.) reduced responses to similar levels (15-25% of control). Memantine was less effective against stronger intensity responses of the same neurons and this difference was reflected in a strong correlation between ID<sub>50</sub> and control firing rate. (+)MK-801 was equieffective and ketamine was somewhat less effective against stronger responses. This difference likely reflected the stronger voltage-dependency of memantine and probably underlies the differences observed in the <italic>in vivo</italic> potencies of memantine in different laboratories (see [<xref ref-type="bibr" rid="R100">100</xref>,<xref ref-type="bibr" rid="R184"> 184</xref>]).</p></sec><sec><title>5-HT<sub>3 </sub>Receptors</title><p>5-HT<sub>3</sub> receptors are also ligand-gated ionotropic receptors permeable for monovalent cations. 5-HT<sub>3</sub> receptors not only have a high density in the area postrema but also in the hippocampal and amygdala regions of the limbic system. The immediate consequence of neuronal depolarization resulting from 5-HT<sub>3</sub> receptor activation is neurotransmitter release, particularly dopamine in mesolimbic pathways, which suggests a potentially important role for this receptor system in neuronal circuitry involved in drug abuse. As such, 5-HT<sub>3 </sub>receptor antagonists may, in addition to their well characterized efficacy in emesis and irritable bowel syndrome, also be useful in the treatment of drug abuse, anxiety, cognitive deficits and depression [<xref ref-type="bibr" rid="R51">51</xref>,<xref ref-type="bibr" rid="R90"> 90</xref>,<xref ref-type="bibr" rid="R93"> 93</xref>,<xref ref-type="bibr" rid="R128"> 128</xref>,<xref ref-type="bibr" rid="R155"> 155</xref>,<xref ref-type="bibr" rid="R155"> 155</xref>,<xref ref-type="bibr" rid="R166"> 166</xref>,<xref ref-type="bibr" rid="R210"> 210</xref>,<xref ref-type="bibr" rid="R210"> 210</xref>].</p><p>We investigated the effects of memantine, amantadine and neramexane on human 5-HT<sub>3</sub> receptors stably expressed in HEK-293 cells and on native murine 5-HT<sub>3 </sub>receptors in the N1E-115 cell line [<xref ref-type="bibr" rid="R220">220</xref>]. Our results clearly showed that memantine, neramexane and other amino-alkyl-cyclohexanes are, in addition to their well characterized action as uncompetitive NMDA receptor antagonists, also antagonists of 5-HT<sub>3</sub> receptors. These effects were seen at concentrations similar to those required for uncompetitive antagonistic effects at NMDA receptors. These uncompetitive NMDA receptor antagonists had similar effects on 5-HT<sub>3</sub> receptors to those previously reported for different classes of anti-depres-sants [<xref ref-type="bibr" rid="R69">69</xref>] and antipsychotics [<xref ref-type="bibr" rid="R218">218</xref>] i.e., they probably antagonized responses by inducing desensitization. The effects were not voltage- or use-dependent and there was no evidence for open channel blockade. Importantly, similar effects were not seen with ketamine.</p><p>Moreover, it seemed possible that combined antagonistic effects at NMDA and 5-HT<sub>3</sub> receptors by e.g. memantine would lead to positive synergistic effects, which could contribute to the therapeutic safety and efficacy in AD by increasing desired effects - cognitive enhancement [<xref ref-type="bibr" rid="R294">294</xref>] and antidepressive activity [<xref ref-type="bibr" rid="R69">69</xref>,<xref ref-type="bibr" rid="R70"> 70</xref>,<xref ref-type="bibr" rid="R293"> 293</xref>] whilst further reducing possible negative effects of NMDA receptor antagonism e.g. by reducing mesolimbic dopamine hyperactivity [<xref ref-type="bibr" rid="R93">93</xref>].</p><p>However, antagonism of the 5-HT<sub>3</sub> receptor does not seem to play a major role for the good tolerability of memantine versus e.g. ketamine <italic>in vivo</italic> in rats. Thus, recent data indicate that 5-HT<sub>3</sub> receptor blockade with MDL 72222 (0.3-3 mg/kg) does not ameliorate the behavioural deficits (ataxia, stereotypes, deficits in prepulse inhibition and learning) of ketamine [<xref ref-type="bibr" rid="R127">127</xref>] - an NMDA receptor antagonist that does not itself block 5-HT<sub>3</sub> receptors [<xref ref-type="bibr" rid="R220">220</xref>]. However, these authors proposed that 5-HT<sub>3</sub> antagonism might still contribute to certain effects, such as the antidepressant-like actions [<xref ref-type="bibr" rid="R127">127</xref>]. Memantine (5 mg/kg) had no anti-emetic effect in cisplatin-treated ferrets, in contrast to treatment with odansetron or granisetron [<xref ref-type="bibr" rid="R146">146</xref>], indicating a lack of 5-HT<sub>3</sub> receptor blockade after a behaviorally active dose. One caveat here, however, is that we have little information on the pharmacokinetics of memantine in this species.</p></sec><sec><title>Neuronal Nicotinic Receptors</title><p>Changes in neuronal nicotinic receptors have been implicated in a number of diseases [<xref ref-type="bibr" rid="R163">163</xref>,<xref ref-type="bibr" rid="R208"> 208</xref>,<xref ref-type="bibr" rid="R238"> 238</xref>,<xref ref-type="bibr" rid="R244"> 244</xref>,<xref ref-type="bibr" rid="R287"> 287</xref>]. These include AD, Parkinson's disease, Tourette&#x000b4;s syndrome, schizophrenia, drug abuse and pain. Based on the observation that the nicotinic agonist nicotine itself seems to have beneficial effects, most drug development effort so far has aimed at the discovery of selective nicotinic agonists, especially for &#x003b1;4&#x003b2;2 receptors. On the other hand, it is unclear whether the effects of nicotinic agonists in e.g. Tourette&#x000b4;s syndrome and schizophrenia are due to the activation or inactivation / desensitization of neuronal nicotinic receptors - e.g. meca-mylamine is also active [<xref ref-type="bibr" rid="R239">239</xref>].</p><p>The effects of agonists on neuronal nicotinic receptors are strongly dependent on the exposure period. Rapid reversible desensitization occurs in milliseconds, rundown occurs in seconds, irreversible inactivation of &#x003b1;4&#x000df;2 and &#x003b1;7 containing receptors occurs in hours and their upregulation occurs within days. In other words, the effects of nicotinic "agonists" may in fact be due to partial agonism, inactivation and/or desensitization and adaptive changes in the expression of neuronal nicotinic receptors. In turn, moderate concentrations of neuronal nicotinic receptor channel blockers could produce the same effects as reported for nicotinic agonists in the above mentioned indications. This is especially likely for &#x003b1;7 receptors, which show complete desensitization.</p><p>As an example, there is considerable evidence that nicotinic antagonists might produce similar effects to agonist in animal models of learning. Thus, under certain conditions, both nicotine and the nicotinic antagonist mecamylamine improve learning [<xref ref-type="bibr" rid="R148">148</xref>]. Although nicotine improves memory, &#x003b2;2-deficient mice actually show improved learning and show no additional beneficial effects of nicotine [<xref ref-type="bibr" rid="R209">209</xref>]. <italic>In vitro</italic> experiments also indicate that both the activation of non-&#x003b1;7 nAChRs and inactivation of &#x003b1;7 nAChRs contribute to LTP induction [<xref ref-type="bibr" rid="R80">80</xref>]. Moreover, chronic nicotine-mediated facilitation of LTP induction was probably due to chronic nicotine-induced desensitization of &#x003b1;7 nAChRs [<xref ref-type="bibr" rid="R80">80</xref>]. Similarly, chronic treatment with both nicotine and mecamylamine increased nicotinic receptor number [<xref ref-type="bibr" rid="R205">205</xref>,<xref ref-type="bibr" rid="R206"> 206</xref>] and both nicotine and mecamylamine enhanced haloperidol-induced catalepsy [<xref ref-type="bibr" rid="R149">149</xref>].</p><p>Memantine has been found to inhibit &#x003b1;4&#x003b2;2 responses with an IC<sub>50</sub>=6.6 or 11.3 &#x000b5;M [<xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R63"> 63</xref>], however, this level is probably too high to be of real therapeutic significance. In line with this, <italic>in vivo</italic> memantine at 10 mg/kg had only mild effect on nicotine discrimination [<xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R305"> 305</xref>] mediated by &#x003b1;4&#x003b2;2 receptors [<xref ref-type="bibr" rid="R162">162</xref>] at doses that also affected saline responding indicating lack of selectivity. The reported potency of memantine at &#x003b1;7 receptors varies considerably, from 0.33-1.68 &#x000b5;M seen in rat receptors [<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R63"> 63</xref>], to 5&#x000b5;M observed in human receptors [<xref ref-type="bibr" rid="R165">165</xref>], the latter finding making it seem less likely to be of therapeutic relevance for AD patients. Moreover, even in rats, recent studies (Nagel, personal communication) indicate that at 5-10 mg/kg, memantine does not produce changes in dopamine levels in the striatum that would be consistent with the blockade of &#x003b1;7 receptors [<xref ref-type="bibr" rid="R222">222</xref>] &#x02013; in fact, memantine caused an increased release of dopamine, not a decrease as would be expected for an &#x003b1;7 antagonist. These results were confirmed by a micro-dialysis study showing that memantine (20mg/kg) resulted in significant increases in extracellular dopamine, norepinephrine and their metabolites in cortical regions [<xref ref-type="bibr" rid="R251">251</xref>].</p><p>Although memantine blocks &#x003b1;9/&#x003b1;10 nicotinic receptors with similar affinity to NMDA [<xref ref-type="bibr" rid="R191">191</xref>], these receptors show a very discrete distribution e.g. in cochlear hair cells and this action is therefore highly unlikely to be responsible for therapeutic effects of memantine on symptoms in AD [<xref ref-type="bibr" rid="R65">65</xref>,<xref ref-type="bibr" rid="R119"> 119</xref>]. In agreement with published data [<xref ref-type="bibr" rid="R191">191</xref>], memantine blocked &#x003b1;9/&#x003b1;10 receptors expressed in <italic>Xenopus</italic> oocytes at &#x02013;70 mV with an IC<sub>50</sub> of 1.20 &#x000b5;M and in a weakly voltage-dependent manner [<xref ref-type="bibr" rid="R64">64</xref>].</p><p>Interestingly, the effect of memantine on all tested &#x0201c;neuronal&#x0201d; nicotinic receptors was only weakly voltage-dependent, as is the case for 5-HT<sub>3</sub> receptors (see above), which often share a common pharmacology with neuronal nicotinic receptors and implies a site of action, which is not deep inside the channel.</p></sec><sec><title>Summary</title><p>Taken together with data reviewed previously [<xref ref-type="bibr" rid="R55">55</xref>,<xref ref-type="bibr" rid="R124"> 124</xref>], it seems clear that NMDA receptor antagonism is the primary mechanism of action of therapeutic relevance for memantine although additional effects at 5-HT<sub>3</sub> receptors and neuronal nicotinic receptors may be supportive for therapeutic tolerability. The effects on NMDA are far more consistent across species i.e., human and rat, whereas effects on neuronal nicotinic receptors seem to be species-dependent and findings specific for neuronal nicotinic receptors from rodent studies may bear little or no relevance for the human therapeutic situation. Additional support for NMDA receptor antagonism <italic>in vivo</italic> at therapeutically-relevant doses is provided by its strong neuroprotective activity in animal models discussed later.</p></sec></sec><sec><title>PRIMARY PHARMACODYNAMICS</title><p>AD is the most common form of dementia, the other two major forms being vascular dementia (VD) and mixed Alzheimer's / vascular dementia (AD/VD). Acetylcholine esterase inhibitors (AChEi) aim to improve cognitive and symptomatic behavioral symptoms and thereby, the quality of life for the patients / caregiver. NMDA-receptor-mediated glutamate excitotoxicity is hypothesized to play a major role in both the symptoms and pathomechanism of this disease. Memantine is a clinically proven effective therapy for symptomatic treatment of Alzheimer's disease [<xref ref-type="bibr" rid="R224">224</xref>,<xref ref-type="bibr" rid="R271"> 271</xref>,<xref ref-type="bibr" rid="R297"> 297</xref>]. The preclinical data discussed below provide reason to believe that memantine, in addition to symptomatic treatment for AD, could also be an effective disease-modifying agent in this devastating disorder.</p><sec><title>Alzheimer&#x02019;s Disease</title><sec><title>Symptomatic Effects</title><p>Removal or reduction of magnesium in hippocampal slices causes deficits in LTP [<xref ref-type="bibr" rid="R49">49</xref>] and this could be reversed by memantine with a bell-shaped concentration-response curve with near complete reversal of this deficit by therapeutically-relevant concentrations [<xref ref-type="bibr" rid="R74">74</xref>]. Similarly, in hippocampal slices, low concentrations of NMDA also caused a reduction of LTP induction / expression in the CA1 region [<xref ref-type="bibr" rid="R109">109</xref>,<xref ref-type="bibr" rid="R304"> 304</xref>]. This deficit was also reversed by memantine at a concentration of 1 &#x003bc;M [<xref ref-type="bibr" rid="R304">304</xref>]. In support of these effects of memantine, in knockout mice lacking the glutamate transporter GLT-1, LTP was also impaired in the hippocampal CA1 region <italic>in vitro</italic>. When tetanic stimulation was applied in the presence of a very low concentration of the competitive NMDA receptor antagonist AP5 (0.5 &#x000b5;M), the impairment was reversed [<xref ref-type="bibr" rid="R118">118</xref>].</p><p>Memantine (20 mg/kg/day, 7&#x02013;13 days after lesioning and 4 days before training) caused a symptomatic improvement of spatial learning of rats in the radial maze following lesions of the entorhinal cortex with quinolinic acid. These memory improving effects of memantine were not related to changes in brain NGF content or choline acetyltransferase (ChAT) activity [<xref ref-type="bibr" rid="R143">143</xref>].</p><p>Memantine was confirmed to improve learning in a radial water maze task where rats were given 4 trials and then tested 1 h later and 1 day later. Only one arm was reinforced (safe platform) and the start on each trial was from a different position. Memantine (at 5 and 7.5 but not 2.5 mg/kg), administered 30 min before day 1 training, did not affect performance on day 1 but enhanced learning (decreased the number of errors) 24 h later. This result was explained by tempering over-activation of NMDA receptors resulting from massive glutamate release in stressful conditions such as in the water maze [<xref ref-type="bibr" rid="R310">310</xref>]. Withdrawal from chronic (6 month) alcohol ingestion produced robust learning deficits in rats in the Morris water maze. Treatment with memantine starting at the beginning of the withdrawal phase (20 mg/kg bolus followed by 1 mg/kg every 12 h for 4 weeks) resulted in a complete reversal of these behavioral impairments [<xref ref-type="bibr" rid="R158">158</xref>].</p><p>Memantine 10 mg/kg re-instated experience dependent place field neuronal firing field expansion in aged rats. This effect was claimed to be due to a dampening of Ca<sup>2+</sup> overload by memantine, which fits perfectly to the signal-to-noise hypothesis [<xref ref-type="bibr" rid="R39">39</xref>].</p><p>Even in much lower species, memantine has been claimed to improve learning by reversing noise at glutamatergic synapses. The glutamate transporter inhibitor (L-trans-2,4-PDC)-induced olfactory amnesia in honeybees (<italic>Apis mellifera</italic>) was 'rescued' by memantine (1-10mM, 1&#x000b5;l per bee) injected either before training, or before testing, suggesting that memantine restores memory recall rather than memory formation or storage. When injected alone, memantine also had a mild facilitating effect on memory. In contrast, MK-801 also impaired memory in all tests [<xref ref-type="bibr" rid="R254">254</xref>].</p><p>Memantine (30 mg/kg/day; p.o.) for 2-3 weeks significantly improved the acquisition of the water maze task in APP/PS1 mice without affecting swimming speed. Memantine affected neither locomotor activity nor aggressive behavior in transgenic or wild type mice. These data indicate that memantine improves hippocampus-based spatial learning in a transgenic murine model of AD without producing non-specific effects on locomotion/exploratory activity [<xref ref-type="bibr" rid="R174">174</xref>].</p><p>Low doses of memantine (2 mg/kg i.p. daily for 1 week) had mild symptomatic effects on cognition in the Morris water maze in APP23 mice, especially during the probe trial. Higher doses of 10 mg/kg were ineffective. This study compared memantine to AChE inhibitors, where a consistent biphasic dose-response curve was also observed &#x02013; low doses were shown to be effective, but higher doses were not. However, the difference in doses of the AChE inhibitors was two-fold, but for memantine it was 5-fold. Biphasic effects on cognition / synaptic plasticity are well known for memantine and it seems likely that better effects would have been seen had 5 mg/kg also been tested [<xref ref-type="bibr" rid="R277">277</xref>].</p><p>Zhao <italic>et al</italic>. discussed <italic>in vitro </italic>data to support the beneficial actions of galanthamine and memantine combinations [<xref ref-type="bibr" rid="R309">309</xref>]. Memantine was reported to block extrasynaptic NMDA receptors (IC<sub>50</sub> = 22 nM) 100 times more potently than the synaptic NMDA receptors at negative membrane potentials (IC<sub>50</sub> = 2.5 &#x000b5;M) and the block of both types of NMDA receptor was strongly voltage-dependent. Galanthamine (1&#x000b5;M) potentiated NMDA receptors in a non voltage-dependent manner. Co-application of memantine with galanthamine prevented the galanthamine potentiation and the activation of extrasynaptic NMDA receptors, but membrane depolarization revealed the galanthamine potentiation of proposed synaptic receptors. The authors therefore hypothesized that, in the presence of both drugs, cell death is expected to be prevented by memantine near the resting potential, while NMDA-mediated synaptic transmission would be further potentiated by galanthamine. These results were claimed to provide an <italic>in vitro </italic>basis for the beneficial actions of galanthamine and memantine combinations [<xref ref-type="bibr" rid="R309">309</xref>].</p><p>It has been shown <italic>in vitro</italic> that memantine does not attenuate the effects of AChE inhibitors used clinically in AD such as donepezil, tacrine or galanthamine, in contrast to clear attenuation of irreversible inhibition by DFP [<xref ref-type="bibr" rid="R291">291</xref>]. In an <italic>in vivo</italic> study, memantine (10mg/kg) did not inhibit AChE in any brain areas and did not interact with donepezil and rivastigmine [<xref ref-type="bibr" rid="R92">92</xref>]. This lack of negative interaction is also supported by recent studies investigating AChE activity in man and in clinical studies focusing on symptomatic effects [<xref ref-type="bibr" rid="R59a">59a</xref>,<xref ref-type="bibr" rid="R67"> 67</xref>,<xref ref-type="bibr" rid="R207"> 207</xref>].</p></sec><sec><title>Neuroprotection</title><sec><title>Introduction</title><p>Wenk <italic>et al</italic>. have published many studies indicating that memantine is neuroprotective against various insults to the cholinergic NBM. These effects were expressed both in histological and functional terms [<xref ref-type="bibr" rid="R290">290</xref>]. Inflammatory changes are closely related to the cognitive and neuropathological manifestations of AD [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4"> 4</xref>]. Infusion with lipopolysaccharide (LPS, a component of Gram-negative bacteria cell walls) led to a massive inflammatory reaction followed by cell loss in the NBM. Memantine, (20 mg/kg/day) infused s.c. in parallel to LPS, provided significant protection of NBM neurons [<xref ref-type="bibr" rid="R290">290</xref>,<xref ref-type="bibr" rid="R292"> 292</xref>,<xref ref-type="bibr" rid="R296"> 296</xref>]. </p><p>In conformation of these positive findings, following infusion of ibotenic acid into the NBM of rats, acute administration of memantine (10 mg/kg, i.p.) blocked the increase of astrocytes and microglia activation in the cortex [<xref ref-type="bibr" rid="R2">2</xref>]. In a recent study from Wenk&#x000b4;s group, memantine did not prevent the neurotoxic effects of TNF-alpha on cholinergic neurons [<xref ref-type="bibr" rid="R289">289</xref>]. This, taken together with the previous studies described above, indicates that NMDA receptors are involved in neurodegeneration resulting from inflammation produced by LPS, but not TNF-alpha infusion. In this study, TNF-alpha was infused for a prolonged time, which contrasts to the short lasting increase of this cytokine following treatment with LPS as in the previous work. </p><p>Systemic oral administration of memantine 2 mg/kg daily for 13 days, to rats with chronic partial AF64A-induced deprivation of cholinergic functions, improved their learning in a Morris water maze [<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R147"> 147</xref>]. This effect of memantine had a longer duration of action than the acetylcholine esterase (AChE) inhibitor donepezil [<xref ref-type="bibr" rid="R147">147</xref>]. Importantly, memantine shows no negative interaction <italic>in vitro</italic> and <italic>in vivo</italic> with AChE inhibitors used in the treatment of AD [<xref ref-type="bibr" rid="R67">67</xref>,<xref ref-type="bibr" rid="R207"> 207</xref>,<xref ref-type="bibr" rid="R291"> 291</xref>].</p><p>Memantine (20 mg/kg/day) was able to prevent and reverse the occurrence of learning and spatial memory deficits after cortical devascularization injury (inducing cortical cholinergic terminal loss and retrograde degeneration of the cholinergic projections from NBM) in rats [<xref ref-type="bibr" rid="R233">233</xref>].</p><p>In rats chronically infused into the 4th ventricle for 28 days with LPS (<italic>via</italic> osmotic minipump), there was a region-selective microglia activation, impaired hippocampal-depen-dent memory and altered behaviorally-induced expression of the immediate early gene Arc [<xref ref-type="bibr" rid="R234">234</xref>]. A therapeutically relevant dose of memantine (10 mg/kg/day s.c. for 28 days) was also able to restore <italic>Arc</italic> gene expression to normal levels, reduce the number of activated microglia an expression of brain inflammation - and ameliorate spatial memory impairments [<xref ref-type="bibr" rid="R234">234</xref>]. These results confirm the role of dynamic changes in Arc expression in neuronal plasticity and demonstrate the ability of memantine to reinstate the dynamic balance of cellular processes that were disturbed by chronic brain inflammation.</p></sec><sec><title>&#x003b2;-Amyloid</title><p>Chronic s.c. osmotic pump infusion of memantine (steady-state plasma concentrations of 2.34 &#x000b5;M, for 9 days) reduced local neuronal cell loss produced by intra-hippo-campal injection of A&#x003b2;<sub>1-40 </sub>[<xref ref-type="bibr" rid="R172">172</xref>]. Recently, the same group reported inhibition of apoptosis induced by A&#x003b2;<sub>1-40</sub> infused in the hippocampus by memantine [<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R173"> 173</xref>].</p><p>Neuroprotective effects of memantine against A&#x000df; toxicity have also been shown in functional terms. Indeed, it was recently shown that infusion of memantine prevented the development of delayed non-matching to sample lever pressing task impairments produced by infusion of A&#x003b2;<sub>1-40</sub> in rats [<xref ref-type="bibr" rid="R301">301</xref>]. Rats injected in the hippocampus with aggregated A&#x000df;<sub>1-40</sub> (4 &#x000b5;g/&#x000b5;l), and two days later, with the NMDA receptor agonist ibotenic acid (0.3 &#x000b5;g/0.5 &#x000b5;l) showed learning deficits in the Morris water maze task and neuronal damage in the hippocampus from 5 to 6 weeks after the injection [<xref ref-type="bibr" rid="R180">180</xref>]. Memantine (10, 20 mg/kg/day s.c. infusion for 6 weeks starting 24 h before the A&#x000df;<sub>1-40</sub> injection) caused a significant inhibition of the learning deficits, but a lower dose of memantine (5 mg/kg/day) and both tested doses of MK-801 (0.312, 0.624 mg/kg/day) did not have significant effects. In naive rats, MK-801 produced a significant learning impairment in the water maze task at a dose of 0.624 mg/kg/day, whilst memantine (20 mg/kg/day s.c. infusion) did not [<xref ref-type="bibr" rid="R180">180</xref>].</p><p>In a murine transgenic model of AD (APP23), memantine treatment prevented the time-dependent decrease in performance seen in vehicle-treated animals. This &#x0201c;disease-modifying&#x0201d; effect was observed three weeks after treatment termination, an important control in such functional studies supporting neuroprotective effects in the absence of interference from potential symptomatic effects in the continuous presence of drug [<xref ref-type="bibr" rid="R278">278</xref>]. Also, transgenic mice (APPswe) treated chronically with memantine showed lower levels of membrane-bound APP [<xref ref-type="bibr" rid="R275">275</xref>].</p><p>In studies in cultured human neuroblastoma (SK-N-SH) cells, treatment with memantine for 24 to 48 hours provided evidence that the drug may decrease disturbed APP processing [<xref ref-type="bibr" rid="R142">142</xref>]. Memantine treatment of cultured human neuroblastoma cells and primary fetal rat cortical neurons, albeit for a longer duration of 12 days, also decreased levels of A&#x003b2;<sub>1-40</sub> starting at a therapeutically relevant concentration of 1 &#x000b5;M [<xref ref-type="bibr" rid="R142">142</xref>].</p><p>Memantine (1&#x000b5;M), APV (10 &#x000b5;M) as well as soluble tumor necrosis factor alpha (TNF&#x003b1;) receptor protected neurons from A&#x000df;<sub>1-42</sub> stimulation microglial-conditioned media-induced toxicity, implicating the excitatory neurotransmitter glutamate and the pro-inflammatory cytokine TNF&#x003b1; as effectors of microglial-stimulated death [<xref ref-type="bibr" rid="R73">73</xref>]. Interestingly, <italic>in vitro</italic>, brief exposure of cultured cortical neurons to memantine (1-20 &#x000b5;M), which would produce only a transient block of NMDA receptors, inhibited the toxicity of NMDA for up to 48 hours with an IC<sub>50</sub> of around 5&#x000b5;M [<xref ref-type="bibr" rid="R272">272</xref>]. In the same study, a high concentration of MK-801 (1&#x000b5;M) provided long-term protection against toxicity due to NMDA, AMPA, staurospo-rine, etoposide, hypoxia and A&#x000df;<sub>1-40</sub>, applied 48 hours later, but the relevance of this for memantine with regard to chronic therapy in AD remains to be investigated [<xref ref-type="bibr" rid="R272">272</xref>].</p><p>Chronic exposure of hippocampal cultures to soluble A&#x000df; oligomers induced reactive oxygen species and produced abnormal spine morphology and a decrease in their density. Subsequent consequences of this, such as synaptic deterioration including loss of the synaptic spine cytoskeletal protein debrin, were completely prevented by memantine (5-10 &#x000b5;M) [<xref ref-type="bibr" rid="R123">123</xref>,<xref ref-type="bibr" rid="R141"> 141</xref>].</p><p>Memantine (1-10 &#x000b5;M) did not protect against A&#x000df;<sub>1-42</sub> toxicity in cultured rat septal cholinergic neurons, but this is not surprising, as these neurons themselves are relatively resistant to NMDA toxicity [<xref ref-type="bibr" rid="R122">122</xref>].</p></sec><sec><title>Tau</title><p>Overexpression of human tau and of some of its N-terminal fragments in primary neuronal cultures leads to an NMDA receptor-mediated, caspase-independent pathway that was completely prevented by treatment with memantine (10 &#x000b5;M) [<xref ref-type="bibr" rid="R7">7</xref>]. The authors proposed that &#x0201c;death&#x0201d; signalling likely originates from stimulation of extrasynaptic NR2B subunit-containing NMDA receptors and sustained phosphorylation of extracellular-regulated kinases 1 and 2. Moreover, NMDA receptor involvement causes the fatal activation of calpain, which, in turn, degrades tau protein into a 17-kDa peptide and possibly other highly toxic N-terminal peptides.</p><p>The activity of protein phosphatase (PP)-2A, which regulates tau phosphorylation, is compromised in the AD brain. Memantine (1&#x000b5;M) reduced phosphorylation of tau (ser262) and prevented neurotoxicity produced by okadaic acid in a rat hippocampal slice preparation [<xref ref-type="bibr" rid="R150">150</xref>]. Transient transfection of PC12 cells with inhibitor-2 of PP2A (I(2)(PP2A)) also causes abnormal hyperphosphorylation of tau at Ser396/ Ser404 and Ser262/Ser356. Memantine (10 &#x000b5;M) inhibited this abnormal phosphorylation of tau and cell death and prevented the I(2)(PP2A)-induced inhibition of PP2A activity with no effect on basal activity [<xref ref-type="bibr" rid="R47">47</xref>]. It is not clear whether this effect is solely due to NMDA antagonism, since a competitive antagonist and an antagonist acting at the glycine site of the NMDA receptor were ineffective, at least at the concentrations used (ibid.).</p><p>It has also recently been shown that after chronic treatment of AD patients with memantine for 12 months, the CSF levels of phosphorylated tau decrease while non-phosphory-lated tau and A&#x000df; remain unchanged [<xref ref-type="bibr" rid="R59b">59b</xref>].</p><p>Recently, further insights into the possible MOA for this effect became available. It was reported that memantine caused an increase <italic>in vivo</italic> in phosphorylation of GSK-3, which inhibits its function and could thereby reduce phosphorylation of presenilin 1, 2 and tau [<xref ref-type="bibr" rid="R58">58</xref>], but it is very unclear whether this has anything to do with NMDA receptor blockade due to the very high dose used (50 mg/kg). </p><p>Taken together, these findings suggest that memantine might also be useful for the treatment of related tauopathies.</p></sec><sec><title>Summary of Neuroprotection in AD</title><p>On the basis of the animal experiments detailed here and in many previous studies, memantine at therapeutic doses in AD patients [<xref ref-type="bibr" rid="R224">224</xref>,<xref ref-type="bibr" rid="R271"> 271</xref>] could provide inhibition of disease progression due to its neuroprotective properties [<xref ref-type="bibr" rid="R196">196</xref>].</p></sec></sec><sec><title>Neurorestorative Effect</title><p>Memantine enhanced neurogenesis at therapeutically relevant concentrations in cortical cultures <italic>in vitro</italic> (the best effects were seen at 1 &#x000b5;M, with 140% of control neurogenesis) and in the DG and forebrain sub-ventricular zone <italic>in vivo</italic> (7.5 mg/kg p.o. once daily for 14 days, around 126% of control neurogenesis) [<xref ref-type="bibr" rid="R112">112</xref>]. However, in another study, although acute treatment of rats with memantine (20 mg/kg) also led to an increase in neurogenesis in the hippocampus, this effect disappeared after 7 days. Moreover, in contrast to acute treatment, chronic infusion of memantine with mini-pumps (20 mg/kg/d) failed to increase neurogenesis [<xref ref-type="bibr" rid="R253">253</xref>].</p></sec></sec></sec><sec><title>SECONDARY PHARMACODYNAMICS</title><p>As a reminder, this review is intended to provide an update on preclinical studies on the pharmacodynamics of memantine. For most studies prior to 1999, the reader is referred to a previous review [<xref ref-type="bibr" rid="R196">196</xref>]. Apart from studies which are supportive of the neuroprotective effects of memantine, new data on secondary pharmacodynamic effects are presented with no ordered preference for validity or relevance.</p><sec><title>Activity in Models of Neurodegenerative Conditions</title><sec><title>Introduction</title><p>It is widely accepted that NMDA receptor antagonists have neuroprotective activity in a variety of animal models of acute excitotoxicity. In acute ischemia, they are generally more active in models of focal, rather than global ischemia, when confounding factors such as changes in body temperature are taken into account [<xref ref-type="bibr" rid="R35">35</xref>]. Concerning the acute neuroprotective effects of memantine, the literature before 1999 has been reviewed in detail by [<xref ref-type="bibr" rid="R196">196</xref>]. For the sake of completeness, we included this information in a somewhat abbreviated form to provide a preface for new studies.</p></sec><sec><title>General Neuroprotective Activity</title><sec><title>In Vitro</title><p>Numerous studies indicate that memantine protects against the toxic effects of exogenous NMDA receptor agonist in cultured neurones with an IC<sub>50</sub> close to 1&#x000b5;M [<xref ref-type="bibr" rid="R196">196</xref>]. More recently, memantine was shown to protect rat neurons in organotypic hippocampal slices from NMDA-induced excitotoxicity (IC<sub>50</sub> around 1 &#x000b5;M) and was similarly protective in cerebellar granule cell cultures when assessed as cell death with H-33342, but was less potent on viability assessed with MTT (IC<sub>50</sub> around 10 &#x000b5;M) [<xref ref-type="bibr" rid="R280">280</xref>]. In the same study, (+)MK-801 negatively interfered with neuronal migration after excitotoxic insult in cerebellar micro-explant cultures, since the directed movement of neurons is dependent on physiological NMDA receptor activity. In contrast, memantine caused significant recovery from these deficits providing further evidence for the ability of memantine to differentiate between physiological and pathological activation of NMDA receptors [<xref ref-type="bibr" rid="R280">280</xref>].</p><p>Memantine alone (0.05-2.0 &#x000b5;M) concentration-depen-dently attenuated staurosporine-induced caspase-3 activity and lactate dehydrogenase (LDH) release in hippocampal cultured neurons after 7 and 12 days <italic>in vitro</italic> but had no effect in control cultures. These effects of memantine were more pronounced in hippocampal cultures than in neocortical and striatal cultures, which can be explained by different expression patterns of NMDA receptor subtypes [<xref ref-type="bibr" rid="R111">111</xref>]. Another group claimed that a higher concentration of memantine (10&#x000b5;M) potentiated neuronal death caused by exposure to staurosporine (10-30 nM for 48 h) in cultured murine neocortical neurons, but in their hands, caffeine 1 mM also exacerbated this death, which somewhat questions the validity of the model used [<xref ref-type="bibr" rid="R257">257</xref>,<xref ref-type="bibr" rid="R258"> 258</xref>].</p><p>Memantine and (+)MK-801 blocked strong hypoxia / hypoglycemia-induced suppression of fEPSPs in rat hippocampal slices with EC<sub>50</sub>s of 14.1 and 0.53 &#x000b5;M respectively [<xref ref-type="bibr" rid="R76">76</xref>]. Whereas memantine blocked this effect with a similar potency to at which it blocks the induction of LTP, (+)MK-801 was four times less potent in this model than against LTP [<xref ref-type="bibr" rid="R77">77</xref>]. The calculated relative therapeutic indices (IC<sub>50</sub> LTP over EC<sub>50</sub> hypoxia / hypoglycaemia) for memantine and (+)MK-801 were 0.82 and 0.28, respectively. These results show that, even in a severe model of hypoxia / hypoglycemia, moderate affinity channel blockers exhibit a better therapeutic index than high affinity channel blockers. The authors proposed that it is likely that in milder forms of pathology, the observed differences in the therapeutic indices remain the same but the absolute values can be expected to be higher. Similarly, memantine (10 &#x000b5;M) also reduced LDH release from hippocampal slices by 40% following 1 hour of oxygen glucose deprivation (OGD) plus reoxygenation for 3 hours when treatment was started 30&#x000b4; prior to OGD and continued for the duration of the study [<xref ref-type="bibr" rid="R261">261</xref>].</p><p>Memantine also protected cultured cerebellar granule cells from apoptosis induced by OGD (IC<sub>50</sub> around 10 &#x000b5;M) or treatment with the mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP+) or nitric oxide (NO) donors (IC<sub>50</sub> around 10 &#x000b5;M) [<xref ref-type="bibr" rid="R280">280</xref>]. A very high concentration of memantine (50&#x000b5;M) blocked NMDA receptor currents and completely protected against 3hrs of OGD in a human embryonic teratocarcinoma cell line (NT2) that expresses NMDA receptors (NR2B&#x0003e;BNR2C&#x0003e;NR1&#x0003e;NR2A) [<xref ref-type="bibr" rid="R83">83</xref>]. Unfortunately, lower concentrations were apparently not tested.</p><p>Memantine (i.p. 5-50 mg/kg; 4 h) markedly increased BDNF mRNA levels in the limbic cortex and this effect was more widespread and pronounced at higher doses [<xref ref-type="bibr" rid="R164">164</xref>]. The effects of memantine on BDNF mRNA were also reflected in changes in BDNF protein levels. Moreover, memantine induced isoforms of the BDNF receptor trkB. The authors suggested that the neuroprotective properties of memantine could be mediated by the increased endogenous production of BDNF in the brain.</p><p>Memantine was somewhat less effective in protecting against acute excitotoxic insult by 3-nitrophenol (3-NP) in cerebellar micro-explant cultures [<xref ref-type="bibr" rid="R280">280</xref>], but these experiments were after acute 3-NP (0.5 mM) treatment c.f. treatment with 3-NP (35 &#x000b5;M) for 7-12 days in other studies more relevant for chronic excitotoxicity [<xref ref-type="bibr" rid="R115">115</xref>] - see below. Memantine (10 &#x000b5;M) reduced depolarization-induced superoxide radical formation in hippocampal slices following acute exposure to high extracellular K<sup>+</sup> (50 mM). The block was less pronounced than that seen with MK-801 (1&#x000b5;M), possibly due to the greater voltage-dependency of memantine and/or the very high concentration of MK-801 used [<xref ref-type="bibr" rid="R242">242</xref>]. Exposure of cultured cortical neurons to elevated extracellular K<sup>+</sup> concentrations (25 mM) induced membrane depolarization and an increase in action-potential firing that was associated with increased neuronal cell death following long-term treatment (15 DIV) [<xref ref-type="bibr" rid="R110">110</xref>]. This excitotoxicity was prevented by the continuous presence of an extremely high concentration of memantine (50&#x000b5;M) but lower concentrations were not tested [<xref ref-type="bibr" rid="R110">110</xref>].</p><p>In an organotypic hippocampal slice model with more relevance for the chronic, low level excitotoxicity proposed to occur in e.g. AD, memantine was protective with IC<sub>50</sub> of c.a. 1-2 &#x000b5;M against semi-chronic excitotoxicity (4-20 days) produced by low concentrations of 3-NP (35 &#x000b5;M) as measured as changes in LDH release [<xref ref-type="bibr" rid="R115">115</xref>]. In this study, memantine also reduced both the cytoskeletal damage and synaptic decline in a concentration-dependent manner. Phase contrast microscopy, propidium iodide fluorescence and cresyl violet staining confirmed memantine&#x000b4;s neuroprotective effects. Furthermore, the protected tissue exhibited normal neuronal density and morphology in major hippocampal subfields.</p><p>The toxic effects of the scrapie prion protein, PrP(Sc), and its peptide fragment, PrP106-126, can be blocked by memantine (10 &#x000b5;M), which was therefore proposed to be a promising approach to prevent neuronal death in Creutzfeldt-Jakob disease [<xref ref-type="bibr" rid="R179">179</xref>].</p><p>The combination of 10 <underline>nM</underline> memantine and clenbuterol was also reported to be very effective against staurosporine toxicity <italic>in vitro</italic>, but it is very difficult to reconcile this concentration with the MOA as an NMDA receptor antagonist [<xref ref-type="bibr" rid="R52">52</xref>]. It is conceivable that this was a typo, and in fact memantine 10 &#x000b5;M was tested &#x02013; see [<xref ref-type="bibr" rid="R55">55</xref>,<xref ref-type="bibr" rid="R203"> 203</xref>].</p></sec><sec><title>In Vivo</title><p>As noted above, acute ischemia models are generally of a severe nature and the doses of NMDA receptor antagonist required are therefore very high. It is likely that lower doses provide neuroprotection inhibiting the progression of chronic neurodegenerative disorders such as AD.</p><p>Chronic dietary intake of memantine (31 mg/kg/day) for 14 days prevented death, convulsions and hippocampal damage induced by i.c.v. quinolinic acid [<xref ref-type="bibr" rid="R120">120</xref>]. Memantine also significantly attenuated malonate-induced striatal lesions implicating utility in chronic neurodegenerative diseases associated with deficits in mitochondrial function [<xref ref-type="bibr" rid="R246">246</xref>].</p><p>Rats infused i.c.v. with quinolinic acid alone showed clear learning deficits in the T-maze whilst those infused in parallel with memantine (20 mg/kg/day s.c.) were able to acquire the task normally [<xref ref-type="bibr" rid="R176">176</xref>]. Similarly, a decrease in choline uptake sites (an indicator of the density of ACh terminals potentially relevant for AD) was seen in the cortex of animals treated with quinolinic acid but not in those receiving additional treatment with memantine. In this context, it is important that infusion of this same dose of memantine in normal rats had no effect on T-maze learning or LTP in hippocampal slices <italic>ex vivo</italic> [<xref ref-type="bibr" rid="R176">176</xref>].</p></sec><sec><title>Ischemic Tolerance</title><p>It has been known for several years that under certain conditions, a short ischemic/hypoxic episode or pharmacological blockade of mitochondrial oxidative processes [<xref ref-type="bibr" rid="R227a">227a</xref>] can decrease the susceptibility of neuronal tissue to subsequent severe insult - a phenomenon called ischemic tolerance. This fact might be of particular clinical importance in situations where a danger of succeeding episodes after moderate ischemic insult can be anticipated, such as in vascular dementia (VD) or combined AD / VD.</p><p>Memantine (5 mg/kg) did not inhibit ischemic tolerance to global ischemia in gerbils<italic> in vivo</italic> [<xref ref-type="bibr" rid="R62">62</xref>]. In fact, subchronic 3 day infusion of memantine (30 mg/kg/day) significantly decreased neurodegeneration on its own and potentiated the neuroprotective effects of ischemic pre-conditioning [<xref ref-type="bibr" rid="R62">62</xref>]. In a similar manner, memantine (20 mg/kg/day for 3 days <italic>via</italic> Alzet minipumps) did not block 3-NP (20 mg/kg i.p.) - induced delayed ischemic tolerance in rat hippocampal slices<italic> ex vivo</italic> [<xref ref-type="bibr" rid="R75">75</xref>]. In contrast, 3 days pre-treatment with a high dose of (+)MK-801 (2 mg/kg/day) tended to reduce ischemic tolerance following 3-NP preconditioning.</p><p>As such, although NMDA receptors do seem to be involved in ischemic / chemical tolerance, semi-chronic pre-treatment with therapeutically-relevant doses of memantine does not block this phenomenon [<xref ref-type="bibr" rid="R75">75</xref>].</p></sec></sec><sec><title>Models of Acute Excitotoxicity</title><sec><title>Stroke</title><p>The &#x0201c;real&#x0201d; effective acute neuroprotective doses / concentrations in almost all reported preclinical acute, focal and global ischemia models were always higher than, or similar to, those producing other behavioral effects regarded either as positive (chronic neuroprotective, anticataleptic, or antinociceptive effects) or as side effects (amnesia, ataxia, stereotypy) [<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R40"> 40</xref>,<xref ref-type="bibr" rid="R171"> 171</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R243"> 243</xref>]. This fits perfectly with the known voltage-dependency of memantine and assumed strong depolarization during such strong acute insults. These acute ischemia models have less direct quantitative relevance for judgement of potential neuroprotective activity that would be useful for the inhibition of progression of chronic neurodegenerative disorders such as AD but are still useful for qualitative comparison of neuroprotective efficacies / side effects of different classes of NMDA receptor antagonist [<xref ref-type="bibr" rid="R76">76</xref>]. </p><p>Interestingly, there is one clinical study conducted on 140 stroke patients showing a beneficial effect of memantine given i.v. at 20 mg/kg for 5 days following stroke [<xref ref-type="bibr" rid="R66">66</xref>]. </p><p>In more recent preclinical reports, memantine (10 mg/kg) reduced neurological deficits and infarct volume when applied 15 minutes after three hours of middle coronary artery (MCA) occlusion in a temporary focal cerebral ischemia model [<xref ref-type="bibr" rid="R89">89</xref>]. In addition, memantine attenuated brain edema formation and BBB permeability. Additionally, memantine (20 mg/kg once daily i.p. for 3 days, first treatment started 30 min after the induction of intracerebral hemorrhage - ICH) caused a 47% reduction of hemorrhage volume, coupled with an inhibitory effect on the tissue plasminogen activator/urokinase plasminogen activator and matrix metalloproteinase-9 level in a rodent model of ICH (stereotaxic intrastriatal administration of type IV bacterial collagenase). This memantine treatment was also found to reduce inflammatory infiltration and apoptosis and was also determined to induce functional recovery after ICH [<xref ref-type="bibr" rid="R145">145</xref>]. </p><p>Memantine (20 mg/kg i.p. 30 mins post infarct followed by 1 mg/kg b.i.d. for 48 hours) reduced infarct volumes (37 mm<sup>3</sup> c.f. 81mm<sup>3</sup> for controls) in a photothrombotic model of ischemia / stroke [<xref ref-type="bibr" rid="R263">263</xref>]. In a similar treatment paradigm, memantine was also effective against 2 hours of MCA occlusion in spontaneously hypertensive rats [<xref ref-type="bibr" rid="R45">45</xref>,<xref ref-type="bibr" rid="R60"> 60</xref>,<xref ref-type="bibr" rid="R285"> 285</xref>]. Even this apparently relatively high dose of memantine was reported to have no negative effect on learning in the Morris maze whereas (+)MK-801 1 mg/kg blocked learning [<xref ref-type="bibr" rid="R262">262</xref>]. However, there were errors in the rationale for these experiments &#x02013; the memantine group was only on twice daily maintenance doses of 1 mg/kg (the necessity of which for the neuroprotective activity was not demonstrated) at the time of memory testing 72 hours after the high dose 20 mg/kg bolus which clearly, and not surprisingly, provided protection against the acute insult.</p><p>In 7-day-old newborn rats, memantine (20 mg/kg) had long term functional neuroprotective effects against learning deficits in the Morris maze when administered immediately following global hypoxic-ischemic brain injury and assessed 3-4 weeks later [<xref ref-type="bibr" rid="R82">82</xref>].</p><p>In a rabbit acute embolic infarct model, bolus i.v. injections of memantine at 1 mg/kg and 10 mg/kg did not alter the P(50) value and memantine and a dose of 25 mg/kg was lethal (NB: P(50) value = the amount of microclots (in mg) that produce neurological dysfunction in 50% of a group of animals). However, slowly infused memantine (25 mg/kg over 60 mins) significantly and substantially increased the P(50) value even when started 60 min following embolization. Memantine administered 180 min following embolization also increased the P(50) value but the response was more variable [<xref ref-type="bibr" rid="R144">144</xref>].</p><p>Memantine (5 mg/kg) showed no neuroprotection to mitigate cerebral injury after hypothermic circulatory arrest in a porcine model [<xref ref-type="bibr" rid="R227b">227b</xref>].</p></sec><sec><title>TBI</title><p>Memantine (10 and 20 mg/kg, i.p.) showed neuroprotection after traumatic brain injury (TBI) induced in adult rats with a controlled cortical impact device. TBI led to significant neuronal death in the hippocampal CA2 and CA3 regions (by 50 and 59%, respectively), by 7 days after the injury. Treatment of rats with memantine immediately after the injury significantly prevented the neuronal loss in both CA2 and CA3 regions [<xref ref-type="bibr" rid="R221">221</xref>]. Memantine (10 mg/kg, i.p. 15 min after trauma) also significantly reduced lipid peroxidation levels in a rat model of closed head trauma in rats [<xref ref-type="bibr" rid="R194">194</xref>].</p></sec></sec><sec><title>Models of Chronic Excitotoxicity</title><p>In a murine model of amyotrophic lateral sclerosis (ALS, SOD1(G93A) mice), memantine treatment (10 mg/kg b.i.d. s.c. starting on postnatal day 70 until end point) caused a significant, but very moderate delay in disease progression and also moderately increased the life span [<xref ref-type="bibr" rid="R283">283</xref>].</p></sec><sec><title>Glaucoma</title><p>In macaque monkeys, systemic treatment with memantine 4 mg/kg/day p.o. for 16 months was both safe and effective for reduction of functional loss associated with experimental glaucoma - argon laser treatment of the anterior chamber angle, whilst having no effect on intraocular pressure (IOP). These functional effects were seen at 3 and 5 months but not 16 months after an elevation of the intraocular pressure [<xref ref-type="bibr" rid="R95">95</xref>-<xref ref-type="bibr" rid="R97">97</xref>]. Moreover, histological measurements showed that this memantine treatment still promoted retinal ganglion cell (RGC) survival even at the 16 month observation period [<xref ref-type="bibr" rid="R96">96</xref>]. Furthermore, memantine improved tomographic measurements of nerve head topography taken at 3, 5 and 10 months after an elevation of IOP. The same group and others [<xref ref-type="bibr" rid="R91">91</xref>,<xref ref-type="bibr" rid="R97"> 97</xref>] could also show similar results in a rat model for experimental glaucoma, where systemic treatment with memantine (10 mg/kg/day) was associated with a significant reduction in glaucoma-induced loss of retinal ganglion cells.</p><p>Memantine 5 mg/kg i.p. following optic nerve crush in rats caused a two-fold increase in compound action potential amplitude and a 1.7-fold increase in survival of RGCs respectively, two weeks after injury [<xref ref-type="bibr" rid="R298">298</xref>]. Memantine (10 mg/ kg/day <italic>via</italic> osmotic minipumps for three weeks) reduced ganglion cell loss to 12% when applied immediately after insult in a chronic ocular hypertension model induced by laser photocoagulation of episcleral and limbal veins. The same treatment also prevented any further loss when started 10 days after the first laser photocoagulation [<xref ref-type="bibr" rid="R298">298</xref>]. Memantine (5 mg/kg) significantly reduced ganglion cell loss after optic nerve crush in rats and memantine (1 &#x000b5;M) blunted the rise in intracellular calcium seen after administration of glutamate (125 &#x000b5;M) to retinal ganglion cells <italic>in vitro</italic> [<xref ref-type="bibr" rid="R182">182</xref>]. Optic nerve crush in Long-Evans rats led to a rise in extracellular glutamate; this rise was blocked by treatment with memantine 2 mg/kg daily starting 7 days prior to injury and continuing for 7 days thereafter [<xref ref-type="bibr" rid="R281">281</xref>].</p><p>In a model of glaucomatous optic neuropathy in an experimental glaucoma model in the rat, systemically applied memantine was injected intraperitoneally just before trabecular photocoagulation and provided neuroprotection [<xref ref-type="bibr" rid="R91">91</xref>].</p><p>DBA/2J mice spontaneously developed essential iris atrophy, pigment dispersion and glaucomatous changes (including cupping) over time. These changes were prevented by twice daily treatment with memantine 5 mg/kg i.p. for 4, 6 or 9 months, with significant differences to control for the later two time points [<xref ref-type="bibr" rid="R245">245</xref>].</p><p>Memantine 1 mg/kg i.m. once daily for 8 weeks protected against experimental optic nerve ischemia induced by chronic endothelin-1 (0.1 &#x000b5;g/day for 8 weeks <italic>via</italic> minipumps to perineural region of the anterior optic nerve) in rabbits [<xref ref-type="bibr" rid="R121">121</xref>]. In another study, memantine (5 mg/kg, i.p.) given at the onset of ischemia protected the rabbit retina from changes in GABA and ChAT immunoreactivities and induced a recovery of the reduced &#x003b2;-wave of the ERG [<xref ref-type="bibr" rid="R192">192</xref>]. Oral memantine (20 mg/kg) was also neuroprotective in a model of acute retinal ischemia in rabbits. The effect was evident at later follow-up time points as assessed by functional measures, but not by retinal imaging evaluating anatomical hallmarks [<xref ref-type="bibr" rid="R38">38</xref>].</p><p>A very high concentration of memantine (20 &#x000b5;M but not 500 &#x000b5;M) also blocked the increased levels of CaMKII subunits induced by intravitreal injection of glutamate in the adult rat retina [<xref ref-type="bibr" rid="R140">140</xref>].</p><p>In summary, the neuroprotective effects of memantine seen in various animal models of glaucoma seem to be very reproducible and provide a sound basis for the belief that memantine could be clinically neuroprotective in various excitotoxic diseases. As such, the results from ongoing clinical trials in glaucoma are eagerly awaited as a kind of clinical proof of concept.</p></sec><sec><title>Huntington&#x000b4;s Disease</title><p>Following infusion of 3-NP (12 and 24 mg/kg per day over 28 days <italic>via</italic> osmotic minipumps) into the basal ganglia of 24- to 28-month-old female rats, NMDA receptor antagonists, including memantine (24 mg/kg/day also <italic>via</italic> osmotic minipumps), were ineffective [<xref ref-type="bibr" rid="R108">108</xref>], or even increased neurodegeneration. An explanation for this contra-intuitive observation offered by the authors was the hypothesis that progressive neurodegeneration induced by low levels of energy may involve NMDA receptor-dependent protection of cells from caspase-mediated apoptosis and enhancement of mRNA levels of neurotrophins in the injured brain. They proposed that prevention of neurotrophin synthesis and the induction of caspase activity by NMDA antagonists may be deleterious for neuronal survival following injuries. However, in internal studies comparing the same age, strain and gender of rats used in this study with young male rats usually used for pharmacodynamic studies, plasma levels of memantine were 4.4 &#x000b1; 1.6 &#x000b5;M versus 1.3 &#x000b1; 0.24 &#x000b5;M with the same dosing regime (see below). As such, interpretation of the potential therapeutic consequences implied by the conclusions of this study is problematic. However, in a recent study, it has been shown that memantine (0.05&#x02013;2.0 &#x003bc;M) did not induce any cytotoxic effect but attenuated the stauro-sporine-induced caspase-3 activity and LDH release in hippocampal cultured neurons <italic>in vitro</italic> [<xref ref-type="bibr" rid="R111">111</xref>]. The mematine-induced neuroprotection was more efficient in the hippocampal neurons than in the neocortical and striatal ones, which points to tissue specificity of effects of this neuroprotectant.</p><p>A small clinical study in Huntington&#x02019;s patients already gave some indication for the neuroprotective activity of memantine in the clinical setting [<xref ref-type="bibr" rid="R16">16</xref>] giving a very good reason to follow this indication from a preclinical perspective.</p></sec><sec><title>Multiple Sclerosis</title><p>Semi-prophylactic administration of a very high dose of memantine (60 mg/kg p.o. from day 7 post-inoculation (PI)) significantly restored BBB integrity, reduced symptoms, and limited inflammatory lesions in a rodent of multiple sclerosis - experimental allergic encephalomyelitis (EAE) in Lewis rats - when assessed 12 days PI [<xref ref-type="bibr" rid="R204">204</xref>]. In this study, therapeutic application of memantine was found to be as effective as semi-prophylactic dosing [<xref ref-type="bibr" rid="R204">204</xref>]. It should be stressed that the doses used in this study were very high.</p></sec><sec><title>HIV Dementia</title><p>In an animal model of human immunodeficiency virus type 1-associated (HIV-1-associated)dementia - severe combined immuno-deficient (SCID)mouse model of HIV-1 encephalitis (HIVE) &#x02013; memantine (5 mg/kg, i.p. daily for 7 days) reversed the deficits observed in synaptic transmission and long-term potentiation (LTP)in the CA1 region of hippocampal brain slices <italic>ex vivo</italic> [<xref ref-type="bibr" rid="R8">8</xref>]. <italic>In vitro</italic> neurotoxicity of the HIV-1 proteins Tat and gp120 was completely blocked by memantine (2 &#x000b5;M) [<xref ref-type="bibr" rid="R183">183</xref>], presumably by lowering gp120-induced increase Ca<sup>2+</sup> concentrations in neurons [<xref ref-type="bibr" rid="R103">103</xref>].</p></sec><sec><title>Lupus</title><p>The autoimmune antibody R4A present in Lupus patients binds to the channel mouth domain of NR2A and NR2B and increases NMDA receptor EPSCs in a voltage-independent manner [<xref ref-type="bibr" rid="R106">106</xref>]. In this study, the antibody occluded LTP without affecting PPF or AMPA receptors and was toxic and caused memory deficits. These effects provide strong support for the signal-to-noise hypothesis for NMDA receptor dysfunction in synaptic plasticity. Indeed, memantine 5 mg/kg i.p. 30 minutes prior to LPS prevented hippocampal damage in a murine model of lupus (MAP-peptide immunization followed by LPS administration) [<xref ref-type="bibr" rid="R132">132</xref>].</p></sec><sec><title>Chemotherapy</title><p>New data indicate the potential of memantine for the prevention of cognitive impairment produced by cancer therapy treatment. The effect of vincristine - (known to damage neurons), cytarabine &#x02013;(known to produce damage in the cerebellum) and L-asparaginase&#x02013; (known to be toxic through production of ammonia) were studied in rats in tests for exploration/cognition such as the hole board and water radial maze. In all models, clear impairment was noted which was prevented by chronic (14 days) treatment with memantine (10 mg/kg/day) when the test was done 24h after the last memantine dose [<xref ref-type="bibr" rid="R276">276</xref>].</p></sec></sec><sec><title>Symptomatological Activity</title><sec><title>Pain</title><sec><title>Inflammatory Pain</title><p>Memantine (1 mg/kg i.p.) was very effective (75% reduction) in blocking the second phase of pain related behaviour following i.pl. injection of formalin in mice whilst having no effect on motor coordination in the rotarod test [<xref ref-type="bibr" rid="R20">20</xref>]. In contrast, although memantine suppressed biting / licking behaviours in the formalin test in rats at 10 and 30 mg/kg there was no effect at 3 mg/kg or on flinching behaviours [<xref ref-type="bibr" rid="R241">241</xref>]. These same doses also reduced the degree of paw swelling in response to i.pl. formalin [<xref ref-type="bibr" rid="R241">241</xref>]. In relation to this finding, although only tested at therapeutically irrelevant doses, memantine inhibited the proliferation of synoviocytes <italic>in vitro</italic> with an IC<sub>50</sub> of 65&#x000b5;M [<xref ref-type="bibr" rid="R195">195</xref>]. In studies from a different group using the same model in mice [<xref ref-type="bibr" rid="R279">279</xref>], memantine only preferentially inhibited the late phase at a very high dose of 20 mg/kg i.p. &#x02013; this clearly contrasts with a relatively large literature and the additional studies cited above. However, in [<xref ref-type="bibr" rid="R279">279</xref>] memantine produced a partial reversal of both thermal and mechanical hyperalgesia in rats (minimum effective dose (MED) of 10 and 15 mg/kg i.p., respectively) following intraplantar injection of carrageenan [<xref ref-type="bibr" rid="R279">279</xref>].</p><p>In rats, very high therapeutic doses of memantine (21.5 to 46.4 mg/kg i.p.; ED<sub>50 </sub>35.2 &#x000b1; 4.7 mg/kg at the peak effect) dose-dependently increased the mechanical nociceptive threshold in a model of inflammatory pain (i.pl. carrageenan) and inhibited single motor unit wind-up evoked by noxious electrical stimulation [<xref ref-type="bibr" rid="R46">46</xref>]. Injection of memantine (0.1 mg, 0.2 mg, and 1 mg) into the knee joint immediately before carrageenan injection (2%, 40 &#x000b5;L), but not when administered i.p., significantly prevented pain-related behaviours in rats [<xref ref-type="bibr" rid="R308">308</xref>]. The intra-articular injection of memantine (0.2 mg) also suppressed c-Fos expression in the laminae I-II and laminae V-VI at the L3-4 spinal level and the degree of the spinal c-Fos expression was correlated with the extent of the pain-related behaviour [<xref ref-type="bibr" rid="R308">308</xref>].</p></sec><sec><title>Neuropathic Pain</title><p>In a model of diabetic neuropathy, memantine (15 mg/kg i.p.) produced a symptomatic antinociceptive effect, whereas the &#x0201c;gold standard&#x0201d; gabapentin (100 mg/kg p.o.) had no significant effect [<xref ref-type="bibr" rid="R279">279</xref>].</p><p>Memantine showed dose-dependent (1.8-17.8 mg/kg) symptomatic, anti-allodynic activity in the Bennett model of chronic constriction injury (CCI) [<xref ref-type="bibr" rid="R161">161</xref>,<xref ref-type="bibr" rid="R170"> 170</xref>] but there was little separation between anti-allodynic and rotarod effects. Co-administration with morphine or clonidine, each at 6 fixed equi-effective dose ratios, was not able to reveal any supra-additive i.e. synergistic effects (isobolographic analysis) [<xref ref-type="bibr" rid="R161">161</xref>]. In contrast, in this same sciatic nerve injury model, memantine had no symptomatic effects against either cold and mechanical allodynia &#x02013; it should be noted that gabapentin was also inactive against mechanical allodynia in this study, but was active against cold allodynia [<xref ref-type="bibr" rid="R279">279</xref>].</p><p>Spontaneous ongoing single unit activity of spinal cord neurones in anesthetized rats two weeks following L5/6 spinal nerve ligation showed high sensitivity to gabapentin (s.c.) and morphine (i.t.) administration, being significantly reduced in a dose-depen-dent manner [<xref ref-type="bibr" rid="R266">266</xref>]. In contrast, morphine administered <italic>via</italic> the systemic route (1, 3 and 6 mg/kg i.v.) produced only modest and non-significant reductions of spontaneous activity. Similarly, memantine (1, 5 and 20 mg/kg i.v.) produced only minor effects at doses known to be effective on wind-up in a very similar model from the same group [<xref ref-type="bibr" rid="R267">267</xref>].</p><p>Intrathecal injection of memantine (300 nmol) significantly inhibited CCI-induced mechanical allodynia [<xref ref-type="bibr" rid="R181">181</xref>] although this route of administration is very unlikely to have any therapeutic relevance for memantine.</p></sec><sec><title>Visceral Pain</title><p>[<xref ref-type="bibr" rid="R190">190</xref>] explored the role of NMDA receptors in processing acute visceral noxious input, compared with somatic noxious input. Cardiovascular responses to graded uretal distensions or graded pinch stimuli to one hind-paw were inhibited by memantine (4-32 mg/kg, i.v.) with an ID<sub>50</sub> of 14.5 &#x000b1; 1.3 mg/kg, but these results were concluded to be due to a non-specific action. Similarly, a high intravenous dose of memantine (16 mg/kg) inhibited nociceptive responses of neurones in the L6-S2 spinal dorsal horn evoked by urinary bladder distension to 27% of control [<xref ref-type="bibr" rid="R41">41</xref>]. This effect was selective for neurones subject to inhibition from non-segmental cutaneous inputs (type I neurons).</p><p>Behavioural pain responses to visceral noxious mechanical stimulation were inhibited in a reversible, dose-dependent manner by intravenous administration of memantine (1-10 mg/kg, i.v.) [<xref ref-type="bibr" rid="R168">168</xref>]. Single fibre recordings of decentralized pelvic nerves showed that colorectal distension responsive afferent nerve activity was also inhibited by memantine [<xref ref-type="bibr" rid="R168">168</xref>]. Memantine i.v. dose-dependently attenuated the action potential firing of vagal afferent fibres innervating the rat stomach response to antral distension in anesthetized rats with an ID<sub>50</sub> of around 2.5 mg/kg indicating possible peripheral antinociceptive therapeutic utility in visceral pain [<xref ref-type="bibr" rid="R248">248</xref>]. In contrast, memantine (10&#x02013;30 &#x000b5;M) did not affect spontaneous or stretch-evoked firing rate of guinea pig oesophageal or rectal mechanoreceptors recorded extracellularly <italic>in vitro</italic>, whereas some inhibitory effect was seen with very high concentrations (100-300 &#x000b5;M) [<xref ref-type="bibr" rid="R302">302</xref>,<xref ref-type="bibr" rid="R303"> 303</xref>].</p></sec><sec><title>Opioid Tolerance</title><p>Morphine analgesia in the formalin test was increased by memantine (5mg/kg i.p.) [<xref ref-type="bibr" rid="R249">249</xref>]. Pretreatment with memantine (2.5-15 mg/kg) also significantly and dose-dependently potentiated morphine-induced, but not fentanyl-induced [<xref ref-type="bibr" rid="R213">213</xref>], acute antinociception in the tail flick test [<xref ref-type="bibr" rid="R134">134</xref>,<xref ref-type="bibr" rid="R212"> 212</xref>,<xref ref-type="bibr" rid="R213"> 213</xref>]. Following an acute morphine challenge, memantine also enhanced morphine antinociception when tests were conducted 120 but not 30 minutes post-mor-phine [<xref ref-type="bibr" rid="R18">18</xref>]. In contrast, others reported that memantine (3 and 10 mg/kg i.p.) had no effect on acute morphine or fentanyl analgesia in the same model [<xref ref-type="bibr" rid="R223">223</xref>] &#x02013; drugs effects averaged over 0.5 to 4.5 hrs.</p><p>All of these findings might indicate that the apparent synergistic antinociceptive effects could depend on the duration of the pain and the pharmacokinetics of the opioid &#x02013; morphine has a much longer <italic>in vivo</italic> half life than fentanyl &#x02013; and the associated development of rapid tolerance [<xref ref-type="bibr" rid="R136">136</xref>]. Indeed, confirmation for the prevention of morphine tolerance was seen following repeated administration of low-dose morphine (5 mg/kg, 8 days, once a day) - tolerance to morphine analgesia was prevented by memantine (10 and 30 mg/kg) but not dizocilpine (1 mg/kg) [<xref ref-type="bibr" rid="R61">61</xref>]. Memantine (3 or 10 mg/kg) treatment also prevented morphine tolerance in the tail-flick test in pro-oestrous female rats and in ovariectomized rats receiving 17-beta-estradiol [<xref ref-type="bibr" rid="R252">252</xref>]. Similarly, memantine treatment inhibited both the acute antinociceptive effect of morphine and reversed morphine tolerance in morphine-tolerant mice [<xref ref-type="bibr" rid="R214">214</xref>]. </p><p>Memantine (7.5 mg/kg but not 2.5 mg/kg) as well as the metabotropic glutamate receptor type 5 antagonist MPEP (30 mg/kg but not 10 mg/kg) attenuated the development of tolerance to morphine-induced acute thermal antinociception in mice. When given together, the low doses of MPEP (10 mg/kg) and memantine (2.5 mg/kg) also significantly attenuated opiate tolerance. None of the treatments with glutamate antagonists produced antinociceptive effects or significantly affected acute morphine-induced antinociception in the tail flick test [<xref ref-type="bibr" rid="R135">135</xref>].</p><p>The antinociceptive effects of the peripherally restricted opioid agonist loperamide (3-10 mg/kg) in the formalin test were enhanced by memantine (3 mg/kg) but not by NMDA receptor antagonists that don&#x000b4;t penetrate the blood brain barrier suggesting that central NMDA receptor blockade may be necessary to enhance analgesia induced through peripheral opioid mechanisms [<xref ref-type="bibr" rid="R250">250</xref>].</p></sec></sec><sec><title>Drug Dependence</title><sec><title>Opioids</title><p>In accordance with previous literature, memantine (10 mg/kg or 46.3 &#x000b5;mol/kg, i.c.v.) inhibited naloxone-induced jumping in morphine-dependent mice [<xref ref-type="bibr" rid="R286">286</xref>]. Memantine attenuated (5 mg/kg) and even completely blocked (10 mg/kg) the expression of withdrawal-potentiated startle during naloxone (2.5 mg/kg)-precipitated withdrawal from a single dose of morphine sulphate (10 mg/kg). Memantine (2.5 or 5 mg/kg) also blocked expression of withdrawal-induced hyperalgesia [<xref ref-type="bibr" rid="R98">98</xref>] and the occurrence of withdrawal-induced aggressive behaviour at doses of 1-30 mg/kg [<xref ref-type="bibr" rid="R264">264</xref>].</p><p>Memantine (5 and 10 mg/kg) inhibited both the acquisition and expression of conditioned place aversion (CPA) during withdrawal in morphine-dependent rats and also reduced the intensity of the physical signs of withdrawal. When morphine was co-administered with memantine, the animals did not develop CPA and presented less intensity in the physical signs of morphine withdrawal [<xref ref-type="bibr" rid="R159">159</xref>]. However, in another study where morphine (20 mg/kg) pre-treatment significantly potentiated the ability of naloxone (0.01-0.3 mg/kg) to produce place aversion in mice [<xref ref-type="bibr" rid="R31">31</xref>], this effect was attenuated by D-CPPene (1 and 3 mg/kg) but not by memantine (1-10 mg/kg).</p><p>Memantine (2.5-40 mg/kg) produced neither place preference nor place aversion, but the higher doses of memantine tested (20 and 40 mg/kg) were able to completely block morphine-induced conditioned place preference [<xref ref-type="bibr" rid="R225">225</xref>]. Memantine (7.5 mg/kg i.p.) treatment during extinction conditioning abolished the ability of drug-related cues (priming dose of morphine) to evoke reinstatement, suggesting that this NMDA receptor antagonist can be useful in preventing relapse in opioid dependent individuals [<xref ref-type="bibr" rid="R216">216</xref>]. Similar effects were seen with higher doses (20 and 40 mg/kg) in a murine model of reinstatement behaviour [<xref ref-type="bibr" rid="R226">226</xref>].</p><p>In addition, memantine (0.3-10 mg/kg) suppressed the self-administration of morphine (0.125-4.0 mg/kg) in rats, whereas MK-801 (0.1 mg/kg) was ineffective [<xref ref-type="bibr" rid="R247">247</xref>].</p><p>However, memantine (7.5 mg/kg) inhibited the expression of place preferences conditioned with both morphine and sexual encounter, but had no effects in food-conditioned mice [<xref ref-type="bibr" rid="R215">215</xref>,<xref ref-type="bibr" rid="R217"> 217</xref>]. Additionally, memantine (1, 3 or 10 mg/kg) dose-dependently reduced the expression of acute defensive behaviours (assessed using the social interaction paradigm) while increasing motor activity during caffeine withdrawal in mice [<xref ref-type="bibr" rid="R265">265</xref>]. These findings suggest that the effects of NMDA receptor blockade may not be limited to abused drug-reinforced behaviours [<xref ref-type="bibr" rid="R217">217</xref>]. Since memantine administration produced an antiaggressive effect only at doses that affected locomotion (20 and 40mg/kg), it is unlikely that the glutamatergic system mediates the antiaggressive actions of morphine [<xref ref-type="bibr" rid="R228">228</xref>].</p><p>There are also positive clinical data which are beyond the scope of this review to discuss in detail [<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R137"> 137</xref>].</p></sec><sec><title>Cocaine</title><p>Memantine (10 and 40 mg/kg) reverted cocaine-induced social withdrawal and the increase in avoidance and flight / escape in paired male mice [<xref ref-type="bibr" rid="R153">153</xref>]. Acquisition and expression of cocaine-induced place preference was prevented by memantine (7.5 mg/kg, i.p.) but not by the partial glycine<sub>B</sub> site agonist ACPC (50 mg/kg, i.p.) [<xref ref-type="bibr" rid="R131">131</xref>].</p><p>Memantine (1-10 mg/kg) attenuated expression of cocaine-conditioned motor activity at doses that did not significantly affect spontaneous motor activity [<xref ref-type="bibr" rid="R23">23</xref>] and reversed behavioural sensitization, an animal model for the intensification of drug craving in cocaine addiction [<xref ref-type="bibr" rid="R151">151</xref>]. An effective combination was the administration of memantine with the D<sub>2</sub>-preferring DA agonist pergolide (0.08 mg/kg). Reinstatement of cocaine-seeking behaviour may be disrupted by either D-CPPene (0.3-3 mg/kg) or memantine (1-10 mg/kg). However, their effects seem to depend on the reinstating procedure (cocaine injection versus presentation of cocaine-associated cues) and route of cocaine administration (systemic versus intracerebral), as well as upon their own motor stimulant effects [<xref ref-type="bibr" rid="R23">23</xref>].</p><p>Memantine (2.5-20 mg/kg i.p.) dose-dependently decreased cocaine self-administration in rats trained to self-administer cocaine (0.25 mg/infusion). Under a progressive ratio (PR) schedule, MK-801 (0.15 mg/kg i.p.) increased the number of cocaine infusions in a manner similar to increasing the unit dose of cocaine, suggestive of potentiation of cocaine reward. Conversely, memantine (10 mg/kg i.p.) produced rate-decreasing effects on the PR schedule [<xref ref-type="bibr" rid="R107">107</xref>]. Similarly, pre-treatment with memantine protected against cocaine-induced convulsions with an ID<sub>50</sub> of 16mg/kg [<xref ref-type="bibr" rid="R33">33</xref>].</p><p>Memantine (0.3-3 mg/kg <italic>via</italic> i.v. infusion) was tested in Rhesus monkeys trained to press levers reinforced with either cocaine-associated stimuli or 30 &#x000b5;g/kg cocaine infusion. The results were taken to suggest that memantine may indeed attenuate the conditioned reinforcing effects of cocaine-associated stimuli, but may also increase levels of cocaine self-administration [<xref ref-type="bibr" rid="R185">185</xref>].</p><p>Amphetamine-induced increases in carrier-mediated dopamine release in slices of rat nucleus accumbens (NAcc) and this effect was reversed to control levels by memantine (1&#x000b5;M), but not by (+)MK-801 (0.1 and 1 &#x000b5;M). The authors ascribe this difference to a possible involvement of NR1a/ NR2D subunits in this tissue and suggest possible therapeutic relevance for treating drug dependence [<xref ref-type="bibr" rid="R56">56</xref>].</p><p>There are also clinical data indicating a lack of abuse liability in cocaine addicts which are beyond the scope of this review to discuss in detail [<xref ref-type="bibr" rid="R50">50</xref>,<xref ref-type="bibr" rid="R282"> 282</xref>].</p></sec><sec><title>Ethanol</title><p>Acute administration of memantine (10 mg/kg i.p.) induced an upregulation of NR1-1/NR1-2 and NR2B protein levels in the hippocampus and cortex, respectively [<xref ref-type="bibr" rid="R219">219</xref>]. Interestingly, this modulation of subunit expression was similar to the anti-craving compound acamprosate. Additionally, ethanol (50 mM) - induced upregulation of NMDA receptor protein (NR1, NR2A and NR2B) in cultured rat hippocampal neurons, was completely prevented by memantine (10 &#x000b5;M for 5 days; [<xref ref-type="bibr" rid="R160">160</xref>]).</p><p>Withdrawal from chronic (6 month) alcohol ingestion produced robust learning deficits in rats in the Morris water maze. Treatment with memantine starting at the beginning of the withdrawal phase (20 mg/kg bolus followed by 1 mg/kg every 12 h for 4 weeks) resulted in a complete reversal of these behavioural impairments [<xref ref-type="bibr" rid="R158">158</xref>]. In a similar model, memantine also dose-dependently (1-10 mg/kg, i.p.) suppressed ethanol withdrawal seizures [<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R130"> 130</xref>]. Repeated memantine administration decreased the acute motor impairing effects of ethanol [<xref ref-type="bibr" rid="R186">186</xref>].</p><p>Koros and collegues [<xref ref-type="bibr" rid="R125">125</xref>] assessed the effects of restraint stress and memantine (2.25 or 4.5 mg/kg) on the dose-response curve of ethanol discrimination. Stress did not alter the rate of responding. However, both doses of memantine tended to increase the rate of responding when given in combination with lower doses of ethanol (0.25-0.5 g/kg). In contrast, 4.5 mg/kg memantine decreased the response rate when combined with 1 g/kg ethanol. These results suggest that: (1) pre-exposure to acute restraint stress or memantine does not affect the dose-response curve of ethanol discrimination; (2) memantine given in combination with low doses of ethanol may enhance the discriminative stimulus of ethanol but inhibits at high ethanol doses. Accordingly, the memantine-induced decrease in experimental ethanol craving [<xref ref-type="bibr" rid="R104">104</xref>] may not be related to alterations in the cueing properties of ethanol. </p><p>Memantine (13 mg/kg per day) also prevented the increase in the consumption of saccharin after a 1-week deprivation from free-choice, unlimited access to saccharin (0.1%, w/v) [<xref ref-type="bibr" rid="R306">306</xref>] indicating that the previously observed inhibitory action in a similar model following alcohol deprivation can be extended to other conditions of excessive drug/alcohol/ food intake. However, studies on the behavioural specificity of memantine on alcohol drinking in a schedule-induced polydipsia (SIP) task in C57BL/6J mice indicate that drug induced reduction in alcohol drinking was associated with other behavioural effects that included reduction in regulatory drinking, bringing into doubt the therapeutic possibility for ameliorating human alcohol addiction [<xref ref-type="bibr" rid="R68">68</xref>]. Finally, when administered concurrently with binge ethanol exposure, cannabidiol and antioxidants protected against hippocampal and entorhinal cortical neurodegeneration in a dose-dependent fashion whereas memantine (30 mg/kg/ day as 6*5 mg/kg) was without effect [<xref ref-type="bibr" rid="R94">94</xref>].</p><p>Nonetheless, there are some positive clinical data which are beyond the scope of this review to discuss in detail [<xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R138"> 138</xref>].</p></sec><sec><title>Epilepsy</title><p>Memantine effectively prevented both clonic and tonic components of pentylenetetrazole-induced (35 mg/kg i.p.) kindling starting at a dose of 3 mg/kg i.p. [<xref ref-type="bibr" rid="R156">156</xref>]. Similar effects were seen against NMDA convulsions whereas ataxic side effects were first seen at doses some 6-fold higher [<xref ref-type="bibr" rid="R157">157</xref>,<xref ref-type="bibr" rid="R235"> 235</xref>].</p></sec><sec><title>Anxiety</title><p>In our review from 1999 the available data did not give support for anxiolytic activity of memantine in animal models that could possibly be translated into efficacy in humans. Newer data have since been published that support this notion. Memantine (1.25 - 5 mg/kg i.p.) was also inactive in a different rat model of anxiety to those previously reported for memantine - the conditioned emotional response [<xref ref-type="bibr" rid="R175">175</xref>]. Moreover, in an illuminated platform avoidance task in rats, memantine (20 &#x000b5;g), injected into the ventromedial hypothalamus, actually increased anxiety [<xref ref-type="bibr" rid="R270">270</xref>]. Similarly, memantine 5 mg/kg/i.p. daily for 7 days had no effect on stress-induced increases in hippocampal nitrogen oxides in an animal model of post-traumatic stress disorder (sequential exposure of the animals to restraint stress, forced swim stress and finally halothane vapours, followed 7 days later with a brief re-stress forced swimming) [<xref ref-type="bibr" rid="R99">99</xref>].</p><p>However, memantine (4.0 and 8.0 mg/kg) did show anxiolytic effects in rats in the elevated plus-maze (EPM) in a study by [<xref ref-type="bibr" rid="R21">21</xref>] and these effects, as for other anxiolytic compounds tested, diminished after repeated testing exposure but not after repeated drug administration i.e. after adoption of an anxiolytic-insensitive behavioural strategy by the animals &#x02013; the so called 'one-trial tolerance' phenomenon. Scopolamine (0.5-1.5 mg/kg) impaired the acquisition of this behavioural strategy to cope with the subsequent EPM exposure and thereby revealed the anxiolytic-like effects of memantine in a repeat trial [<xref ref-type="bibr" rid="R22">22</xref>]. </p></sec></sec><sec><title>Depression</title><p>Memantine produced a dose-dependent (2.5-15 mg/kg) antidepressant-like effect in the tail-suspension test; and the antidepressant-like effect of the highest memantine dose of 15 mg/kg appeared to persist with sub-chronic administration of memantine (3 days, twice daily) [<xref ref-type="bibr" rid="R126">126</xref>]. In the same study, when administered acutely 5 min before testing in the open field, memantine reduced rearing (1.875-30 mg/kg), ambulation (7.5 and 30 mg/kg) and grooming (30 mg/kg). As measured in three different tests, ataxia and stereotypy appeared only at the single highest dose of 30 mg/kg, 5 and 35 min after administration. In mice treated for 3 days, twice daily, the dose of 30 mg/kg continued to increase ambulation and decrease rearing and grooming, but no signs of ataxia and stereotypy were detected. These data indicate that different doses of memantine are required for therapeutic and side-effects, and that tolerance may develop to some of the side effects e.g. ataxia, but not to therapeutic effects e.g. antidepressant-like actions [<xref ref-type="bibr" rid="R126">126</xref>].</p><p>Memantine (1-3mg/kg) also produced antidepressant-like effects in the forced swimming test (FST) in mice that seemed to be mediated through an interaction with the l-arginine-NO-cGMP pathway [<xref ref-type="bibr" rid="R5">5</xref>] and dependent on the cellular signalling modulated by PKA, CaMKII and MAPK/ERK, but not by PKC [<xref ref-type="bibr" rid="R6">6</xref>].</p><p>Memantine (2.5 and 5 mg/kg) showed synergistic antidepressant activity when combined with imipramine, venlafaxine and fluoxetine in the FST in rats [<xref ref-type="bibr" rid="R232">232</xref>]. Moreover, memantine (10 mg/kg) prevented the development of hyperthermia and the increase in noradrenaline levels in the anterior hypothalamus following administration of serotonin (100 mg/kg) and clorgyline (2 mg/kg) &#x02013; an animal model of serotonin syndrome, one of the most serious side effect of some classical antidepressants [<xref ref-type="bibr" rid="R188">188</xref>]. Combination of sigma ligands with memantine at low doses that were without effect on their own (SA4503 1-10 mg/kg; siramesine 1-3 mg/kg; 1,3 di-0-tolylguanidine (DTG) 2.5 and 5 mg/kg; memantine 2.5 mg/kg i.p.) also decreased immobility time in the FST in rats [<xref ref-type="bibr" rid="R255">255</xref>,<xref ref-type="bibr" rid="R256"> 256</xref>]. This effect was antagonized by sigma receptor antagonists. </p><p>However, memantine (10 mg/kg i.p.) had no effect on the CNS expression pattern of the vesicular glutamate transporter VGLUT1, upregulation of which has been proposed to be a useful marker for antidepressant activity [<xref ref-type="bibr" rid="R178">178</xref>]. Most importantly, in a small, double-blind, placebo-controlled clinical study, in 30 subjects with major depression, memantine (5-20 mg/day) (n = 14) for 8 weeks failed to show a significant antidepressant effect compared to placebo (n= 16) [<xref ref-type="bibr" rid="R307">307</xref>]. </p></sec><sec><title>Parkinson&#x000b4;s Disease</title><p>As previously well documented, memantine was confirmed to block haloperidol-induced catalepsy starting at a dose of 3.5 mg/kg i.p. [<xref ref-type="bibr" rid="R236">236</xref>]. In control and MPTP treated mice, memantine (5 mg/kg i.p.) had no significant effect on dopamine or 3,4-dihydroxyphenyl-acetic acid (DOPAC) levels [<xref ref-type="bibr" rid="R84">84</xref>]. However, homovanillic acid in MPTP-treated mice was claimed to be increased by 300% and this effect was attributed to possible sparing of dopaminergic neurons &#x02013; but there were some discrepancies in the tabular data (e.g. the methods state 5 mg/kg but the legends state 0.5 mg/kg) [<xref ref-type="bibr" rid="R84">84</xref>].</p><p>Intranigral administration of glutamate to rats with Parkinsonian syndrome induced by MPTP augmented the development of Parkinsonian symptoms (oligokinesia and muscular rigidity), but did not affect motor activity of intact animals [<xref ref-type="bibr" rid="R139">139</xref>]. Memantine administered i.p. in parallel with the induction of Parkinsonian syndrome weakened the development of oligokinesia and muscular rigidity in a dose-depen-dent manner starting from 5 mg/kg and abolished the toxic effect of glutamate [<xref ref-type="bibr" rid="R139">139</xref>]. </p><p>In the substantia nigra and corpus striatum of reserpine-treated rats, acute injection of memantine (40 mg/kg) strongly increased L-DOPA decarboxylase (DDC), whilst not affecting or decreasing 5- HTPDC activity [<xref ref-type="bibr" rid="R72">72</xref>]. L-DOPA (25 mg/kg) on its own inhibited both enzymes in either brain region. The ability to increase the activity of DDC could be clinically important in the treatment of Parkinson&#x02019;s disease, where the disappearance of DDC caused by the degeneration of nigrostriatal dopamine could contribute to the eventual loss of effectiveness of dopamine replacement therapy with L-DOPA.</p><p>One group suggested a putative benefit of memantine as an anti-Parkinsonian agent on the basis of its synergistic interactions with L-Dopa i.e. following co-administration of memantine (0.3 to 3 mg/kg) with sub threshold (5 mg/kg) or suprathreshold doses (20 mg/kg) of L-Dopa to hypokinesic drug-na&#x000ef;ve or L-DOPA-tolerant MPTP-treated mice [<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R78"> 78</xref>,<xref ref-type="bibr" rid="R79"> 79</xref>]; see also [<xref ref-type="bibr" rid="R13">13</xref>]). </p></sec><sec><title>Tardive Dyskinesia</title><p>Memantine inhibited the development of haloperidol-induced persistent vacuous chewing movements (VCD) and attenuated the increase in preproenkephalin mRNA expression in a rat model of tardive dyskinesia, in which VCM were induced by 20 weeks of haloperidol administration [<xref ref-type="bibr" rid="R10">10</xref>].</p></sec><sec><title>Cancer</title><p>Even though the effective doses of memantine in this section are far beyond therapeutically relevant concentrations, we here summarize the potential effects of memantine against cancer for the sake of completeness.</p><p>When host rats were treated with very high doses of memantine (25 mg/kg twice daily, i.p.), an implanted glioma cell line secreting glutamate (RG2Glu+) responded with a small, but significant, decrease in tumour volume [<xref ref-type="bibr" rid="R269">269</xref>]. Memantine also restricted the growth of C6Glu+ tumours (subcloned C6 cells which also actively release glutamate).</p><p>On the other hand, <italic>in vitro</italic> memantine did not reduce proliferation of cultured C6Glu+ cells or RG2 glioma cells at therapeutically achievable concentrations although a significant reduction in proliferation of both cell types occurred at huge concentrations of 100-400 &#x003bc;M [<xref ref-type="bibr" rid="R269">269</xref>]. Memantine also inhibited <italic>in vitro</italic> growth of ten human cancer cell lines (four prostate, two breast and four colon) with half-maximal growth inhibition at very high concentrations of memantine (23 to 92 &#x000b5;M) [<xref ref-type="bibr" rid="R1">1</xref>]. Finally, a very high concentration of memantine (50&#x000b5;M) caused a rapid and reversible change in melanocyte morphology, which was associated with disorganisation of actin and tubulin microfilaments that could have implications in the treatment of melanoma [<xref ref-type="bibr" rid="R105">105</xref>]. In all cases, the concentrations of memantine required <italic>in vitro</italic> are probably far too high to be of any real therapeutic relevance.</p><p>The open question is therefore the disaccord between the <italic>in vivo</italic> and <italic>in vitro</italic> data. This could be explained by the theory that aggressive CNS tumours make &#x0201c;place&#x0201d; for their own expansion in the brain by releasing glutamate and destroying neurones <italic>via</italic> excitotoxic mechanisms.</p></sec><sec><title>Diabetes</title><p>Memantine (4 mg/kg/day for 8 weeks) prevented loss of gastric NO neurons and reduction of nNOS protein expression in an animal model of diabetes when administered 3 days after induction of diabetes with streptozotocin (STZ) [<xref ref-type="bibr" rid="R193">193</xref>]. Diabetes results in various biochemical abnormalities such as elevation of glutamate in the retina. Post mortem incubation of the retina of diabetic rats with memantine (30 &#x000b5;M) inhibited such elevations [<xref ref-type="bibr" rid="R133">133</xref>].</p></sec><sec><title>Other</title><p>The incidence of myocardial ischemia-induced ventricular tachycardia, ventricular fibrillation and mortality was not modified by treatment of rats with memantine (1.5 mg/kg), injected 5 minutes prior to occlusion. However, the incidence of ventricular tachy-cardia, ventricular fibrillation and mortality induced by myocardial ischemia-reperfusion was significantly reduced by memantine, and MK-801 and ketamine [<xref ref-type="bibr" rid="R53">53</xref>].</p><p>NMDA receptor channel blockade has also been tested on aggression in isolated male mice by the resident-intruder procedure [<xref ref-type="bibr" rid="R17">17</xref>]. Memantine (1-30 mg/kg) inhibited expression of aggressive behaviours only at doses that produced ataxia and thus, does not exert selective effects on aggression.</p></sec></sec></sec><sec><title>SIDE EFFECTS</title><p>Memantine disrupted prepulse inhibition (PPI) in an acoustic startle gating test at high, supra-therapeutic doses (10 and 17 mg/kg i.p.) but not at lower doses of 1 and 3 mg/ kg. Furthermore, the magnitude of this disruption was reduced relative to high-affinity ligands like (+)MK-801 [<xref ref-type="bibr" rid="R295">295</xref>]. Another group showed that memantine (10 mg/kg) actually increased PPI at short prepulse-pulse intervals (10-20 ms), while inhibition was confirmed at longer intervals (60-120 ms). A higher dose (20 mg/kg) had only inhibitory effects. Ketamine produced similar effects but enhancement of PPI was less evident. The effect of memantine was attenuated by an atypical neuroleptic, quetiapine, but not by haloperidol, which seems to be characteristic for NMDA receptor antagonists. This group is planning a study of memantine in humans, where ketamine has an enhancing effect upon prepulse inhibition and a similar effect is expected from memantine [<xref ref-type="bibr" rid="R268">268</xref>].</p><p>Potential modifications of the behavioural profile of memantine following long-term administration was assessed by [<xref ref-type="bibr" rid="R101">101</xref>]. When memantine (20 mg/kg/day) was either infused or repeatedly injected for 14 days, tolerance was observed to the learning impairing and ataxic effects seen at acute high doses after both repeated administration and infusion. Sensitization to the locomotor stimulation was seen only following repetitive injections but not infusion of memantine, which is the therapeutically more relevant route of administration.</p><p>In organotypic hippocampal cultures chronic treatment with memantine at 1&#x000b5;M for 17-23 days had no effect on bicuculline seizures and actually increased cell death in the DG. Similar results were obtained with the competitive and glycine site antagonists APV (50&#x000b5;M) and DCKA (100&#x000b5;M). In contrast, the NR2B selective antagonist Ro-25 6981 (1&#x000b5;M) was protective following chronic, but not acute, administration. It should be noted that the chosen concentration for memantine was close to its therapeutic range whereas that of the NR2B antagonist was far above the IC<sub>50</sub> for NR2B receptors [<xref ref-type="bibr" rid="R284">284</xref>].</p><p>In summary, the additional non-clinical studies conducted with memantine since our review in 1999 did not reveal any new signalss for potential side effects, drug-drug interactions or toxic changes attributable either to memantine or to it&#x02019;s known degradation products for therapeutic doses relevant for the treatment of AD. </p><sec><title>Abuse Potential</title><p>Memantine has been used in clinical practice for over 20 years, during which no cases of abuse have been reported. However, given the fact that memantine has partially overlapping pharmacology with some drugs that are indeed abused (mainly in the USA) such as ketamine or PCP, it is important to analyze data from animal models related to abuse potential of these agents. </p><p>It should be stressed that, based on plasma levels, an acute dose of 5 mg/kg acute or s.c. infusion of 20 mg/kg/day is the maximum dose that can be considered therapeutically relevant in rats since such treatment leads to a ca. 1 &#x000b5;M plasma concentration which is the maximal concentration seen in humans treated therapeutically with memantine [<xref ref-type="bibr" rid="R55">55</xref>].</p><p>In a drug discrimination paradigm in rats based on lever pressing (indicative of subjective drug effects), memantine partially substituted for PCP first at a dose of 10 mg/kg but a 50 % decrease of the response rate was also seen at this dose which probably reflects myorelaxant activity [<xref ref-type="bibr" rid="R240">240</xref>]. In monkeys a similar picture was seen, i.e. memantine produced PCP-like responding only at doses of 5 mg/kg and above, i.e. at doses that produced a decrease in response rate and which are very high doses in this species [<xref ref-type="bibr" rid="R187">187</xref>]. In contrast, the high affinity antagonist (+)MK-801 caused substitution for PCP at doses which did not impair performance.</p><p>Also, in contrast to PCP, memantine did not substitute for cocaine [<xref ref-type="bibr" rid="R240">240</xref>]. However, when site-specific NMDA receptor antagonists were examined against intravenous cocaine self-administration (0.24 mg/infusion), memantine (2.5-20 mg/ kg, i.p.) and MK-801 (0.05-0.2 mg/kg, i.p.) dose-dependently decreased the number of cocaine infusions [<xref ref-type="bibr" rid="R107">107</xref>]. Antagonists at other NMDA receptor sites, L-701,324 (glycine<sub>B</sub>, 1.25-10 mg/kg p.o.) and CGP 39551 (competitive, 2.5-15 mg/kg, i.p.) were without effect. Memantine (0.3-3 mg/kg <italic>via</italic> i.v. infusion) was also tested in Rhesus monkeys trained to press levers reinforced with either cocaine-associated stimuli or 30 &#x000b5;g/kg cocaine infusion. The results were taken to suggest that memantine may indeed attenuate the conditioned reinforcing effects of cocaine-associated stimuli, but may also increase levels of cocaine self-administration [<xref ref-type="bibr" rid="R185">185</xref>].</p><p>Memantine produced only variable self administration in monkeys [<xref ref-type="bibr" rid="R187">187</xref>]. Memantine was 2-3 times less effectively self administered than PCP, and the effect was very variable depending on the monkey and the test day, and the maximum effect was very weak. According to the author's calculations, in order to obtain equivalent PCP-like intoxication in humans, a dose over 150 mg (p. o.) must be used, which is 7-15 times higher than the usual therapeutic dose. An important aspect is that all of the monkeys used in this study had an history of PCP or cocaine use which probably made them more prone for demonstration of self-administration of memantine. This claim is, in fact, supported by another unpublished study where pentobarbital was used to train the monkeys. All four rhesus moneys in the study did self administer pentobarbital at least 16 times a day for 3 consecutive days. When pentobarbital was replaced with memantine, the self-administration rate was similar to that of saline. Moreover, even forced administration of memantine (1mg/kg per infusion) did not initiate self administration.</p><p>Memantine did not produce place preference on its own, indicating that it has no reinforcing potential in this test [<xref ref-type="bibr" rid="R131">131</xref>,<xref ref-type="bibr" rid="R211"> 211</xref>]. Consistently, dopamine levels were not affected in medial prefrontal cortex by an acute administration of memantine (20 mg/kg, i.p.) which also indicates that memantine is unlikely to possess psychotomimetic activity at therapeutically relevant doses [<xref ref-type="bibr" rid="R102">102</xref>].</p><p>In a self-stimulation test memantine, at doses up to 17 mg/kg, did not have a significant effect on the current frequency threshold for self-stimulation &#x02013; only a slight increase was seen at 10 mg/kg. In contrast, (+)MK-801 decreased the threshold in a range of doses 0.1-0.4 mg/kg i.e. the current intensity that was previously not reinforcing, gained reinforcing value. This indicates substantial differences between different NMDA receptor channel blockers and demonstrates that memantine, in contrast to (+)MK-801, is most likely devoid of abuse potential [<xref ref-type="bibr" rid="R273">273</xref>,<xref ref-type="bibr" rid="R274"> 274</xref>].</p><p>Chronic treatment with memantine did not result in sensitization of the behavioural response, in contrast to the other NMDA receptor antagonist (+)MK-801 [<xref ref-type="bibr" rid="R151">151</xref>].</p><p>In summary, most studies cited above indicate clearly that, at therapeutic doses, memantine has no abuse potential, but in contrast might actually inhibit abuse of addictive drugs such as morphine or ethanol (see above). The effects on cocaine abuse are more controversial as, in monkeys, memantine inhibited the reinforcing effects of conditioned stimuli but may have enhanced cocaine self-adminis-tration [<xref ref-type="bibr" rid="R185">185</xref>]. On the other hand, in rats, memantine produces rate &#x0201c;decreasing&#x0201d; effects under a progressive ratio of cocaine self-administration.</p><p>Therefore, although it cannot be completely excluded that memantine could be abused by a population with a history of abuse of drugs with overlapping pharmacology such as PCP or ketamine, this probably has little relevance for the treatment population i.e. AD patient.</p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdul</surname><given-names>M</given-names></name><name><surname>Hoosein</surname><given-names>N</given-names></name></person-group><article-title>N-methyl-D-aspartate receptor in human prostate cancer</article-title><source>J. Membrane Biol</source><year>2005</year><volume>205</volume><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">16362500</pub-id></citation></ref><ref id="R2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>MM</given-names></name><name><surname>Hoshino</surname><given-names>H</given-names></name><name><surname>Chikuma</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name></person-group><article-title>Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated Alzheimer's disease model</article-title><source>Neuroscience</source><year>2004</year><volume>126</volume><fpage>639</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">15183513</pub-id></citation></ref><ref id="R3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name></person-group><article-title>Inflammatory mechanisms in Alzheimer's disease: implications for therapy</article-title><source>Am. J. Psychiatry</source><year>1994</year><volume>151</volume><fpage>1105</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">7518651</pub-id></citation></ref><ref id="R4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Barger</surname><given-names>S</given-names></name><name><surname>Barnum</surname><given-names>S</given-names></name><name><surname>Bradt</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name><name><surname>Cooper</surname><given-names>NR</given-names></name><name><surname>Eikelenboom</surname><given-names>P</given-names></name><name><surname>Emmerling</surname><given-names>M</given-names></name><name><surname>Fiebich</surname><given-names>BL</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>Frautschy</surname><given-names>S</given-names></name><name><surname>Griffin</surname><given-names>WS</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Hull</surname><given-names>M</given-names></name><name><surname>Landreth</surname><given-names>G</given-names></name><name><surname>Lue</surname><given-names>L</given-names></name><name><surname>Mrak</surname><given-names>R</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>O'Banion</surname><given-names>MK</given-names></name><name><surname>Pachter</surname><given-names>J</given-names></name><name><surname>Pasinetti</surname><given-names>G</given-names></name><name><surname>Plata-Salaman</surname><given-names>C</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Rydel</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Streit</surname><given-names>W</given-names></name><name><surname>Strohmeyer</surname><given-names>R</given-names></name><name><surname>Tooyoma</surname><given-names>I</given-names></name><name><surname>Van Muiswinkel</surname><given-names>FL</given-names></name><name><surname>Veerhuis</surname><given-names>R</given-names></name><name><surname>Walker</surname><given-names>D</given-names></name><name><surname>Webster</surname><given-names>S</given-names></name><name><surname>Wegrzyniak</surname><given-names>B</given-names></name><name><surname>Wenk</surname><given-names>G</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name></person-group><article-title>Inflammation and Alzheimer's disease</article-title><source>Neurobiol. Aging</source><year>2000</year><volume>21</volume><fpage>383</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">10858586</pub-id></citation></ref><ref id="R5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>RC</given-names></name><name><surname>Felisbino</surname><given-names>CS</given-names></name><name><surname>Lopez</surname><given-names>MG</given-names></name><name><surname>Rodrigues</surname><given-names>AL</given-names></name><name><surname>Gabilan</surname><given-names>NH</given-names></name></person-group><article-title>Evidence for the involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice</article-title><source>Behav. Brain Res</source><year>2006</year><volume>168</volume><fpage>318</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">16387371</pub-id></citation></ref><ref id="R6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>RC</given-names></name><name><surname>Souza</surname><given-names>DG</given-names></name><name><surname>Soletti</surname><given-names>RC</given-names></name><name><surname>Lopez</surname><given-names>MG</given-names></name><name><surname>Rodrigues</surname><given-names>AL</given-names></name><name><surname>Gabilan</surname><given-names>NH</given-names></name></person-group><article-title>Involvement of PKA, MAPK/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice</article-title><source>Neurosci. Lett</source><year>2006</year><volume>395</volume><fpage>93</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16289784</pub-id></citation></ref><ref id="R7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amadoro</surname><given-names>G</given-names></name><name><surname>Ciotti</surname><given-names>MT</given-names></name><name><surname>Costanzi</surname><given-names>M</given-names></name><name><surname>Cestari</surname><given-names>V</given-names></name><name><surname>Calissano</surname><given-names>P</given-names></name><name><surname>Canu</surname><given-names>N</given-names></name></person-group><article-title>NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>2892</fpage><lpage>2897</lpage><pub-id pub-id-type="pmid">16477009</pub-id></citation></ref><ref id="R8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>ER</given-names></name><name><surname>Gendelman</surname><given-names>HE</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name></person-group><article-title>Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis</article-title><source>J. Neurosci</source><year>2004</year><volume>24</volume><fpage>7194</fpage><lpage>7198</lpage><pub-id pub-id-type="pmid">15306653</pub-id></citation></ref><ref id="R9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andine</surname><given-names>P</given-names></name><name><surname>Sandberg</surname><given-names>M</given-names></name><name><surname>Bagenholm</surname><given-names>R</given-names></name><name><surname>Lehmann</surname><given-names>A</given-names></name><name><surname>Hagberg</surname><given-names>H</given-names></name></person-group><article-title>Intra- and extracellular changes of amino acids in the cerebral cortex of the neonatal rat during hypoxic-ischemia</article-title><source>Dev. Brain Res</source><year>1991</year><volume>64</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">1786636</pub-id></citation></ref><ref id="R10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Waage</surname><given-names>J</given-names></name><name><surname>Finsen</surname><given-names>B</given-names></name><name><surname>Jorgensen</surname><given-names>HA</given-names></name></person-group><article-title>Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats</article-title><source>Brain Res</source><year>2003</year><volume>994</volume><fpage>188</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">14642644</pub-id></citation></ref><ref id="R11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aracava</surname><given-names>Y</given-names></name><name><surname>Pereira</surname><given-names>EF</given-names></name><name><surname>Maelicke</surname><given-names>A</given-names></name><name><surname>Albuquerque</surname><given-names>EX</given-names></name></person-group><article-title>Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons</article-title><source>J. Pharmacol. Exp. Ther</source><year>2005</year><volume>312</volume><fpage>1195</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">15522999</pub-id></citation></ref><ref id="R12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>T</given-names></name><name><surname>Palomo</surname><given-names>T</given-names></name><name><surname>Fredriksson</surname><given-names>A</given-names></name></person-group><article-title>Restorative effects of glutamate antagonists in experimental parkinsonism</article-title><source>Amino Acids</source><year>2002</year><volume>23</volume><fpage>71</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">12373521</pub-id></citation></ref><ref id="R13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>T</given-names></name><name><surname>Fredriksson</surname><given-names>A</given-names></name></person-group><article-title>Restoration and putative protection in Parkinsonism</article-title><source>Neurotox. Res</source><year>2000</year><volume>2</volume><fpage>251</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">16787845</pub-id></citation></ref><ref id="R14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachurin</surname><given-names>S</given-names></name><name><surname>Tkachenko</surname><given-names>S</given-names></name><name><surname>Baskin</surname><given-names>I</given-names></name><name><surname>Lermontova</surname><given-names>N</given-names></name><name><surname>Mukhina</surname><given-names>T</given-names></name><name><surname>Petrova</surname><given-names>L</given-names></name><name><surname>Ustinov</surname><given-names>A</given-names></name><name><surname>Proshin</surname><given-names>A</given-names></name><name><surname>Grigoriev</surname><given-names>V</given-names></name><name><surname>Lukoyanov</surname><given-names>N</given-names></name><name><surname>Palyulin</surname><given-names>V</given-names></name><name><surname>Zefirov</surname><given-names>N</given-names></name></person-group><article-title>Neuroprotective and cognition-enhancing properties of MK-801 flexible analogs Structure-activity relationships</article-title><source>Ann. N. Y. Acad. Sci</source><year>2001</year><volume>939</volume><fpage>219</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">11462774</pub-id></citation></ref><ref id="R15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>PK</given-names></name><name><surname>Paul</surname><given-names>I</given-names></name><name><surname>Wanzo</surname><given-names>V</given-names></name><name><surname>Adham</surname><given-names>N</given-names></name><name><surname>Miguel-Hidalgo</surname><given-names>J</given-names></name></person-group><source>Soc Neurosci. Abst</source><year>2004</year><volume>30</volume></citation></ref><ref id="R16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beister</surname><given-names>A</given-names></name><name><surname>Kraus</surname><given-names>P</given-names></name><name><surname>Kuhn</surname><given-names>W</given-names></name><name><surname>Dose</surname><given-names>M</given-names></name><name><surname>Weindl</surname><given-names>A</given-names></name><name><surname>Gerlach</surname><given-names>M</given-names></name></person-group><article-title>The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease</article-title><source>J. Neural. Transm. Suppl</source><year>2004</year><volume>68</volume><fpage>117</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15354397</pub-id></citation></ref><ref id="R17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belozertseva</surname><given-names>IV</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Effects of NMDA receptor channel blockade on aggression in isolated male mice</article-title><source>Aggress. Behav</source><year>1999</year><volume>25</volume><fpage>381</fpage><lpage>396</lpage></citation></ref><ref id="R18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belozertseva</surname><given-names>IV</given-names></name><name><surname>Dravolina</surname><given-names>OA</given-names></name><name><surname>Neznanova</surname><given-names>ON</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Antinociceptive activity of combination of morphine and NMDA receptor antagonists depends on the inter-injection interval</article-title><source>Eur. J. Pharmacol</source><year>2000</year><volume>396</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">10822059</pub-id></citation></ref><ref id="R19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benveniste</surname><given-names>H</given-names></name><name><surname>Drejer</surname><given-names>J</given-names></name><name><surname>Schusboe</surname><given-names>A</given-names></name><name><surname>Diemer</surname><given-names>NH</given-names></name></person-group><article-title>Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis</article-title><source>J. Neurochem</source><year>1984</year><volume>43</volume><fpage>1369</fpage><lpage>1374</lpage><pub-id pub-id-type="pmid">6149259</pub-id></citation></ref><ref id="R20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berrino</surname><given-names>L</given-names></name><name><surname>Oliva</surname><given-names>P</given-names></name><name><surname>Massimo</surname><given-names>F</given-names></name><name><surname>Aurilio</surname><given-names>C</given-names></name><name><surname>Maione</surname><given-names>S</given-names></name><name><surname>Grella</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name></person-group><article-title>Antinociceptive effect in mice of intraperitoneal N-methyl-D-aspartate receptor antagonists in the formalin test</article-title><source>Eur. J. Pain</source><year>2003</year><volume>7</volume><fpage>131</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12600794</pub-id></citation></ref><ref id="R21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertoglio</surname><given-names>LJ</given-names></name><name><surname>Carobrez</surname><given-names>AP</given-names></name></person-group><article-title>Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats</article-title><source>Psychopharmacology (Berl.)</source><year>2003</year><volume>170</volume><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">13680083</pub-id></citation></ref><ref id="R22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertoglio</surname><given-names>LJ</given-names></name><name><surname>Carobrez</surname><given-names>AP</given-names></name></person-group><article-title>Scopolamine given pre-Trial 1 prevents the one-trial tolerance phenomenon in the elevated plus-maze Trial 2</article-title><source>Behav. Pharmacol</source><year>2004</year><volume>15</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15075626</pub-id></citation></ref><ref id="R23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bespalov</surname><given-names>AY</given-names></name><name><surname>Dravolina</surname><given-names>OA</given-names></name><name><surname>Zvartau</surname><given-names>EE</given-names></name><name><surname>Beardsley</surname><given-names>PM</given-names></name><name><surname>Balster</surname><given-names>RL</given-names></name></person-group><article-title>Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats</article-title><source>Eur. J. Pharmacol</source><year>2000</year><volume>390</volume><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">10708738</pub-id></citation></ref><ref id="R24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bienkowski</surname><given-names>P</given-names></name><name><surname>Krzascik</surname><given-names>P</given-names></name><name><surname>Koros</surname><given-names>E</given-names></name><name><surname>Kostowski</surname><given-names>W</given-names></name><name><surname>Scinska</surname><given-names>A</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures</article-title><source>Eur. J. Pharmacol</source><year>2001</year><volume>413</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">11173066</pub-id></citation></ref><ref id="R25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bisaga</surname><given-names>A</given-names></name><name><surname>Comer</surname><given-names>SD</given-names></name><name><surname>Ward</surname><given-names>AS</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Kleber</surname><given-names>HD</given-names></name><name><surname>Fischman</surname><given-names>MW</given-names></name></person-group><article-title>The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans</article-title><source>Psychopharmacology (Berl.)</source><year>2001</year><volume>157</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">11512037</pub-id></citation></ref><ref id="R26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bisaga</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>SM</given-names></name></person-group><article-title>Acute effects of memantine in combination with alcohol in moderate drinkers</article-title><source>Psychopharmacology (Berl.)</source><year>2004</year><volume>172</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">14530901</pub-id></citation></ref><ref id="R27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bisaga</surname><given-names>A</given-names></name><name><surname>Krzascik</surname><given-names>P</given-names></name><name><surname>Palejko</surname><given-names>W</given-names></name><name><surname>Jankowska</surname><given-names>E</given-names></name><name><surname>Kostowski</surname><given-names>W</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Effect of glutamate antagonists on NMDA- and AMPA-induced convulsant effects in mice and rats</article-title><source>Eur. J. Pharmacol</source><year>1993</year><volume>242</volume><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">7506658</pub-id></citation></ref><ref id="R28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>M</given-names></name><name><surname>Lanthorn</surname><given-names>T</given-names></name><name><surname>Small</surname><given-names>D</given-names></name><name><surname>Mealing</surname><given-names>G</given-names></name><name><surname>Lam</surname><given-names>V</given-names></name><name><surname>Morley</surname><given-names>P</given-names></name></person-group><article-title>Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2</article-title><source>Eur. J. Pharmacol</source><year>1996</year><volume>317</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">8997624</pub-id></citation></ref><ref id="R29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanpied</surname><given-names>TA</given-names></name><name><surname>Boeckman</surname><given-names>FA</given-names></name><name><surname>Aizenman</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name></person-group><article-title>Trapping channel block of NMDA-activated responses by amantadine and memantine</article-title><source>J. Neurophysiol</source><year>1997</year><volume>77</volume><fpage>309</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">9120573</pub-id></citation></ref><ref id="R30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blokhina</surname><given-names>EA</given-names></name><name><surname>Kashkin</surname><given-names>VA</given-names></name><name><surname>Zvartau</surname><given-names>EE</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Effects of nicotinic and NMDA receptor antagonists on intravenous cocaine and nicotine self-administration in mice</article-title><source>Eur. Neuropsychopharmacol</source><year>2005</year><volume>15</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">15695068</pub-id></citation></ref><ref id="R31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blokhina</surname><given-names>EA</given-names></name><name><surname>Sukhotina</surname><given-names>IA</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Pretreatment with morphine potentiates naloxone-conditioned place aversion in mice effects of NMDA receptor antagonists</article-title><source>Eur. J. Pharmacol</source><year>2000</year><volume>406</volume><fpage>227</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11020485</pub-id></citation></ref><ref id="R32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bolshakov</surname><given-names>KV</given-names></name><name><surname>Gmiro</surname><given-names>VE</given-names></name><name><surname>Tikhonov</surname><given-names>DB</given-names></name><name><surname>Magazanik</surname><given-names>LG</given-names></name></person-group><article-title>Determinants of trapping block of N-methyl-d-aspartate receptor channels</article-title><source>J. Neurochem</source><year>2003</year><volume>87</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">12969252</pub-id></citation></ref><ref id="R33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brackett</surname><given-names>RL</given-names></name><name><surname>Pouw</surname><given-names>B</given-names></name><name><surname>Blyden</surname><given-names>JF</given-names></name><name><surname>Nour</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>RR</given-names></name></person-group><article-title>Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex</article-title><source>Neuropharmacology</source><year>2000</year><volume>39</volume><fpage>407</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">10698007</pub-id></citation></ref><ref id="R34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bresink</surname><given-names>I</given-names></name><name><surname>Benke</surname><given-names>TA</given-names></name><name><surname>Collett</surname><given-names>VJ</given-names></name><name><surname>Seal</surname><given-names>AJ</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Henley</surname><given-names>JM</given-names></name><name><surname>Collingridge</surname><given-names>GL</given-names></name></person-group><article-title>Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells</article-title><source>Br. J. Pharmacol</source><year>1996</year><volume>119</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">8886398</pub-id></citation></ref><ref id="R35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>AM</given-names></name></person-group><article-title>Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted ?</article-title><source>Cerebrovasc. Brain Metab. Rev</source><year>1990</year><volume>2</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">2144995</pub-id></citation></ref><ref id="R36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buisson</surname><given-names>A</given-names></name><name><surname>Callebert</surname><given-names>J</given-names></name><name><surname>Mathieu</surname><given-names>E</given-names></name><name><surname>Plotkine</surname><given-names>M</given-names></name><name><surname>Boulu</surname><given-names>RG</given-names></name></person-group><article-title>Striatal protection induced by lesioning the substantia-nigra of rats subjected to focal ischemia</article-title><source>J. Neurochem</source><year>1992</year><volume>59</volume><fpage>1153</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">1353789</pub-id></citation></ref><ref id="R37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buisson</surname><given-names>B</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name></person-group><article-title>Open-channel blockers at the human alpha 4 beta 2 neuronal nicotinic acetylcholine receptor</article-title><source>Mol. Pharmacol</source><year>1998</year><volume>53</volume><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">9495824</pub-id></citation></ref><ref id="R38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>KM</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Jackson</surname><given-names>B</given-names></name><name><surname>Oyejide</surname><given-names>A</given-names></name><name><surname>Wheeler</surname><given-names>L</given-names></name></person-group><article-title>Oral memantine increases rate of ERG recovery in rabbits following an acute retinal ischemic insult induced by elevated IOP</article-title><source>IOVS</source><year>2005</year><volume>46</volume><fpage>4660</fpage></citation></ref><ref id="R39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>SN</given-names></name><name><surname>Maurer</surname><given-names>AP</given-names></name><name><surname>Insel</surname><given-names>N</given-names></name><name><surname>Navratilova</surname><given-names>Z</given-names></name><name><surname>McNaughton</surname><given-names>BL</given-names></name><name><surname>Wenk</surname><given-names>GL</given-names></name><name><surname>Barnes</surname><given-names>CA</given-names></name></person-group><source>Soc.Neurosci. Abst</source><year>2005</year><volume>31</volume></citation></ref><ref id="R40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>AJ</given-names></name></person-group><article-title>Antagonists of the NMDA receptor-channel complex and motor coordination</article-title><source>Life Sci</source><year>1995</year><volume>57</volume><fpage>917</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">7643717</pub-id></citation></ref><ref id="R41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castroman</surname><given-names>PJ</given-names></name><name><surname>Ness</surname><given-names>TJ</given-names></name></person-group><article-title>Ketamine, an N-methyl-D-aspartate receptor antagonist, inhibits the spinal neuronal responses to distension of the rat urinary bladder</article-title><source>Anesthesiology</source><year>2002</year><volume>96</volume><fpage>1410</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12170054</pub-id></citation></ref><ref id="R42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chatterton</surname><given-names>JE</given-names></name><name><surname>Awobuluyi</surname><given-names>M</given-names></name><name><surname>Premkumar</surname><given-names>LS</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Talantova</surname><given-names>M</given-names></name><name><surname>Shin</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Sevarino</surname><given-names>KA</given-names></name><name><surname>Nakanishi</surname><given-names>N</given-names></name><name><surname>Tong</surname><given-names>G</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name></person-group><article-title>Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits</article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>793</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11823786</pub-id></citation></ref><ref id="R43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HS</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group><article-title>Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells uncompetitive antagonism</article-title><source>J. Physiol. (Lond)</source><year>1997</year><volume>499</volume><issue>Pt 1</issue><fpage>27</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">9061638</pub-id></citation></ref><ref id="R44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HSV</given-names></name><name><surname>Pellegrini</surname><given-names>JW</given-names></name><name><surname>Aggarwal</surname><given-names>SK</given-names></name><name><surname>Lei</surname><given-names>SZ</given-names></name><name><surname>Warach</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>FE</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group><article-title>Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine - therapeutic advantage against NMDA receptor-mediated neurotoxicity</article-title><source>J. Neurosci</source><year>1992</year><volume>12</volume><fpage>4427</fpage><lpage>4436</lpage><pub-id pub-id-type="pmid">1432103</pub-id></citation></ref><ref id="R45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HSV</given-names></name><name><surname>Wang</surname><given-names>YF</given-names></name><name><surname>Rayudu</surname><given-names>PV</given-names></name><name><surname>Edgecomb</surname><given-names>P</given-names></name><name><surname>Neill</surname><given-names>JC</given-names></name><name><surname>Segal</surname><given-names>MM</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Jensen</surname><given-names>FE</given-names></name></person-group><article-title>Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation</article-title><source>Neuroscience</source><year>1998</year><volume>86</volume><fpage>1121</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">9697119</pub-id></citation></ref><ref id="R46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chizh</surname><given-names>BA</given-names></name><name><surname>Reismuller</surname><given-names>E</given-names></name><name><surname>Schlutz</surname><given-names>H</given-names></name><name><surname>Scheede</surname><given-names>M</given-names></name><name><surname>Haase</surname><given-names>G</given-names></name><name><surname>Englberger</surname><given-names>W</given-names></name></person-group><article-title>Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil</article-title><source>Neuropharmacology</source><year>2001</year><volume>40</volume><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">11114400</pub-id></citation></ref><ref id="R47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chohan</surname><given-names>MO</given-names></name><name><surname>Khatoon</surname><given-names>S</given-names></name><name><surname>Iqbal</surname><given-names>IG</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name></person-group><article-title>Involvement of I(2)(PP2A) in the abnormal hyperphosphorylation of tau and its reversal by Memantine</article-title><source>FEBS Lett</source><year>2006</year><volume>580</volume><fpage>3973</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16806196</pub-id></citation></ref><ref id="R48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clements</surname><given-names>JD</given-names></name><name><surname>Lester</surname><given-names>RAJ</given-names></name><name><surname>Tong</surname><given-names>G</given-names></name><name><surname>Jahr</surname><given-names>CE</given-names></name><name><surname>Westbrook</surname><given-names>GL</given-names></name></person-group><article-title>The time course of glutamate in the synaptic cleft</article-title><source>Science</source><year>1992</year><volume>258</volume><fpage>1498</fpage><lpage>1501</lpage><pub-id pub-id-type="pmid">1359647</pub-id></citation></ref><ref id="R49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coan</surname><given-names>EJ</given-names></name><name><surname>Irving</surname><given-names>AJ</given-names></name><name><surname>Collingridge</surname><given-names>GL</given-names></name></person-group><article-title>Low-frequence activation of the NMDA receptor system can prevent the induction of LTP</article-title><source>Neurosci. Lett</source><year>1989</year><volume>105</volume><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">2577224</pub-id></citation></ref><ref id="R50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>ED</given-names></name><name><surname>Vosburg</surname><given-names>SK</given-names></name><name><surname>Ward</surname><given-names>AS</given-names></name><name><surname>Haney</surname><given-names>M</given-names></name><name><surname>Foltin</surname><given-names>RW</given-names></name></person-group><article-title>Memantine increases cardiovascular but not behavioral effects of cocaine in methadone-maintained humans</article-title><source>Pharmacol. Biochem. Behav</source><year>2006</year><volume>83</volume><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16445970</pub-id></citation></ref><ref id="R51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costall</surname><given-names>B</given-names></name><name><surname>Naylor</surname><given-names>RJ</given-names></name><name><surname>Tyers</surname><given-names>MB</given-names></name></person-group><article-title>The psychopharmacology of 5-HT3 receptors</article-title><source>Pharmacol. Ther</source><year>1990</year><volume>47</volume><fpage>181</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">2203069</pub-id></citation></ref><ref id="R52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Culmsee</surname><given-names>C</given-names></name><name><surname>Junker</surname><given-names>V</given-names></name><name><surname>Kremers</surname><given-names>W</given-names></name><name><surname>Thal</surname><given-names>S</given-names></name><name><surname>Plesnila</surname><given-names>N</given-names></name><name><surname>Krieglstein</surname><given-names>J</given-names></name></person-group><article-title>Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol</article-title><source>Stroke</source><year>2004</year><volume>35</volume><fpage>1197</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15060319</pub-id></citation></ref><ref id="R53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DAmico</surname><given-names>M</given-names></name><name><surname>DiFilippo</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name></person-group><article-title>Arrhythmias induced by myocardial ischemia-reperfusion are sensitive to ionotropic excitatory amino acid receptor antagonists</article-title><source>Eur. J. Pharmacol</source><year>1999</year><volume>366</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">10082197</pub-id></citation></ref><ref id="R54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name></person-group><article-title>The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease preclinical evidence</article-title><source>Intern. J. Geriat. Psychiatry</source><year>2003</year><volume>18</volume><fpage>S23</fpage><lpage>S32</lpage></citation></ref><ref id="R55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>WJ</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name></person-group><article-title>Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies</article-title><source>Neurosci. Biobehav. Rev</source><year>1997</year><volume>21</volume><fpage>455</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">9195603</pub-id></citation></ref><ref id="R56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>HN</given-names></name><name><surname>Ansseau</surname><given-names>M</given-names></name><name><surname>Lemaire</surname><given-names>M</given-names></name><name><surname>Abraini</surname><given-names>JH</given-names></name></person-group><article-title>Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization</article-title><source>Biol. Psychiatry</source><year>2006</year><volume>60</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16427030</pub-id></citation></ref><ref id="R57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SN</given-names></name><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Millar</surname><given-names>JD</given-names></name><name><surname>Aram</surname><given-names>JA</given-names></name><name><surname>Church</surname><given-names>J</given-names></name><name><surname>Lodge</surname><given-names>D</given-names></name></person-group><article-title>Differences in results from in vivo and in vitro studies on the use-dependency of N-methyl-aspartate antagonism by MK-801 and other phencyclidine receptor ligands</article-title><source>Eur. J. Pharmacol</source><year>1988</year><volume>145</volume><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">2832187</pub-id></citation></ref><ref id="R58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Sarno</surname><given-names>P</given-names></name><name><surname>Bijur</surname><given-names>GN</given-names></name><name><surname>Zmijewska</surname><given-names>AA</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jope</surname><given-names>RS</given-names></name></person-group><article-title><italic>In vivo</italic> regulation of GSK3 phosphorylation by cholinergic and NMDA receptors</article-title><source>Neurobiol. Aging</source><year>2006</year><volume>27</volume><fpage>413</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16464655</pub-id></citation></ref><ref id="R59a"><label>59a</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Dekundy</surname><given-names>A</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Gupta</surname><given-names>RC</given-names></name></person-group><article-title>Co-administration of Memantine with Acetylcholinesterase Inhibitors: Preclinical and Clinical Evidence</article-title><source>Toxicology of Organophosphate &#x00026; Carbamate Compounds</source><year>2006</year><publisher-loc>San Diego</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>35</fpage><lpage>46</lpage></citation></ref><ref id="R59b"><label>59b</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Degerman</surname><given-names>Gunnarsson</given-names></name><name><surname>M</surname><given-names>Kilander</given-names></name><name><surname>L</surname><given-names>Basun</given-names></name><name><surname>H</surname><given-names>Lannfelt</given-names></name></person-group><article-title>Reduction of phosphorylated tau during memantine treatment of Alzheimer&#x02019;s disease</article-title><source>Dement. Geriatr. Cogn. Disord</source><year>2007</year><volume>24</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">17700020</pub-id></citation></ref><ref id="R60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname><given-names>A</given-names></name><name><surname>Eras</surname><given-names>MA</given-names></name><name><surname>Rao</surname><given-names>VL</given-names></name><name><surname>Dempsey</surname><given-names>RJ</given-names></name></person-group><article-title>Protective effects of memantine against ischemia-reperfusion injury in spontaneously hypertensive rats</article-title><source>Acta Neurochir. (Wien)</source><year>1999</year><volume>141</volume><fpage>1107</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10550658</pub-id></citation></ref><ref id="R61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dravolina</surname><given-names>OA</given-names></name><name><surname>Belozertseva</surname><given-names>IV</given-names></name><name><surname>Sukhotina</surname><given-names>IA</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Morphine tolerance and dependence in mice with history of repeated exposures to NMDA receptor channel blockers</article-title><source>Pharmacol. Biochem. Behav</source><year>1999</year><volume>63</volume><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">10462190</pub-id></citation></ref><ref id="R62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duszczyk</surname><given-names>M</given-names></name><name><surname>Gadamski</surname><given-names>R</given-names></name><name><surname>Ziembowicz</surname><given-names>A</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Lazarewicz</surname><given-names>JW</given-names></name></person-group><article-title>NMDA receptor antagonism does not inhibit induction of ischemic tolerance in gerbil brain <italic>in vivo</italic></article-title><source>Neurotox. Res</source><year>2005</year><volume>7</volume><fpage>283</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">16179265</pub-id></citation></ref><ref id="R63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elgoyhen</surname><given-names>AB</given-names></name></person-group><article-title>Effects of memantine and neramexane on &#x003b1;4&#x003b2;2 and &#x003b1;7 nicotinic cholinergic receptors</article-title><year>2005</year></citation></ref><ref id="R64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plazas</surname><given-names>PV</given-names></name><name><surname>Savino</surname><given-names>J</given-names></name><name><surname>Kracun</surname><given-names>S</given-names></name><name><surname>Gomez-Casati</surname><given-names>ME</given-names></name><name><surname>Katz</surname><given-names>E</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Millar</surname><given-names>NS</given-names></name><name><surname>Elgoyhen</surname><given-names>AB</given-names></name></person-group><article-title>Inhibition of the &#x003b1;9&#x003b1;10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors</article-title><source>Eur. J. Pharmacol</source><year>2007</year><volume>566</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">17466293</pub-id></citation></ref><ref id="R65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elgoyhen</surname><given-names>AB</given-names></name><name><surname>Vetter</surname><given-names>DE</given-names></name><name><surname>Katz</surname><given-names>E</given-names></name><name><surname>Rothlin</surname><given-names>CV</given-names></name><name><surname>Heinemann</surname><given-names>SF</given-names></name><name><surname>Boulter</surname><given-names>J</given-names></name></person-group><article-title>alpha 10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>3501</fpage><lpage>3506</lpage><pub-id pub-id-type="pmid">11248107</pub-id></citation></ref><ref id="R66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enina</surname><given-names>G</given-names></name><name><surname>Miglane</surname><given-names>E</given-names></name><name><surname>Tilgale</surname><given-names>B</given-names></name></person-group><article-title>Results from intrevenous administration of Akatinol Mematine for patients with stroke</article-title><source>Latv. Med. J</source><year>2002</year><volume>3</volume><fpage>25</fpage><lpage>29</lpage></citation></ref><ref id="R67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enz</surname><given-names>A</given-names></name><name><surname>Gentsch</surname><given-names>C</given-names></name></person-group><article-title>Co-administration of memantine has no effect on the <italic>in vitro</italic> or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain</article-title><source>Neuropharmacology</source><year>2004</year><volume>47</volume><fpage>408</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15275830</pub-id></citation></ref><ref id="R68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Escher</surname><given-names>T</given-names></name><name><surname>Call</surname><given-names>SB</given-names></name><name><surname>Blaha</surname><given-names>CD</given-names></name><name><surname>Mittleman</surname><given-names>G</given-names></name></person-group><article-title>Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice</article-title><source>Psychopharmacology (Berl.)</source><year>2006</year><volume>187</volume><fpage>424</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16835770</pub-id></citation></ref><ref id="R69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>P</given-names></name></person-group><article-title>Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones</article-title><source>Br. J. Pharmacol</source><year>1994</year><volume>112</volume><fpage>741</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7522857</pub-id></citation></ref><ref id="R70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fawcett</surname><given-names>J</given-names></name><name><surname>Barkin</surname><given-names>RL</given-names></name></person-group><article-title>Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression</article-title><source>J. Affect. Disord</source><year>1998</year><volume>51</volume><fpage>267</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">10333982</pub-id></citation></ref><ref id="R71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>FerrerMontiel</surname><given-names>AV</given-names></name><name><surname>Merino</surname><given-names>JM</given-names></name><name><surname>PlanellsCases</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Montal</surname><given-names>M</given-names></name></person-group><article-title>Structural determinants of the blocker binding site in glutamate and NMDA receptor channels</article-title><source>Neuropharmacology</source><year>1998</year><volume>37</volume><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">9680238</pub-id></citation></ref><ref id="R72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>A</given-names></name><name><surname>Starr</surname><given-names>MS</given-names></name></person-group><article-title>Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain</article-title><source>Brain Res</source><year>2000</year><volume>868</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">10854579</pub-id></citation></ref><ref id="R73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Floden</surname><given-names>AM</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Combs</surname><given-names>CK</given-names></name></person-group><article-title>Beta-amyloid-stimulated microglia induce neuron death <italic>via</italic> synergistic stimulation of tumor necrosis factor alpha and NMDA receptors</article-title><source>J. Neurosci</source><year>2005</year><volume>25</volume><fpage>2566</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">15758166</pub-id></citation></ref><ref id="R74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankiewicz</surname><given-names>T</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name></person-group><article-title>Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices</article-title><source>Neuropharmacology</source><year>1999</year><volume>38</volume><fpage>1253</fpage><lpage>1259</lpage><pub-id pub-id-type="pmid">10471078</pub-id></citation></ref><ref id="R75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankiewicz</surname><given-names>T</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name></person-group><article-title>Chronic memantine does not block 3-nitropropionic acid-induced delayed ischemic tolerance in rat hippocampal slices <italic>ex vivo</italic></article-title><source>Neurotox. Res</source><year>2004</year><volume>5</volume><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">15111238</pub-id></citation></ref><ref id="R76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankiewicz</surname><given-names>T</given-names></name><name><surname>Pilc</surname><given-names>A</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name></person-group><article-title>Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices</article-title><source>Neuropharmacology</source><year>2000</year><volume>39</volume><fpage>631</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">10728884</pub-id></citation></ref><ref id="R77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankiewicz</surname><given-names>T</given-names></name><name><surname>Potier</surname><given-names>B</given-names></name><name><surname>Bashir</surname><given-names>ZI</given-names></name><name><surname>Collingridge</surname><given-names>GL</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name></person-group><article-title>Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices</article-title><source>Br. J. Pharmacol</source><year>1996</year><volume>117</volume><fpage>689</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">8646415</pub-id></citation></ref><ref id="R78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fredriksson</surname><given-names>A</given-names></name><name><surname>Archer</surname><given-names>T</given-names></name></person-group><article-title>Functional alteration by NMDA antagonist: Effects of L-Dopa, neuroleptics drug and postnatal administration</article-title><source>Amino Acids</source><year>2002</year><volume>23</volume><fpage>111</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">12373526</pub-id></citation></ref><ref id="R79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fredriksson</surname><given-names>A</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name><name><surname>Archer</surname><given-names>T</given-names></name></person-group><article-title>Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice</article-title><source>J. Neural Transm</source><year>2001</year><volume>108</volume><fpage>167</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">11314771</pub-id></citation></ref><ref id="R80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>ZX</given-names></name><name><surname>Sumikawa</surname><given-names>K</given-names></name></person-group><article-title>Inactivation of alpha 7 ACh receptors and activation of non-alpha 7 ACh receptors both contribute to long term potentiation induction in the hippocampal CA1 region</article-title><source>Neurosci. Lett</source><year>2000</year><volume>286</volume><fpage>134</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">10825655</pub-id></citation></ref><ref id="R81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>Y</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Akaike</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Nabekura</surname><given-names>J</given-names></name></person-group><article-title>Reduction of voltage-dependent magnesium block of N-methyl-D-aspartate receptor-mediated current by <italic>in vivo</italic> axonal injury</article-title><source>Neuroscience</source><year>2000</year><volume>96</volume><fpage>385</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">10683578</pub-id></citation></ref><ref id="R82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>HJ</given-names></name><name><surname>Qian</surname><given-names>LH</given-names></name><name><surname>Chen</surname><given-names>GY</given-names></name></person-group><article-title>[Long-term effects of memantine therapy on neonatal rats with hypoxic-ischemic brain damage</article-title><source>Zhongguo Dang Dai Er Ke Za Zhi</source><year>2006</year><volume>8</volume><fpage>38</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16522238</pub-id></citation></ref><ref id="R83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia de Arriba</surname><given-names>S</given-names></name><name><surname>Wegner</surname><given-names>F</given-names></name><name><surname>Gruner</surname><given-names>K</given-names></name><name><surname>Verdaguer</surname><given-names>E</given-names></name><name><surname>Pallas</surname><given-names>M</given-names></name><name><surname>Camins</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Wohlfahrt</surname><given-names>K</given-names></name><name><surname>Allgaier</surname><given-names>C</given-names></name></person-group><article-title>Different capacities of various NMDA receptor antagonists to prevent ischemia-induced neurodegeneration in human cultured NT2 neurons</article-title><source>Neurochem. Int</source><year>2006</year><volume>49</volume><fpage>466</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">16650914</pub-id></citation></ref><ref id="R84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geldenhuys</surname><given-names>WJ</given-names></name><name><surname>Terre'Blanche</surname><given-names>G</given-names></name><name><surname>Van der Schyf</surname><given-names>CJ</given-names></name><name><surname>Malan</surname><given-names>SF</given-names></name></person-group><article-title>Screening of novel pentacyclo-undecylamines for neuroprotective activity</article-title><source>Eur. J. Pharmacol</source><year>2003</year><volume>458</volume><fpage>73</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12498909</pub-id></citation></ref><ref id="R85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geter-Douglass</surname><given-names>B</given-names></name><name><surname>Witkin</surname><given-names>JM</given-names></name></person-group><article-title>Behavioral effects and anticonvulsant efficacies of low- affinity, uncompetitive NMDA antagonists in mice</article-title><source>Psychopharmacology</source><year>1999</year><volume>146</volume><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">10541728</pub-id></citation></ref><ref id="R86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilling</surname><given-names>KE</given-names></name><name><surname>Jatzke</surname><given-names>C</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name></person-group><article-title>Agonist concentration-dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine</article-title><source>Neuropharmacology</source><year>2007</year><volume>53</volume><fpage>415</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">17632186</pub-id></citation></ref><ref id="R87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Globus</surname><given-names>MYT</given-names></name><name><surname>Busto</surname><given-names>R</given-names></name><name><surname>Martinez</surname><given-names>E</given-names></name><name><surname>Valdes</surname><given-names>I</given-names></name><name><surname>Dietrich</surname><given-names>WD</given-names></name><name><surname>Ginsberg</surname><given-names>MD</given-names></name></person-group><article-title>Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat</article-title><source>J. Neurochem</source><year>1991</year><volume>57</volume><fpage>470</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">2072098</pub-id></citation></ref><ref id="R88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Globus</surname><given-names>MYT</given-names></name><name><surname>Ginsberg</surname><given-names>MD</given-names></name><name><surname>Busto</surname><given-names>R</given-names></name></person-group><article-title>Excitotoxic index - a biochemical marker of selective vulnerability</article-title><source>Neurosci. Lett</source><year>1991</year><volume>127</volume><fpage>39</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">1679223</pub-id></citation></ref><ref id="R89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorgulu</surname><given-names>A</given-names></name><name><surname>Kins</surname><given-names>T</given-names></name><name><surname>Cobanoglu</surname><given-names>S</given-names></name><name><surname>Unal</surname><given-names>F</given-names></name><name><surname>Izgi</surname><given-names>NI</given-names></name><name><surname>Yanik</surname><given-names>B</given-names></name><name><surname>Kucuk</surname><given-names>M</given-names></name></person-group><article-title>Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischemia and reperfusion in rat</article-title><source>Acta Neurochir. (Wien)</source><year>2000</year><volume>142</volume><fpage>1287</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11201645</pub-id></citation></ref><ref id="R90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenshaw</surname><given-names>AJ</given-names></name><name><surname>Silverstone</surname><given-names>PH</given-names></name></person-group><article-title>The non-antiemetic uses of serotonin 5-HT3 receptor antagonists.Clinical pharmacology and therapeutic applications</article-title><source>Drugs</source><year>1997</year><volume>53</volume><fpage>20</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">9010647</pub-id></citation></ref><ref id="R91"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Kawase</surname><given-names>C</given-names></name><name><surname>Matsubara</surname><given-names>M</given-names></name><name><surname>Kawase</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>A</given-names></name><name><surname>Kitazawa</surname><given-names>Y</given-names></name></person-group><article-title>Neuroprotective effect of N-methyl-D-aspartate receptor antagonists in an experimental glaucoma model in the rat</article-title><source>Nippon Ganka Gakkai Zasshi</source><year>2000</year><volume>104</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">10659620</pub-id></citation></ref><ref id="R92"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RC</given-names></name><name><surname>Dekundy</surname><given-names>A</given-names></name></person-group><article-title>Memantine does not influence ache inhibition in rat brain by donepezil or rivastigmine but does with dfp and metrifonate in <italic>in vivo</italic> studies</article-title><source>Drug Dev. Res</source><year>2005</year><volume>64</volume><fpage>71</fpage><lpage>81</lpage></citation></ref><ref id="R93"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hagan</surname><given-names>RM</given-names></name><name><surname>Kilpatrick</surname><given-names>GJ</given-names></name><name><surname>Tyers</surname><given-names>MB</given-names></name></person-group><article-title>Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse</article-title><source>Psychopharmacology (Berl)</source><year>1993</year><volume>112</volume><fpage>S68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">7831443</pub-id></citation></ref><ref id="R94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamelink</surname><given-names>C</given-names></name><name><surname>Hampson</surname><given-names>A</given-names></name><name><surname>Wink</surname><given-names>DA</given-names></name><name><surname>Eiden</surname><given-names>LE</given-names></name><name><surname>Eskay</surname><given-names>RL</given-names></name></person-group><article-title>Comparison of cannabidiol, antioxidants and diuretics in reversing binge ethanol-induced neurotoxicity</article-title><source>J. Pharmacol. Exp. Ther</source><year>2005</year><volume>314</volume><fpage>780</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">15878999</pub-id></citation></ref><ref id="R95"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>WA</given-names></name><name><surname>WoldeMussie</surname><given-names>E</given-names></name><name><surname>Lai</surname><given-names>RK</given-names></name><name><surname>Ton</surname><given-names>H</given-names></name><name><surname>Ruiz</surname><given-names>G</given-names></name><name><surname>Chun</surname><given-names>T</given-names></name><name><surname>Wheeler</surname><given-names>L</given-names></name></person-group><article-title>Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures</article-title><source>Invest. Ophthalmol. Vis. Sci</source><year>2004</year><volume>45</volume><fpage>2625</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">15277486</pub-id></citation></ref><ref id="R96"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>WA</given-names></name><name><surname>WoldeMussie</surname><given-names>E</given-names></name><name><surname>Weinreb</surname><given-names>RN</given-names></name><name><surname>Ton</surname><given-names>H</given-names></name><name><surname>Ruiz</surname><given-names>G</given-names></name><name><surname>Wijono</surname><given-names>M</given-names></name><name><surname>Feldmann</surname><given-names>B</given-names></name><name><surname>Zangwill</surname><given-names>L</given-names></name><name><surname>Wheeler</surname><given-names>L</given-names></name></person-group><article-title>Efficacy and Safety of Memantine Treatment for Reduction of Changes Associated with Experimental Glaucoma in Monkey, II: Structural Measures</article-title><source>Invest. Ophthalmol. Vis. Sci</source><year>2004</year><volume>45</volume><fpage>2640</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15277487</pub-id></citation></ref><ref id="R97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>WE</given-names></name><name><surname>Woldemussie</surname><given-names>E</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Ton</surname><given-names>H</given-names></name><name><surname>Ruiz</surname><given-names>GFB</given-names></name></person-group><article-title>Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey</article-title><source>Surv. Ophthalmol</source><year>2001</year><volume>45</volume><fpage>S284</fpage><lpage>S289</lpage><pub-id pub-id-type="pmid">11377450</pub-id></citation></ref><ref id="R98"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>AC</given-names></name><name><surname>Gallus</surname><given-names>NJ</given-names></name><name><surname>Under</surname><given-names>S</given-names></name><name><surname>Gewirtz</surname><given-names>JC</given-names></name></person-group><article-title>Soc</article-title><source>Neurosci. Abst</source><year>2004</year><volume>30</volume></citation></ref><ref id="R99"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>BH</given-names></name><name><surname>Bothma</surname><given-names>T</given-names></name><name><surname>Nel</surname><given-names>A</given-names></name><name><surname>Wegener</surname><given-names>G</given-names></name><name><surname>Stein</surname><given-names>DJ</given-names></name></person-group><article-title>Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor K-beta in an animal model of repeated trauma</article-title><source>Hum. Psychopharmacol</source><year>2005</year><volume>20</volume><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">15912566</pub-id></citation></ref><ref id="R100"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herrero</surname><given-names>JF</given-names></name><name><surname>Headley</surname><given-names>PM</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name></person-group><article-title>Memantine selectively depresses NMDA receptor-mediated responses of rat spinal neurones <italic>in vivo</italic></article-title><source>Neurosci. Lett</source><year>1994</year><volume>165</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">7517024</pub-id></citation></ref><ref id="R101"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hesselink</surname><given-names>MB</given-names></name><name><surname>DeBoer</surname><given-names>AG</given-names></name><name><surname>Breimer</surname><given-names>DD</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Adaptations of NMDA and dopamine D-2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists</article-title><source>J. Neural Transm</source><year>1999</year><volume>106</volume><fpage>409</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">10443547</pub-id></citation></ref><ref id="R102"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hesselink</surname><given-names>MB</given-names></name><name><surname>DeBoer</surname><given-names>BG</given-names></name><name><surname>Breimer</surname><given-names>DD</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: A quantitative microdialysis study</article-title><source>Pharm. Res</source><year>1999</year><volume>16</volume><fpage>637</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">10350004</pub-id></citation></ref><ref id="R103"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holden</surname><given-names>CP</given-names></name><name><surname>Haughey</surname><given-names>NJ</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Geiger</surname><given-names>JD</given-names></name></person-group><article-title>Role of Na+/H+ exchangers, excitatory amino acid receptors and voltage-operated Ca2+ channels in human immunodeficiency virus type 1 gp120-mediated increases in intracellular Ca2+ in human neurons and astrocytes</article-title><source>Neuroscience</source><year>1999</year><volume>91</volume><fpage>1369</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">10391443</pub-id></citation></ref><ref id="R104"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holter</surname><given-names>SM</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Spanagel</surname><given-names>R</given-names></name></person-group><article-title>Evidence for alcohol anti-craving properties of memantine</article-title><source>Eur. J. Pharmacol</source><year>1996</year><volume>314</volume><fpage>R1</fpage><lpage>R2</lpage><pub-id pub-id-type="pmid">8957265</pub-id></citation></ref><ref id="R105"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoogduijn</surname><given-names>MJ</given-names></name><name><surname>Hitchcock</surname><given-names>IS</given-names></name><name><surname>Smit</surname><given-names>NP</given-names></name><name><surname>Gillbro</surname><given-names>JM</given-names></name><name><surname>Schallreuter</surname><given-names>KU</given-names></name><name><surname>Genever</surname><given-names>PG</given-names></name></person-group><article-title>Glutamate receptors on human melanocytes regulate the expression of MiTF</article-title><source>Pigment. Cell Res</source><year>2006</year><volume>19</volume><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">16420247</pub-id></citation></ref><ref id="R106"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huerta</surname><given-names>PT</given-names></name><name><surname>Chang</surname><given-names>EH</given-names></name><name><surname>Digiorgio</surname><given-names>LA</given-names></name><name><surname>Volpe</surname><given-names>BT</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kowal</surname><given-names>C</given-names></name><name><surname>Diamond</surname><given-names>B</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>2006</year><volume>32</volume></citation></ref><ref id="R107"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hyytia</surname><given-names>P</given-names></name><name><surname>Backstrom</surname><given-names>P</given-names></name><name><surname>Liljequist</surname><given-names>S</given-names></name></person-group><article-title>Site-specific NMDA receptor antagonists produce differential effects on cocaine self-administration in rats</article-title><source>Eur. J. Pharmacol</source><year>1999</year><volume>378</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">10478559</pub-id></citation></ref><ref id="R108"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikonomidou</surname><given-names>C</given-names></name><name><surname>Stefovska</surname><given-names>V</given-names></name><name><surname>Turski</surname><given-names>L</given-names></name></person-group><article-title>Neuronal death enhanced by N-methyl-D-aspartate antagonists</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>12885</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">11058158</pub-id></citation></ref><ref id="R109"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Izumi</surname><given-names>Y</given-names></name><name><surname>Clifford</surname><given-names>DB</given-names></name><name><surname>Zorumski</surname><given-names>CF</given-names></name></person-group><article-title>Low concentrations of N-methyl-D-aspartate inhibit the induction of long-term potentiation in rat hippocampal slices</article-title><source>Neurosci. Lett</source><year>1992</year><volume>137</volume><fpage>245</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">1350078</pub-id></citation></ref><ref id="R110"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaekel</surname><given-names>B</given-names></name><name><surname>Muhlberg</surname><given-names>K</given-names></name><name><surname>Garcia de Arriba</surname><given-names>S</given-names></name><name><surname>Reichenbach</surname><given-names>A</given-names></name><name><surname>Verdaguer</surname><given-names>E</given-names></name><name><surname>Pallas</surname><given-names>M</given-names></name><name><surname>Camins</surname><given-names>A</given-names></name><name><surname>Norenberg</surname><given-names>W</given-names></name><name><surname>Allgaier</surname><given-names>C</given-names></name></person-group><article-title>Neuroprotection associated with alternative splicing of NMDA receptors in rat cortical neurons</article-title><source>Br. J. Pharmacol</source><year>2006</year><volume>147</volume><fpage>622</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">16314856</pub-id></citation></ref><ref id="R111"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jantas-Skotniczna</surname><given-names>D</given-names></name><name><surname>Kajta</surname><given-names>M</given-names></name><name><surname>Lason</surname><given-names>W</given-names></name></person-group><article-title>Memantine attenuates staurosporine-induced activation of caspase-3 and LDH release in mouse primary neuronal cultures</article-title><source>Brain Res</source><year>2006</year><volume>1069</volume><fpage>145</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16386235</pub-id></citation></ref><ref id="R112"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>XO</given-names></name><name><surname>Greenberg</surname><given-names>DA</given-names></name></person-group><article-title>Alzheimer's disease drugs promote neurogenesis</article-title><source>Brain Res</source><year>2006</year><volume>1085</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">16580645</pub-id></citation></ref><ref id="R113"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JW</given-names></name><name><surname>Kotermanski</surname><given-names>SE</given-names></name></person-group><article-title>Mechanism of action of memantine</article-title><source>Curr. Opin. Pharmacol</source><year>2006</year><volume>6</volume><fpage>61</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16368266</pub-id></citation></ref><ref id="R114"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>MW</given-names></name><name><surname>McClean</surname><given-names>M</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Headley</surname><given-names>PM</given-names></name></person-group><article-title>The <italic>in vivo</italic> significance of the varied channel blocking properties of uncompetitive NMDA receptor antagonists</article-title><source>Neuropharmacology</source><year>2001</year><volume>41</volume><fpage>50</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11445185</pub-id></citation></ref><ref id="R115"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karanian</surname><given-names>DA</given-names></name><name><surname>Baude</surname><given-names>AS</given-names></name><name><surname>Brown</surname><given-names>QB</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Bahr</surname><given-names>BA</given-names></name></person-group><article-title>3-Nitropropionic acid toxicity in hippocampus: Protection through N-methyl-D-aspartate receptor antagonism</article-title><source>Hippocampus</source><year>2006</year><volume>16</volume><fpage>834</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">16897723</pub-id></citation></ref><ref id="R116"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kashiwagi</surname><given-names>K</given-names></name><name><surname>Masuko</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>CD</given-names></name><name><surname>Kuno</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>I</given-names></name><name><surname>Igarashi</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name></person-group><article-title>Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore</article-title><source>Mol. Pharmacol</source><year>2002</year><volume>61</volume><fpage>533</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">11854433</pub-id></citation></ref><ref id="R117"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kashiwagi</surname><given-names>K</given-names></name><name><surname>Pahk</surname><given-names>AJ</given-names></name><name><surname>Masuko</surname><given-names>T</given-names></name><name><surname>Igarashi</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name></person-group><article-title>Block and modulation of N-methyl-D-aspartate receptors by polyamines and protons: Role of amino acid residues in the transmembrane and pore-forming regions of NR1 and NR2 subunits</article-title><source>Mol. Pharmacol</source><year>1997</year><volume>52</volume><fpage>701</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">9380034</pub-id></citation></ref><ref id="R118"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katagiri</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Manabe</surname><given-names>T</given-names></name></person-group><article-title>Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction</article-title><source>Eur. J. Neurosci</source><year>2001</year><volume>14</volume><fpage>547</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">11553304</pub-id></citation></ref><ref id="R119"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>E</given-names></name><name><surname>Elgoyhen</surname><given-names>AB</given-names></name><name><surname>Gomez-Casati</surname><given-names>ME</given-names></name><name><surname>Knipper</surname><given-names>M</given-names></name><name><surname>Vetter</surname><given-names>DE</given-names></name><name><surname>Fuchs</surname><given-names>PA</given-names></name><name><surname>Glowatzki</surname><given-names>E</given-names></name></person-group><article-title>Developmental regulation of nicotinic synapses on cochlear inner hair cells</article-title><source>J. Neurosci</source><year>2004</year><volume>24</volume><fpage>7814</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15356192</pub-id></citation></ref><ref id="R120"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keilhoff</surname><given-names>G</given-names></name><name><surname>Wolf</surname><given-names>G</given-names></name></person-group><article-title>Memantine prevents quinolinic acid-induced hippocampal damage</article-title><source>Eur. J. Pharmacol</source><year>1992</year><volume>219</volume><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">1425971</pub-id></citation></ref><ref id="R121"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Kim</surname><given-names>DM</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name></person-group><article-title>Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia</article-title><source>Korean J. Ophthalmol</source><year>2002</year><volume>16</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12162511</pub-id></citation></ref><ref id="R122"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Komatsu</surname><given-names>H</given-names></name><name><surname>Ogura</surname><given-names>H</given-names></name><name><surname>Sawada</surname><given-names>K</given-names></name></person-group><article-title>Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons</article-title><source>Neurosci. Lett</source><year>2005</year><volume>391</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16154269</pub-id></citation></ref><ref id="R123"><label>123</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>WL</given-names></name><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>De Felice</surname><given-names>FG</given-names></name><name><surname>Ferreira</surname><given-names>ST</given-names></name></person-group><article-title>Molecules that disrupt memory circuits in Alzheimer's disease the attack on synapses by A? oligomers (ADDLs)</article-title><source>Anonymous,Memories Molecules and Circuits</source><year>2007</year></citation></ref><ref id="R124"><label>124</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Schoppmeyer</surname><given-names>K</given-names></name><name><surname>Riederer</surname><given-names>P</given-names></name></person-group><article-title>Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties</article-title><source>J. Neural Transm., Suppl</source><year>1994</year><volume>43</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">7884411</pub-id></citation></ref><ref id="R125"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koros</surname><given-names>E</given-names></name><name><surname>Kostowski</surname><given-names>W</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bienkowski</surname><given-names>P</given-names></name></person-group><article-title>Ethanol discrimination in the rat: lack of modulation by restraint stress and memantine</article-title><source>Naunyn Schmied. Arch. Pharmacol</source><year>1999</year><volume>359</volume><fpage>117</fpage><lpage>122</lpage></citation></ref><ref id="R126"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>T</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name></person-group><article-title>A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice Behav</article-title><source>Pharmacol</source><year>2005</year><volume>16</volume><fpage>155</fpage><lpage>61</lpage></citation></ref><ref id="R127"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>T</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Pietraszek</surname><given-names>M</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>D</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Dravolina</surname><given-names>O</given-names></name><name><surname>Blokhina</surname><given-names>E</given-names></name><name><surname>Galankin</surname><given-names>T</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice</article-title><source>Eur. Neuropsychopharmacol</source><year>2006</year><volume>16</volume><fpage>297</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">16288851</pub-id></citation></ref><ref id="R128"><label>128</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kostowski</surname><given-names>W</given-names></name></person-group><article-title>5-HT3 receptors and central effects of ethanol</article-title><source>Pol. J. Pharmacol</source><year>1996</year><volume>48</volume><fpage>243</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">9112659</pub-id></citation></ref><ref id="R129"><label>129</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kotermanski</surname><given-names>SE</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>2005</year><volume>31</volume></citation></ref><ref id="R130"><label>130</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kotlinska</surname><given-names>J</given-names></name></person-group><article-title>NMDA antagonists inhibit the development of ethanol dependence in rats</article-title><source>Pol. J. Pharmacol</source><year>2001</year><volume>53</volume><fpage>47</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11785910</pub-id></citation></ref><ref id="R131"><label>131</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kotlinska</surname><given-names>J</given-names></name><name><surname>Biala</surname><given-names>G</given-names></name></person-group><article-title>Memantine and ACPC affect conditioned place preference induced by cocaine in rats</article-title><source>Pol. J. Pharmacol</source><year>2000</year><volume>52</volume><fpage>179</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">11055574</pub-id></citation></ref><ref id="R132"><label>132</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kowal</surname><given-names>C</given-names></name><name><surname>DeGiorgio</surname><given-names>LA</given-names></name><name><surname>Nakaoka</surname><given-names>T</given-names></name><name><surname>Hetherington</surname><given-names>H</given-names></name><name><surname>Huerta</surname><given-names>PT</given-names></name><name><surname>Diamond</surname><given-names>B</given-names></name><name><surname>Volpe</surname><given-names>BT</given-names></name></person-group><article-title>Cognition and immunity antibody impairs memory</article-title><source>Immunity</source><year>2004</year><volume>21</volume><fpage>179</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">15308099</pub-id></citation></ref><ref id="R133"><label>133</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kowluru</surname><given-names>RA</given-names></name><name><surname>Engerman</surname><given-names>RL</given-names></name><name><surname>Case</surname><given-names>GL</given-names></name><name><surname>Kern</surname><given-names>TS</given-names></name></person-group><article-title>Retinal glutamate in diabetes and effect of antioxidants</article-title><source>Neurochem. Int</source><year>2001</year><volume>38</volume><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">11222918</pub-id></citation></ref><ref id="R134"><label>134</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozela</surname><given-names>E</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name></person-group><article-title>Uncompetitive NMDA receptor antagonists potentiate morphine antinociception recorded from the tail but not from the hind paw in rats</article-title><source>Eur. J. Pharmacol</source><year>2001</year><volume>423</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">11438302</pub-id></citation></ref><ref id="R135"><label>135</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozela</surname><given-names>E</given-names></name><name><surname>Pilc</surname><given-names>A</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name></person-group><article-title>Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N- methyl- D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice</article-title><source>Psychopharmacology (Berl)</source><year>2003</year><volume>165</volume><fpage>245</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12442203</pub-id></citation></ref><ref id="R136"><label>136</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozela</surname><given-names>E</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name></person-group><article-title>The effects of NMDA receptor antagonists on acute morphine antinociception in mice</article-title><source>Amino Acids</source><year>2002</year><volume>23</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">12373532</pub-id></citation></ref><ref id="R137"><label>137</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krupitsky</surname><given-names>E</given-names></name><name><surname>Masalov</surname><given-names>D</given-names></name><name><surname>Burakov</surname><given-names>A</given-names></name><name><surname>Didenko</surname><given-names>T</given-names></name><name><surname>Romanova</surname><given-names>T</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name><name><surname>Neznanova</surname><given-names>ON</given-names></name><name><surname>Grinenko</surname><given-names>NI</given-names></name><name><surname>Grinenko</surname><given-names>AY</given-names></name><name><surname>Slavina</surname><given-names>TY</given-names></name><name><surname>Tcheremissine</surname><given-names>OV</given-names></name><name><surname>Zvartau</surname><given-names>EE</given-names></name></person-group><article-title>A pilot study of memantine effects on protracted withdrawal (syndrome of anhedonia) in heroin addicts</article-title><source>Addict. Disord. Their. Treat</source><year>2002</year><volume>1</volume><fpage>143</fpage><lpage>146</lpage></citation></ref><ref id="R138"><label>138</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krupitsky</surname><given-names>EM</given-names></name><name><surname>Neznanova</surname><given-names>ON</given-names></name><name><surname>Masalov</surname><given-names>DV</given-names></name><name><surname>Burakov</surname><given-names>AM</given-names></name><name><surname>Didenko</surname><given-names>TY</given-names></name><name><surname>Romanova</surname><given-names>TN</given-names></name><name><surname>Tsoy</surname><given-names>MV</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name><name><surname>Slavina</surname><given-names>TY</given-names></name><name><surname>Grinenko</surname><given-names>AY</given-names></name><name><surname>Zvartau</surname><given-names>EE</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name></person-group><article-title>The NMDA receptor antagonist, memantine, reduces alcohol cue-induced craving even though it has mild ethanol-like effects in alcohol dependent patients</article-title><source>Alcoholism</source><year>2005</year><volume>29</volume><fpage>161A</fpage></citation></ref><ref id="R139"><label>139</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kucheryanu</surname><given-names>VG</given-names></name><name><surname>Kryzhanovskii</surname><given-names>GN</given-names></name></person-group><article-title>Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats</article-title><source>Bull. Exp. Biol. Med</source><year>2000</year><volume>130</volume><fpage>629</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11140570</pub-id></citation></ref><ref id="R140"><label>140</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laabich</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>NG</given-names></name></person-group><article-title>Regulation of calcium/calmodulin-dependent protein kinase II in the adult rat retina is mediated by ionotropic glutamate receptors</article-title><source>Exp. Eye Res</source><year>1999</year><volume>68</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">10375434</pub-id></citation></ref><ref id="R141"><label>141</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacor</surname><given-names>P-N</given-names></name><name><surname>Buniel</surname><given-names>MC</given-names></name><name><surname>Furlow</surname><given-names>PW</given-names></name><name><surname>Clemente</surname><given-names>AS</given-names></name><name><surname>Velasco</surname><given-names>PT</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name><name><surname>Viola</surname><given-names>KL</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name></person-group><article-title>A&#x003b2; oligomers-induced aberrations in synapse composition, shape and density provide a molecular basis for loss of connectivity in Alzheimer&#x000b4;s disease</article-title><source>J. Neurosci</source><year>2007</year><volume>27</volume><fpage>796</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">17251419</pub-id></citation></ref><ref id="R142"><label>142</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lahiri</surname><given-names>DK</given-names></name><name><surname>Alley</surname><given-names>GM</given-names></name><name><surname>Morgan</surname><given-names>C</given-names></name><name><surname>Banerjee</surname><given-names>PK</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name></person-group><article-title>Effect of memantine on levels of the amyloid beta peptide in cell cultures II</article-title><source>J. Neurochem</source><year>2003</year><volume>85</volume><fpage>42</fpage></citation></ref><ref id="R143"><label>143</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>UE</given-names></name><name><surname>Muhlbacher</surname><given-names>M</given-names></name><name><surname>Hesselink</surname><given-names>MB</given-names></name><name><surname>Zajaczkowski</surname><given-names>W</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Danker-Hopfe</surname><given-names>H</given-names></name><name><surname>Hellweg</surname><given-names>R</given-names></name></person-group><article-title>No nerve growth factor response to treatment with memantine in adult rats</article-title><source>J. Neural Transm</source><year>2004</year><volume>111</volume><fpage>181</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">14767721</pub-id></citation></ref><ref id="R144"><label>144</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lapchak</surname><given-names>PA</given-names></name></person-group><article-title>Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits</article-title><source>Brain Res</source><year>2006</year><volume>1088</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">16626666</pub-id></citation></ref><ref id="R145"><label>145</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>ST</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Sinn</surname><given-names>DI</given-names></name><name><surname>Ko</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Roh</surname><given-names>JK</given-names></name></person-group><article-title>Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement</article-title><source>J. Cereb. Blood Flow Metab</source><year>2006</year><volume>26</volume><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">16107786</pub-id></citation></ref><ref id="R146"><label>146</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>A</given-names></name><name><surname>Karrberg</surname><given-names>L</given-names></name></person-group><article-title>Effects of n-methyl-d-aspartate receptor antagonists on cisplatin-induced emesis in the ferret</article-title><source>Neuropharmacology</source><year>1996</year><volume>35</volume><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">8793910</pub-id></citation></ref><ref id="R147"><label>147</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lermontova</surname><given-names>NN</given-names></name><name><surname>Mukhina</surname><given-names>TV</given-names></name><name><surname>Van'kin</surname><given-names>GI</given-names></name><name><surname>Serkova</surname><given-names>TP</given-names></name><name><surname>Bachurin</surname><given-names>SO</given-names></name></person-group><article-title>Comparison of the effect of NT-0409 and antidementia drugs on learning and memory in rats with chronic cerebral cholinergic deficiency</article-title><source>Bull. Exp. Biol. Med</source><year>2003</year><volume>135</volume><fpage>48</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12717512</pub-id></citation></ref><ref id="R148"><label>148</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>ED</given-names></name><name><surname>Christopher</surname><given-names>NC</given-names></name><name><surname>Briggs</surname><given-names>SJ</given-names></name></person-group><article-title>Chronic nicotinic agonist and antagonist effects on T-maze alternation</article-title><source>Physiol. Behav</source><year>1997</year><volume>61</volume><fpage>863</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">9177558</pub-id></citation></ref><ref id="R149"><label>149</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>ED</given-names></name><name><surname>Lippiello</surname><given-names>P</given-names></name></person-group><article-title>Mutually potentiating effects of mecamylamine and haloperidol in producing catalepsy in rats</article-title><source>Drug. Dev. Res</source><year>1999</year><volume>47</volume><fpage>90</fpage><lpage>96</lpage></citation></ref><ref id="R150"><label>150</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Haque</surname><given-names>N</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name></person-group><article-title>Memantine inhibits and reverses the Alzheimer type abnormal phosphorylation of tau and associated neurodegeneration</article-title><source>FEBS Lett</source><year>2004</year><volume>566</volume><fpage>261</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">15147906</pub-id></citation></ref><ref id="R151"><label>151</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>FJ</given-names></name><name><surname>Wolf</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat</article-title><source>Psychopharmacology</source><year>2000</year><volume>151</volume><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">10972463</pub-id></citation></ref><ref id="R152"><label>152</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group><article-title>Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond</article-title><source>Nat. Rev. Drug Discov</source><year>2006</year><fpage>1</fpage><lpage>11</lpage></citation></ref><ref id="R153"><label>153</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lluch</surname><given-names>J</given-names></name><name><surname>Rodriguez-Arias</surname><given-names>M</given-names></name><name><surname>Aguilar</surname><given-names>MA</given-names></name><name><surname>Minarro</surname><given-names>J</given-names></name></person-group><article-title>Role of dopamine and glutamate receptors in cocaine-induced social effects in isolated and grouped male OF1 mice</article-title><source>Pharmacol. Biochem. Behav</source><year>2005</year><volume>82</volume><fpage>478</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">16313950</pub-id></citation></ref><ref id="R154"><label>154</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Losi</surname><given-names>G</given-names></name><name><surname>Lanza</surname><given-names>M</given-names></name><name><surname>Makovec</surname><given-names>F</given-names></name><name><surname>Artusi</surname><given-names>R</given-names></name><name><surname>Caselli</surname><given-names>G</given-names></name><name><surname>Puia</surname><given-names>G</given-names></name></person-group><article-title>Functional <italic>in vitro</italic> characterization of CR 3394: A novel voltage dependent N-methyl-d-aspartate (NMDA) receptor antagonist</article-title><source>Neuropharmacology</source><year>2006</year><volume>50</volume><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">16236334</pub-id></citation></ref><ref id="R155"><label>155</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lovinger</surname><given-names>DR</given-names></name></person-group><article-title>5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic</article-title><source>Neurochem. Int</source><year>1999</year><volume>35</volume><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">10405996</pub-id></citation></ref><ref id="R156"><label>156</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lukomskaia</surname><given-names>NI</given-names></name><name><surname>Lavrent'eva</surname><given-names>VV</given-names></name><name><surname>Starshinova</surname><given-names>LA</given-names></name><name><surname>Zhabko</surname><given-names>EP</given-names></name><name><surname>Gorbunova</surname><given-names>LV</given-names></name><name><surname>Tikhonova</surname><given-names>TB</given-names></name><name><surname>Gmiro</surname><given-names>VE</given-names></name><name><surname>Magazanik</surname><given-names>LG</given-names></name></person-group><article-title>Effects of blockade of ionotropic glutamate receptors on the development of pentylenetetrazole kindling in mice</article-title><source>Rossiiskii Fiziologicheskii Zhurnal Imeni I.M.Sechenova</source><year>2005</year><volume>91</volume><fpage>1241</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">16408633</pub-id></citation></ref><ref id="R157"><label>157</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lukomskaia</surname><given-names>NI</given-names></name><name><surname>Rukoiatkina</surname><given-names>NI</given-names></name><name><surname>Gorbunova</surname><given-names>LV</given-names></name><name><surname>Gmiro</surname><given-names>VE</given-names></name><name><surname>Bol'shakov</surname><given-names>KV</given-names></name><name><surname>Magazanik</surname><given-names>LG</given-names></name></person-group><article-title>Comparison of the anticonvulsant activity of organic mono- and di-cations and their potential to inhibit NMDA and AMPA glutamate receptors Original Title: Sopostavlenie protivosudorozhnoi aktivnosti organicheskikh mono- i dikationov s ikh sposobnost'iu ingibirovat' NMDA i AMPA glutamatnye retseptory</article-title><source>Rossiiskii Fiziologicheskii Zhurnal Imeni I.M.Sechenova</source><year>2002</year><volume>88</volume><fpage>1161</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">12503423</pub-id></citation></ref><ref id="R158"><label>158</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lukoyanov</surname><given-names>NV</given-names></name><name><surname>Paula-Barbosa</surname><given-names>MM</given-names></name></person-group><article-title>Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol</article-title><source>Neurosci. Lett</source><year>2001</year><volume>309</volume><fpage>45</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">11489543</pub-id></citation></ref><ref id="R159"><label>159</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>C</given-names></name><name><surname>Cauli</surname><given-names>O</given-names></name><name><surname>Rodriguez-Arias</surname><given-names>M</given-names></name><name><surname>Aguilar</surname><given-names>MA</given-names></name><name><surname>Minarro</surname><given-names>J</given-names></name></person-group><article-title>Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal</article-title><source>Behav. Brain Res</source><year>2003</year><volume>144</volume><fpage>25</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12946592</pub-id></citation></ref><ref id="R160"><label>160</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maler</surname><given-names>JM</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Kunz</surname><given-names>N</given-names></name><name><surname>Lewczuk</surname><given-names>P</given-names></name><name><surname>Reulbach</surname><given-names>U</given-names></name><name><surname>Bleich</surname><given-names>S</given-names></name><name><surname>Ruther</surname><given-names>E</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name></person-group><article-title>Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons</article-title><source>Brain Res</source><year>2005</year><volume>1052</volume><fpage>156</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">16009352</pub-id></citation></ref><ref id="R161"><label>161</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malyshkin</surname><given-names>A</given-names></name><name><surname>Medvedev</surname><given-names>I</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Anti-allodynic interactions between NMDA receptor channel blockers and morphine or clonidine in neuropathic rats</article-title><source>Eur. J. Pharmacol</source><year>2005</year><volume>519</volume><fpage>80</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16109402</pub-id></citation></ref><ref id="R162"><label>162</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mansbach</surname><given-names>RS</given-names></name><name><surname>Chambers</surname><given-names>LK</given-names></name><name><surname>Rovetti</surname><given-names>CC</given-names></name></person-group><article-title>Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine</article-title><source>Psychopharmacology</source><year>2000</year><volume>148</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">10755736</pub-id></citation></ref><ref id="R163"><label>163</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marubio</surname><given-names>LM</given-names></name><name><surname>Changeux</surname><given-names>JP</given-names></name></person-group><article-title>Nicotinic acetylcholine receptor knockout mice as animal models for studying receptor function</article-title><source>Eur. J. Pharmacol</source><year>2000</year><volume>393</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">10771004</pub-id></citation></ref><ref id="R164"><label>164</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marvanova</surname><given-names>M</given-names></name><name><surname>Lakso</surname><given-names>M</given-names></name><name><surname>Pirhonen</surname><given-names>J</given-names></name><name><surname>Nawa</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Castren</surname><given-names>E</given-names></name></person-group><article-title>The Neuroprotective Agent Memantine Induces Brain-Derived Neurotrophic Factor and trkB Receptor Expression in Rat Brain</article-title><source>Mol. Cell. Neurosci</source><year>2001</year><volume>18</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">11591126</pub-id></citation></ref><ref id="R165"><label>165</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maskell</surname><given-names>PD</given-names></name><name><surname>Speder</surname><given-names>P</given-names></name><name><surname>Newberry</surname><given-names>NR</given-names></name><name><surname>Bermudez</surname><given-names>I</given-names></name></person-group><article-title>Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors</article-title><source>Br. J. Pharmacol</source><year>2003</year><volume>140</volume><fpage>1313</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14645141</pub-id></citation></ref><ref id="R166"><label>166</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>WJ</given-names></name><name><surname>Li</surname><given-names>TK</given-names></name></person-group><article-title>Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents</article-title><source>Crit. Rev. Neurobiol</source><year>1998</year><volume>12</volume><fpage>339</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">10348615</pub-id></citation></ref><ref id="R167"><label>167</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McClean</surname><given-names>M</given-names></name><name><surname>Chizh</surname><given-names>BA</given-names></name><name><surname>Jones</surname><given-names>MW</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Headley</surname><given-names>PM</given-names></name></person-group><source>Soc.Neurosci. Abst</source><year>1996</year><volume>22</volume></citation></ref><ref id="R168"><label>168</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McRoberts</surname><given-names>JA</given-names></name><name><surname>Coutinho</surname><given-names>SV</given-names></name><name><surname>Marvizon</surname><given-names>JC</given-names></name><name><surname>Grady</surname><given-names>EF</given-names></name><name><surname>Tognetto</surname><given-names>M</given-names></name><name><surname>Sengupta</surname><given-names>JN</given-names></name><name><surname>Ennes</surname><given-names>HS</given-names></name><name><surname>Chaban</surname><given-names>VV</given-names></name><name><surname>Amadesi</surname><given-names>S</given-names></name><name><surname>Creminon</surname><given-names>C</given-names></name><name><surname>Lanthorn</surname><given-names>T</given-names></name><name><surname>Geppetti</surname><given-names>P</given-names></name><name><surname>Bunnett</surname><given-names>NW</given-names></name><name><surname>Mayer</surname><given-names>EA</given-names></name></person-group><article-title>Role of peripheral N-Methyl-D-Aspartate (NMDA) receptors in visceral nociception in rats</article-title><source>Gastroenterology</source><year>2001</year><volume>120</volume><fpage>1737</fpage><lpage>1748</lpage><pub-id pub-id-type="pmid">11375955</pub-id></citation></ref><ref id="R169"><label>169</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mealing</surname><given-names>GA</given-names></name><name><surname>Lanthorn</surname><given-names>TH</given-names></name><name><surname>Murray</surname><given-names>CL</given-names></name><name><surname>Small</surname><given-names>DL</given-names></name><name><surname>Morley</surname><given-names>P</given-names></name></person-group><article-title>Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block</article-title><source>J. Pharmacol. Exp. Ther</source><year>1999</year><volume>288</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">9862772</pub-id></citation></ref><ref id="R170"><label>170</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medvedev</surname><given-names>IO</given-names></name><name><surname>Malyshkin</surname><given-names>AA</given-names></name><name><surname>Belozertseva</surname><given-names>IV</given-names></name><name><surname>Sukhotina</surname><given-names>IA</given-names></name><name><surname>Sevostianova</surname><given-names>NY</given-names></name><name><surname>Aliev</surname><given-names>K</given-names></name><name><surname>Zvartau</surname><given-names>EE</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain</article-title><source>Neuropharmacology</source><year>2004</year><volume>47</volume><fpage>175</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">15223296</pub-id></citation></ref><ref id="R171"><label>171</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Meldrum</surname><given-names>B</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bazan</surname><given-names>NG</given-names></name><name><surname>Braquet</surname><given-names>P</given-names></name><name><surname>Ginsberg</surname><given-names>MD</given-names></name></person-group><article-title>Protection against ischemic brain damage by excitatory amino acid antagonists</article-title><source>Neurochemical correlates of cerebrai ischemia.Vol. 7, Advances in Neurochemistry</source><year>1992</year><volume>7</volume><publisher-loc>New York</publisher-loc><publisher-name>Plenum Press</publisher-name><fpage>245</fpage><lpage>263</lpage></citation></ref><ref id="R172"><label>172</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miguel-Hidalgo</surname><given-names>JJ</given-names></name><name><surname>Alvarez</surname><given-names>XA</given-names></name><name><surname>Cacabelos</surname><given-names>R</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name></person-group><article-title>Neuroprotection by memantine against neurodegeneration induced by beta- amyloid(1-40)</article-title><source>Brain Res</source><year>2002</year><volume>958</volume><fpage>210</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">12468047</pub-id></citation></ref><ref id="R173"><label>173</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miguel-Hidalgo</surname><given-names>JJ</given-names></name><name><surname>Paul</surname><given-names>IA</given-names></name><name><surname>Wanzo</surname><given-names>V</given-names></name><name><surname>Banerjee</surname><given-names>PK</given-names></name></person-group><article-title>Memantine inhibits the expression of caspase-8 and improves learning in rats injected with [beta]-amyloid 140</article-title><source>FASEB J</source><year>2006</year><volume>20</volume><fpage>A1135</fpage></citation></ref><ref id="R174"><label>174</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minkeviciene</surname><given-names>R</given-names></name><name><surname>Banerjee</surname><given-names>P</given-names></name><name><surname>Tanila</surname><given-names>H</given-names></name></person-group><article-title>Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease</article-title><source>J. Pharmacol. Exp. Ther</source><year>2004</year><volume>311</volume><fpage>677</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15192085</pub-id></citation></ref><ref id="R175"><label>175</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mirza</surname><given-names>NR</given-names></name><name><surname>Bright</surname><given-names>JL</given-names></name><name><surname>Stanhope</surname><given-names>KJ</given-names></name><name><surname>Wyatt</surname><given-names>A</given-names></name><name><surname>Harrington</surname><given-names>NR</given-names></name></person-group><article-title>Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?</article-title><source>Psychopharmacology (Berl)</source><year>2005</year><volume>180</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">15682295</pub-id></citation></ref><ref id="R176"><label>176</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Misztal</surname><given-names>M</given-names></name><name><surname>Frankiewicz</surname><given-names>T</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and memantine</article-title><source>Eur. J. Pharmacol</source><year>1996</year><volume>296</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8720470</pub-id></citation></ref><ref id="R177"><label>177</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitani</surname><given-names>A</given-names></name><name><surname>Andou</surname><given-names>Y</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name></person-group><article-title>Selective vulnerability of hippocampal CA1 neurons cannot be explained in terms of an increase in glutamate concentration during ischemia in the gerbil: Brain microdialysis study</article-title><source>Neuroscience</source><year>1992</year><volume>48</volume><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">1351267</pub-id></citation></ref><ref id="R178"><label>178</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moutsimilli</surname><given-names>L</given-names></name><name><surname>Farley</surname><given-names>S</given-names></name><name><surname>Dumas</surname><given-names>S</given-names></name><name><surname>El Mestikawy</surname><given-names>S</given-names></name><name><surname>Giros</surname><given-names>B</given-names></name><name><surname>Tzavara</surname><given-names>ET</given-names></name></person-group><article-title>Selective cortical VGLUT1 increase as a marker for antidepressant activity</article-title><source>Neuropharmacology</source><year>2005</year><volume>49</volume><fpage>890</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">16111724</pub-id></citation></ref><ref id="R179"><label>179</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>WE</given-names></name><name><surname>Laplanche</surname><given-names>J</given-names></name><name><surname>Ushijima</surname><given-names>H</given-names></name><name><surname>Schroder</surname><given-names>HC</given-names></name></person-group><article-title>Novel approaches in diagnosis and therapy of creutzfeldt-jakob disease</article-title><source>Mech. Ageing Dev</source><year>2000</year><volume>116</volume><fpage>193</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">10996019</pub-id></citation></ref><ref id="R180"><label>180</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Murayama</surname><given-names>N</given-names></name><name><surname>Noshita</surname><given-names>T</given-names></name><name><surname>Ogino</surname><given-names>R</given-names></name><name><surname>Ohno</surname><given-names>T</given-names></name></person-group><article-title>Cognitive dysfunction induced by sequential injection of amyloid beta and ibotenate into the bilateral hippocampus protection by memantine and MK-801</article-title><source>J. Pharmacol. Sci</source><year>2006</year><volume>100</volume><fpage>142P</fpage><pub-id pub-id-type="pmid">16474205</pub-id></citation></ref><ref id="R181"><label>181</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakazato</surname><given-names>E</given-names></name><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name></person-group><article-title>Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model</article-title><source>Pharmacology</source><year>2005</year><volume>73</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15452358</pub-id></citation></ref><ref id="R182"><label>182</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naskar</surname><given-names>R</given-names></name><name><surname>Quinto</surname><given-names>K</given-names></name><name><surname>Romann</surname><given-names>I</given-names></name><name><surname>Schuettauf</surname><given-names>F</given-names></name><name><surname>Zurakowski</surname><given-names>D</given-names></name></person-group><article-title>Phenytoin blocks retinal ganglion cell death after partial optic nerve crush</article-title><source>Exp. Eye Res</source><year>2002</year><volume>74</volume><fpage>747</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">12126947</pub-id></citation></ref><ref id="R183"><label>183</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Haughey</surname><given-names>NJ</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>JE</given-names></name><name><surname>Geiger</surname><given-names>JD</given-names></name></person-group><article-title>Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: Protection by memantine</article-title><source>Ann. Neurol</source><year>2000</year><volume>47</volume><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">10665489</pub-id></citation></ref><ref id="R184"><label>184</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neugebauer</surname><given-names>V</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Lucke</surname><given-names>T</given-names></name><name><surname>Schaible</surname><given-names>HG</given-names></name></person-group><article-title>The clinically available NMDA receptor antagonist memantine is antinociceptive on rat spinal neurones</article-title><source>Neuroreport</source><year>1993</year><volume>4</volume><fpage>1259</fpage><lpage>1262</lpage><pub-id pub-id-type="pmid">7693015</pub-id></citation></ref><ref id="R185"><label>185</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>JL</given-names></name><name><surname>Beardsley</surname><given-names>PM</given-names></name></person-group><article-title>Effects of memantine, haloperidol, and cocaine on primary and conditioned reinforcement associated with cocaine in rhesus monkeys</article-title><source>Psychopharmacology (Berl)</source><year>2006</year><volume>185</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">16425059</pub-id></citation></ref><ref id="R186"><label>186</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neznanova</surname><given-names>ON</given-names></name><name><surname>Blokhina</surname><given-names>EA</given-names></name><name><surname>Sukhotina</surname><given-names>IA</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Motor impairment produced by ethanol and site-selective NMDA receptor antagonists in mice: tolerance and cross-tolerance</article-title><source>Alcohol</source><year>2000</year><volume>20</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">10680714</pub-id></citation></ref><ref id="R187"><label>187</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>KL</given-names></name><name><surname>Jones</surname><given-names>HE</given-names></name><name><surname>Balster</surname><given-names>RL</given-names></name></person-group><article-title>Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine</article-title><source>Behav. Pharmacol</source><year>1998</year><volume>9</volume><fpage>231</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">9832937</pub-id></citation></ref><ref id="R188"><label>188</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nisijima</surname><given-names>K</given-names></name><name><surname>Shioda</surname><given-names>K</given-names></name><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Takano</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name></person-group><article-title>Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome</article-title><source>Pharmacopsychiatry</source><year>2004</year><volume>37</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15048612</pub-id></citation></ref><ref id="R189"><label>189</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>L</given-names></name><name><surname>Bregestovski</surname><given-names>P</given-names></name><name><surname>Ascher</surname><given-names>P</given-names></name><name><surname>Herbert</surname><given-names>A</given-names></name><name><surname>Prochiantz</surname><given-names>A</given-names></name></person-group><article-title>Magnesium gates glutamate-activated channels in mouse central neurons</article-title><source>Nature</source><year>1984</year><volume>307</volume><fpage>462</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">6320006</pub-id></citation></ref><ref id="R190"><label>190</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olivar</surname><given-names>T</given-names></name><name><surname>Laird</surname><given-names>JM</given-names></name></person-group><article-title>Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes</article-title><source>Pain</source><year>1999</year><volume>79</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">9928778</pub-id></citation></ref><ref id="R191"><label>191</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>D</given-names></name><name><surname>Ludwig</surname><given-names>J</given-names></name><name><surname>Reisinger</surname><given-names>E</given-names></name><name><surname>Zoellner</surname><given-names>W</given-names></name><name><surname>Ruppersberg</surname><given-names>JP</given-names></name><name><surname>Fakler</surname><given-names>B</given-names></name></person-group><article-title>Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells</article-title><source>Mol. Pharmacol</source><year>2001</year><volume>60</volume><fpage>183</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11408613</pub-id></citation></ref><ref id="R192"><label>192</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>NN</given-names></name></person-group><article-title>Memantine reduces alterations to the mammalian retina, <italic>in situ,</italic> induced by ischemia</article-title><source>Visual Neurosci</source><year>1999</year><volume>16</volume><fpage>45</fpage><lpage>52</lpage></citation></ref><ref id="R193"><label>193</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owyang</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>SY</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Chronic activation of NMDA receptors is responsible for selective nitrergic neuropathy in diabetic rats</article-title><source>Gastroenterology</source><year>2005</year><volume>128</volume><fpage>A550</fpage></citation></ref><ref id="R194"><label>194</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozsuer</surname><given-names>H</given-names></name><name><surname>Gorgulu</surname><given-names>A</given-names></name><name><surname>Kiris</surname><given-names>T</given-names></name><name><surname>Cobanoglu</surname><given-names>S</given-names></name></person-group><article-title>The effects of memantine on lipid peroxidation following closed-head trauma in rats</article-title><source>Neurosurg. Rev</source><year>2005</year><volume>28</volume><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">15789251</pub-id></citation></ref><ref id="R195"><label>195</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parada-Turska</surname><given-names>J</given-names></name><name><surname>Rzeski</surname><given-names>W</given-names></name><name><surname>Majdan</surname><given-names>M</given-names></name><name><surname>Kandefer-Szerszen</surname><given-names>M</given-names></name><name><surname>Turski</surname><given-names>WA</given-names></name></person-group><article-title>Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes <italic>in vitro</italic></article-title><source>Eur. J. Pharmacol</source><year>2006</year><volume>535</volume><fpage>95</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16533508</pub-id></citation></ref><ref id="R196"><label>196</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name></person-group><article-title>Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data</article-title><source>Neuropharmacology</source><year>1999</year><volume>38</volume><fpage>735</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">10465680</pub-id></citation></ref><ref id="R197"><label>197</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Gilling</surname><given-names>K</given-names></name></person-group><article-title>Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate (NMDA) receptor blocker</article-title><source>Patch Clamp Methiods and Protocols</source><year>2006</year><publisher-loc>Humana</publisher-loc><fpage>15</fpage><lpage>36</lpage></citation></ref><ref id="R198"><label>198</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Gruner</surname><given-names>R</given-names></name><name><surname>Rozental</surname><given-names>J</given-names></name><name><surname>Millar</surname><given-names>J</given-names></name><name><surname>Lodge</surname><given-names>D</given-names></name></person-group><article-title>Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)</article-title><source>Neuropharmacology</source><year>1993</year><volume>32</volume><fpage>1337</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">8152525</pub-id></citation></ref><ref id="R199"><label>199</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Hartmann</surname><given-names>S</given-names></name><name><surname>Spielmanns</surname><given-names>P</given-names></name></person-group><article-title>Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones</article-title><source>Neuropharmacology</source><year>1998</year><volume>37</volume><fpage>719</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">9707285</pub-id></citation></ref><ref id="R200"><label>200</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Panchenko</surname><given-names>VA</given-names></name><name><surname>Pinchenko</surname><given-names>VO</given-names></name><name><surname>Tsyndrenko</surname><given-names>AY</given-names></name><name><surname>Krishtal</surname><given-names>OA</given-names></name></person-group><article-title>Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine</article-title><source>Eur. J. Neurosci</source><year>1996</year><volume>8</volume><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">8963435</pub-id></citation></ref><ref id="R201"><label>201</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name><name><surname>Bresink</surname><given-names>I</given-names></name><name><surname>Baran</surname><given-names>L</given-names></name><name><surname>Przegalinski</surname><given-names>E</given-names></name><name><surname>Kostowski</surname><given-names>W</given-names></name><name><surname>Krzascik</surname><given-names>P</given-names></name><name><surname>Hartmann</surname><given-names>S</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists <italic>in vitro</italic> with anticonvulsive and motor impairment activity <italic>in vivo</italic></article-title><source>Neuropharmacology</source><year>1995</year><volume>34</volume><fpage>1239</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">8570022</pub-id></citation></ref><ref id="R202"><label>202</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Spielmanns</surname><given-names>P</given-names></name><name><surname>Ruppersberg</surname><given-names>JP</given-names></name><name><surname>Plinkert</surname><given-names>P</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>1999</year><volume>25</volume></citation></ref><ref id="R203"><label>203</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>St&#x000f6;ffler</surname><given-names>A</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Memantine a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system too little activation is bad, too much is even worse</article-title><source>Neuropharmacology </source><year>2007</year><comment>[Epub ahead of print]</comment></citation></ref><ref id="R204"><label>204</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>C</given-names></name><name><surname>Bolton</surname><given-names>C</given-names></name></person-group><article-title>Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D- aspartate receptor antagonist memantine</article-title><source>J. Pharmacol. Exp. Ther</source><year>2002</year><volume>302</volume><fpage>50</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">12065699</pub-id></citation></ref><ref id="R205"><label>205</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pauly</surname><given-names>JR</given-names></name><name><surname>Marks</surname><given-names>MJ</given-names></name><name><surname>Robinson</surname><given-names>SF</given-names></name><name><surname>van de Kamp</surname><given-names>JL</given-names></name><name><surname>Collins</surname><given-names>AC</given-names></name></person-group><article-title>Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels</article-title><source>J. Pharmacol. Exp. Ther</source><year>1996</year><volume>278</volume><fpage>361</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8764371</pub-id></citation></ref><ref id="R206"><label>206</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Gerzanich</surname><given-names>V</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Whiting</surname><given-names>PJ</given-names></name><name><surname>Lindstrom</surname><given-names>J</given-names></name></person-group><article-title>Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover</article-title><source>Mol. Pharmacol</source><year>1994</year><volume>46</volume><fpage>523</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">7935334</pub-id></citation></ref><ref id="R207"><label>207</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Periclou</surname><given-names>AP</given-names></name><name><surname>Ventura</surname><given-names>D</given-names></name><name><surname>Sherman</surname><given-names>T</given-names></name><name><surname>Rao</surname><given-names>N</given-names></name><name><surname>Abramowitz</surname><given-names>WT</given-names></name></person-group><article-title>Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil</article-title><source>Ann. Pharmacother</source><year>2004</year><volume>38</volume><fpage>1389</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15266045</pub-id></citation></ref><ref id="R208"><label>208</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Picciotto</surname><given-names>MR</given-names></name><name><surname>Caldarone</surname><given-names>BJ</given-names></name><name><surname>King</surname><given-names>SL</given-names></name><name><surname>Zachariou</surname><given-names>V</given-names></name></person-group><article-title>Nicotinic receptors in the brain: Links between molecular biology and behavior</article-title><source>Neuropsychopharmacology</source><year>2000</year><volume>22</volume><fpage>451</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">10731620</pub-id></citation></ref><ref id="R209"><label>209</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Picciotto</surname><given-names>MR</given-names></name><name><surname>Zoli</surname><given-names>M</given-names></name><name><surname>Zachariou</surname><given-names>V</given-names></name><name><surname>Changeux</surname><given-names>JP</given-names></name></person-group><article-title>Contribution of nicotinic acetylcholine receptors containing the beta 2- subunit to the behavioural effects of nicotine</article-title><source>Biochem. Soc. Trans</source><year>1997</year><volume>25</volume><fpage>824</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9388554</pub-id></citation></ref><ref id="R210"><label>210</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plaznik</surname><given-names>A</given-names></name><name><surname>Kostowski</surname><given-names>W</given-names></name><name><surname>Stefanski</surname><given-names>R</given-names></name></person-group><article-title>Limbic mechanisms of anxiolytics acting on 5-HT receptors</article-title><source>Pol. J. Pharmacol</source><year>1994</year><volume>46</volume><fpage>473</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7894537</pub-id></citation></ref><ref id="R211"><label>211</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine</article-title><source>J. Pharmacol. Exp. Ther</source><year>1997</year><volume>280</volume><fpage>854</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">9023300</pub-id></citation></ref><ref id="R212"><label>212</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Kozela</surname><given-names>E</given-names></name></person-group><article-title>Clinically available NMDA antagonist, memantine, attenuates tolerance to analgesic effects of morphine in a mouse tail flick test</article-title><source>Pol. J. Pharmacol</source><year>1999</year><volume>51</volume><fpage>223</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10600036</pub-id></citation></ref><ref id="R213"><label>213</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Kozela</surname><given-names>E</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice</article-title><source>Naunyn Schmied. Arch. Pharmacol</source><year>2000</year><volume>361</volume><fpage>425</fpage><lpage>432</lpage></citation></ref><ref id="R214"><label>214</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Kozela</surname><given-names>E</given-names></name><name><surname>Pilc</surname><given-names>A</given-names></name></person-group><article-title>Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice</article-title><source>Br. J. Pharmacol</source><year>2000</year><volume>130</volume><fpage>1425</fpage><lpage>1431</lpage><pub-id pub-id-type="pmid">10903986</pub-id></citation></ref><ref id="R215"><label>215</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Kozela</surname><given-names>E</given-names></name><name><surname>Wrobel</surname><given-names>M</given-names></name><name><surname>Wozniak</surname><given-names>KM</given-names></name><name><surname>Slusher</surname><given-names>BS</given-names></name></person-group><article-title>Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA</article-title><source>Neuropsychopharmacology</source><year>2003</year><volume>28</volume><fpage>457</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">12629525</pub-id></citation></ref><ref id="R216"><label>216</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Wrobel</surname><given-names>M</given-names></name><name><surname>Bisaga</surname><given-names>A</given-names></name></person-group><article-title>Reinstatement of Morphine-Conditioned Reward is Blocked by Memantine</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>160</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">15886718</pub-id></citation></ref><ref id="R217"><label>217</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popik</surname><given-names>P</given-names></name><name><surname>Wrobel</surname><given-names>M</given-names></name><name><surname>Rygula</surname><given-names>R</given-names></name><name><surname>Bisaga</surname><given-names>A</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Effects of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforcers in mice</article-title><source>Behav. Pharmacol</source><year>2003</year><volume>14</volume><fpage>237</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12799526</pub-id></citation></ref><ref id="R218"><label>218</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rammes</surname><given-names>G</given-names></name><name><surname>Eisensamer</surname><given-names>B</given-names></name><name><surname>Ferrari</surname><given-names>U</given-names></name><name><surname>Shapa</surname><given-names>M</given-names></name><name><surname>Gimpl</surname><given-names>G</given-names></name><name><surname>Gilling</surname><given-names>K</given-names></name><name><surname>Parsons</surname><given-names>C</given-names></name><name><surname>Riering</surname><given-names>K</given-names></name><name><surname>Hapfelmeier</surname><given-names>G</given-names></name><name><surname>Bondy</surname><given-names>B</given-names></name><name><surname>Zieglgansberger</surname><given-names>W</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name><name><surname>Rupprecht</surname><given-names>R</given-names></name></person-group><article-title>Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner</article-title><source>Mol. Psychiatry</source><year>2004</year><volume>9</volume><fpage>846</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">15024394</pub-id></citation></ref><ref id="R219"><label>219</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rammes</surname><given-names>G</given-names></name><name><surname>Mahal</surname><given-names>B</given-names></name><name><surname>Putzke</surname><given-names>J</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Spielmanns</surname><given-names>P</given-names></name><name><surname>Pestel</surname><given-names>E</given-names></name><name><surname>Spanagel</surname><given-names>R</given-names></name><name><surname>Zieglgansberger</surname><given-names>W</given-names></name><name><surname>Schadrack</surname><given-names>J</given-names></name></person-group><article-title>The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801</article-title><source>Neuropharmacology</source><year>2001</year><volume>40</volume><fpage>749</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11369029</pub-id></citation></ref><ref id="R220"><label>220</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rammes</surname><given-names>G</given-names></name><name><surname>Rupprecht</surname><given-names>R</given-names></name><name><surname>Ferrari</surname><given-names>U</given-names></name><name><surname>Zieglg&#x000e4;nsberger</surname><given-names>W</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name></person-group><article-title>The NMDA receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes also antagonise 5-HT<sub>3</sub> receptor currents in HEK-293 and N1E-115 cells in a non-competitive manner</article-title><source>Neurosci. Lett</source><year>2001</year><volume>306</volume><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">11403963</pub-id></citation></ref><ref id="R221"><label>221</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>VLR</given-names></name><name><surname>Dogan</surname><given-names>A</given-names></name><name><surname>Todd</surname><given-names>KG</given-names></name><name><surname>Bowen</surname><given-names>KK</given-names></name><name><surname>Dempsey</surname><given-names>RJ</given-names></name></person-group><article-title>Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats</article-title><source>Brain Res</source><year>2001</year><volume>911</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">11489449</pub-id></citation></ref><ref id="R222"><label>222</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rassoulpour</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>HQ</given-names></name><name><surname>Ferre</surname><given-names>S</given-names></name><name><surname>Schwarcz</surname><given-names>R</given-names></name></person-group><article-title>Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum</article-title><source>J. Neurochem</source><year>2005</year><volume>93</volume><fpage>762</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15836634</pub-id></citation></ref><ref id="R223"><label>223</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redwine</surname><given-names>KE</given-names></name><name><surname>Trujillo</surname><given-names>KA</given-names></name></person-group><article-title>Effects of NMDA receptor antagonists on acute mu-opioid analgesia in the rat</article-title><source>Pharmacol. Biochem. Behav</source><year>2003</year><volume>76</volume><fpage>361</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">14592689</pub-id></citation></ref><ref id="R224"><label>224</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Stoffler</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>F</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>Mobius</surname><given-names>HJ</given-names></name></person-group><article-title>Memantine in moderate-to-severe Alzheimer's disease</article-title><source>N. Engl. J. Med</source><year>2003</year><volume>348</volume><fpage>1333</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">12672860</pub-id></citation></ref><ref id="R225"><label>225</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro Do Couto</surname><given-names>B</given-names></name><name><surname>Aguilar</surname><given-names>MA</given-names></name><name><surname>Manzanedo</surname><given-names>C</given-names></name><name><surname>Rodriguez-Arias</surname><given-names>M</given-names></name><name><surname>Minarro</surname><given-names>J</given-names></name></person-group><article-title>Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2004</year><volume>28</volume><fpage>1035</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">15380865</pub-id></citation></ref><ref id="R226"><label>226</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro Do Couto</surname><given-names>B</given-names></name><name><surname>Aguilar</surname><given-names>MA</given-names></name><name><surname>Manzanedo</surname><given-names>C</given-names></name><name><surname>Rodriguez-Arias</surname><given-names>M</given-names></name><name><surname>Minarro</surname><given-names>J</given-names></name></person-group><article-title>NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference</article-title><source>Brain Res. Bull</source><year>2005</year><volume>64</volume><fpage>493</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">15639545</pub-id></citation></ref><ref id="R227a"><label>227a</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riepe</surname><given-names>MW</given-names></name><name><surname>Esclaire</surname><given-names>F</given-names></name><name><surname>Kasischke</surname><given-names>K</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Nakase</surname><given-names>H</given-names></name><name><surname>Kempski</surname><given-names>O</given-names></name><name><surname>Ludolph</surname><given-names>AC</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Hugon</surname><given-names>J</given-names></name></person-group><article-title>Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation &#x0201c;chemical preconditioning&#x0201d;</article-title><source>J. Cereb. Blood Flow Metab</source><year>1997</year><volume>17</volume><fpage>257</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">9119898</pub-id></citation></ref><ref id="R227b"><label>227b</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rimpilainen</surname><given-names>J</given-names></name><name><surname>Pokela</surname><given-names>M</given-names></name><name><surname>Kiviluoma</surname><given-names>K</given-names></name><name><surname>Vainionpaa</surname><given-names>V</given-names></name><name><surname>Hirvonen</surname><given-names>J</given-names></name><name><surname>Ohtonen</surname><given-names>P</given-names></name><name><surname>Jantti</surname><given-names>V</given-names></name><name><surname>Anttila</surname><given-names>V</given-names></name><name><surname>Heinonen</surname><given-names>H</given-names></name><name><surname>Juvonen</surname><given-names>T</given-names></name></person-group><article-title>The N-methyl-D-aspartate antagonist memantine has no neuroprotective effect during hypothermic circulatory arrest a study in the chronic porcine model</article-title><source>J. Thorac. Cardiovasc. Surg</source><year>2001</year><volume>121</volume><fpage>957</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">11326240</pub-id></citation></ref><ref id="R228"><label>228</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Arias</surname><given-names>M</given-names></name><name><surname>Maldonado</surname><given-names>C</given-names></name><name><surname>Aguilar</surname><given-names>MA</given-names></name><name><surname>Minarro</surname><given-names>J</given-names></name></person-group><article-title>Memantine does not block antiaggressive effects of morphine in mice</article-title><source>Behav. Pharmacol</source><year>2002</year><volume>13</volume><fpage>249</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">12122316</pub-id></citation></ref><ref id="R229"><label>229</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogawski</surname><given-names>MA</given-names></name></person-group><article-title>Therapeutic potential of excitatory amino acid antagonists - channel blockers and 2,3-benzodiazepines</article-title><source>Trends Pharmacol. Sci</source><year>1993</year><volume>14</volume><fpage>325</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">7504360</pub-id></citation></ref><ref id="R230"><label>230</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogawski</surname><given-names>MA</given-names></name><name><surname>Wenk</surname><given-names>GL</given-names></name></person-group><article-title>The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease</article-title><source>CNS Drug Rev</source><year>2003</year><volume>9</volume><fpage>275</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">14530799</pub-id></citation></ref><ref id="R231"><label>231</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogawski</surname><given-names>MA</given-names></name><name><surname>Yamaguchi</surname><given-names>SI</given-names></name><name><surname>Jones</surname><given-names>SM</given-names></name><name><surname>Rice</surname><given-names>KC</given-names></name><name><surname>Thurkauf</surname><given-names>A</given-names></name><name><surname>Monn</surname><given-names>JA</given-names></name></person-group><article-title>Anticonvulsant activity of the low-affinity uncompetitive N-Methyl-D-Aspartate antagonist (+/-)-5-Aminocarbonyl-10,11-dihydro-5H-dibenzo&#x0003c;a,d&#x0003e;cyclohepten-5, 10-imine (ADCI) - Comparison with the structural analogs dizocilpine (mK-801) and carbamazepine</article-title><source>J. Pharmacol. Exp. Ther</source><year>1991</year><volume>259</volume><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">1920122</pub-id></citation></ref><ref id="R232"><label>232</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogoz</surname><given-names>Z</given-names></name><name><surname>Skuza</surname><given-names>G</given-names></name><name><surname>Maj</surname><given-names>J</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats</article-title><source>Neuropharmacology</source><year>2002</year><volume>42</volume><fpage>1024</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">12128003</pub-id></citation></ref><ref id="R233"><label>233</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ros Bernal</surname><given-names>F</given-names></name><name><surname>Nombela</surname><given-names>C</given-names></name><name><surname>Gomez</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>M</given-names></name><name><surname>Antunez</surname><given-names>C</given-names></name><name><surname>Herrero</surname><given-names>M</given-names></name></person-group><article-title>Soc</article-title><source>Neurosci. Abst</source><year>2005</year><volume>31</volume></citation></ref><ref id="R234"><label>234</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosi</surname><given-names>S</given-names></name><name><surname>Vazdarjanova</surname><given-names>A</given-names></name><name><surname>Ramirez-Amaya</surname><given-names>V</given-names></name><name><surname>Worley</surname><given-names>PF</given-names></name><name><surname>Barnes</surname><given-names>CA</given-names></name><name><surname>Wenk</surname><given-names>GL</given-names></name></person-group><article-title>Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat</article-title><source>Neuroscience</source><year>2006</year><volume>142</volume><fpage>1303</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">16989956</pub-id></citation></ref><ref id="R235"><label>235</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rukoiatkina</surname><given-names>NI</given-names></name><name><surname>Gorbunova</surname><given-names>LV</given-names></name><name><surname>Gmiro</surname><given-names>VE</given-names></name><name><surname>Lukomskaia</surname><given-names>NI</given-names></name></person-group><article-title>[Ability of novel non-competitive glutamate receptor blocking agents to weaken motor disorders in animals]</article-title><source>Sposobnost' novykh nekonkurentnykh blokatorov glutamatnykh retseptorov oslabliat' dvigatel'nye narusheniia u zhivotnykh. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M.Sechenova</source><year>2001</year><volume>87</volume><fpage>1260</fpage><lpage>1267</lpage></citation></ref><ref id="R236"><label>236</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rukoyatkina</surname><given-names>NI</given-names></name><name><surname>Gorbunova</surname><given-names>LV</given-names></name><name><surname>Gmiro</surname><given-names>VE</given-names></name><name><surname>Lukomskaya</surname><given-names>NY</given-names></name></person-group><article-title>The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals</article-title><source>Neurosci. Behav. Physiol</source><year>2003</year><volume>33</volume><fpage>273</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12762595</pub-id></citation></ref><ref id="R237"><label>237</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruppersberg</surname><given-names>JP</given-names></name><name><surname>Mosbacher</surname><given-names>J</given-names></name><name><surname>Gunther</surname><given-names>W</given-names></name><name><surname>Schoepfer</surname><given-names>R</given-names></name><name><surname>Fakler</surname><given-names>B</given-names></name></person-group><article-title>Studying block in cloned N-methyl-D-aspartate (NMDA) receptors</article-title><source>Biochem. Pharmacol</source><year>1993</year><volume>46</volume><fpage>1877</fpage><lpage>1885</lpage><pub-id pub-id-type="pmid">8267638</pub-id></citation></ref><ref id="R238"><label>238</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rusted</surname><given-names>JM</given-names></name><name><surname>Newhouse</surname><given-names>PA</given-names></name><name><surname>Levin</surname><given-names>ED</given-names></name></person-group><article-title>Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease</article-title><source>Behav. Brain Res</source><year>2000</year><volume>113</volume><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">10942039</pub-id></citation></ref><ref id="R239"><label>239</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanberg</surname><given-names>PR</given-names></name><name><surname>Shytle</surname><given-names>RD</given-names></name><name><surname>Silver</surname><given-names>AA</given-names></name></person-group><article-title>Treatment of Tourette's syndrome with mecamylamine</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>705</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9728992</pub-id></citation></ref><ref id="R240"><label>240</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanger</surname><given-names>DJ</given-names></name><name><surname>Terry</surname><given-names>P</given-names></name><name><surname>Katz</surname><given-names>JL</given-names></name></person-group><article-title>Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats</article-title><source>Behav. Pharmacol</source><year>1992</year><volume>3</volume><fpage>265</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">11224125</pub-id></citation></ref><ref id="R241"><label>241</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawynok</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>A</given-names></name></person-group><article-title>Modulation of formalin-induced behaviors and edema by local and systemic administration of dextromethorphan, memantine and ketamine</article-title><source>Eur. J. Pharmacol</source><year>2002</year><volume>450</volume><fpage>153</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">12206853</pub-id></citation></ref><ref id="R242"><label>242</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saybasili</surname><given-names>H</given-names></name><name><surname>Yuksel</surname><given-names>M</given-names></name><name><surname>Haklar</surname><given-names>G</given-names></name><name><surname>Yalcin</surname><given-names>AS</given-names></name></person-group><article-title>Depolarization-induced superoxide radical formation in rat hippocampal slices</article-title><source>Neurochem. Res</source><year>2002</year><volume>27</volume><fpage>473</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12199151</pub-id></citation></ref><ref id="R243"><label>243</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scatton</surname><given-names>B</given-names></name></person-group><article-title>Excitatory amino acid receptor antagonists a novel treatment for ischemic cerebrovascular diseases</article-title><source>Life Sci</source><year>1994</year><volume>55</volume><fpage>2115</fpage><lpage>2124</lpage><pub-id pub-id-type="pmid">7997070</pub-id></citation></ref><ref id="R244"><label>244</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>JD</given-names></name></person-group><article-title>Exploring the nature of molecular recognition in nicotinic acetylcholine receptors</article-title><source>Curr. Med. Chem</source><year>2000</year><volume>7</volume><fpage>749</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">10828287</pub-id></citation></ref><ref id="R245"><label>245</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuettauf</surname><given-names>F</given-names></name><name><surname>Quinto</surname><given-names>K</given-names></name><name><surname>Naskar</surname><given-names>R</given-names></name><name><surname>Zurakowski</surname><given-names>D</given-names></name></person-group><article-title>Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model</article-title><source>Vision Res</source><year>2002</year><volume>42</volume><fpage>2333</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12350421</pub-id></citation></ref><ref id="R246"><label>246</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>JB</given-names></name><name><surname>Matthews</surname><given-names>RT</given-names></name><name><surname>Henshaw</surname><given-names>DR</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name></person-group><article-title>Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases</article-title><source>Neuroscience (Oxford)</source><year>1996</year><volume>71</volume><fpage>1043</fpage><lpage>8</lpage></citation></ref><ref id="R247"><label>247</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semenova</surname><given-names>S</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>A</given-names></name></person-group><article-title>Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice</article-title><source>Eur. J. Pharmacol</source><year>1999</year><volume>378</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10478558</pub-id></citation></ref><ref id="R248"><label>248</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>JN</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Peles</surname><given-names>S</given-names></name><name><surname>Shaker</surname><given-names>R</given-names></name></person-group><article-title>Response properties of antral mechanosensitive afferent fibers and effects of ionotropic glutamate receptor antagonists</article-title><source>Neuroscience</source><year>2004</year><volume>125</volume><fpage>711</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15099685</pub-id></citation></ref><ref id="R249"><label>249</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sevostianova</surname><given-names>N</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Analgesic effects of mGlu1 and mGlu5 receptor antagonists in the rat formalin test</article-title><source>Neuropharmacology</source><year>2006</year><volume>51</volume><fpage>623</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">16793067</pub-id></citation></ref><ref id="R250"><label>250</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sevostianova</surname><given-names>N</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Analgesic effects of morphine and loperamide in the rat formalin test Interactions with NMDA receptor antagonists</article-title><source>Eur. J. Pharmacol</source><year>2005</year><volume>525</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16297905</pub-id></citation></ref><ref id="R251"><label>251</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shearman</surname><given-names>E</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Szasz</surname><given-names>B</given-names></name><name><surname>Juranyi</surname><given-names>Z</given-names></name><name><surname>Fallon</surname><given-names>S</given-names></name><name><surname>Pomara</surname><given-names>N</given-names></name><name><surname>Sershen</surname><given-names>H</given-names></name><name><surname>Lajtha</surname><given-names>A</given-names></name></person-group><article-title>Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations a microdialysis study</article-title><source>Brain Res. Bull</source><year>2006</year><volume>69</volume><fpage>204</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">16533671</pub-id></citation></ref><ref id="R252"><label>252</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shekunova</surname><given-names>EV</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Effects of memantine on estrogen-dependent acute tolerance to the morphine analgesia in female rats</article-title><source>Eur. J. Pharmacol</source><year>2006</year><volume>535</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">16546163</pub-id></citation></ref><ref id="R253"><label>253</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shore</surname><given-names>LE</given-names></name><name><surname>Dayer</surname><given-names>AG</given-names></name><name><surname>Ambrose</surname><given-names>JB</given-names></name><name><surname>Cameron</surname><given-names>HA</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>2004</year><volume>30</volume></citation></ref><ref id="R254"><label>254</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>A</given-names></name><name><surname>Helliwell</surname><given-names>P</given-names></name><name><surname>Maleszka</surname><given-names>R</given-names></name></person-group><article-title>Effects of NMDA receptor antagonists on olfactory learning and memory in the honeybee (Apis mellifera)</article-title><source>Pharmacol. Biochem. Behav</source><year>2004</year><volume>77</volume><fpage>191</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14751445</pub-id></citation></ref><ref id="R255"><label>255</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skuza</surname><given-names>G</given-names></name><name><surname>Rogoz</surname><given-names>Z</given-names></name></person-group><article-title>The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats</article-title><source>J. Physiol. Pharmacol</source><year>2006</year><volume>57</volume><fpage>217</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">16845227</pub-id></citation></ref><ref id="R256"><label>256</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skuza</surname><given-names>G</given-names></name><name><surname>Rogoz</surname><given-names>Z</given-names></name></person-group><article-title>Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-0-tolylguanidine (DTG) and memantine in the forced swimming test in rats</article-title><source>Pol. J. Pharmacol</source><year>2003</year><volume>55</volume><fpage>1149</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">14730114</pub-id></citation></ref><ref id="R257"><label>257</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snider</surname><given-names>B</given-names></name><name><surname>Tee</surname><given-names>LY</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>2003</year><volume>29</volume></citation></ref><ref id="R258"><label>258</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snider</surname><given-names>B</given-names></name><name><surname>Wilson</surname><given-names>T</given-names></name><name><surname>Warmke</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>2005</year><volume>31</volume></citation></ref><ref id="R259"><label>259</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobolevsky</surname><given-names>A</given-names></name><name><surname>Koshelev</surname><given-names>S</given-names></name></person-group><article-title>Two blocking sites of amino-adamantane derivatives in open N-methyl-D- aspartate channels</article-title><source>Biophys. J</source><year>1998</year><volume>74</volume><fpage>1305</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">9512028</pub-id></citation></ref><ref id="R260"><label>260</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobolevsky</surname><given-names>AI</given-names></name><name><surname>Koshelev</surname><given-names>SG</given-names></name><name><surname>Khodorov</surname><given-names>BI</given-names></name></person-group><article-title>Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons</article-title><source>J. Physiol. (Lond)</source><year>1998</year><volume>512 </volume><issue>Pt 1</issue><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9729616</pub-id></citation></ref><ref id="R261"><label>261</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobrado</surname><given-names>M</given-names></name><name><surname>Roda</surname><given-names>JM</given-names></name><name><surname>Lopez</surname><given-names>MG</given-names></name><name><surname>Egea</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>AG</given-names></name></person-group><article-title>Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation</article-title><source>Neurosci. Lett</source><year>2004</year><volume>365</volume><fpage>132</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15245794</pub-id></citation></ref><ref id="R262"><label>262</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stieg</surname><given-names>PE</given-names></name><name><surname>Sathi</surname><given-names>S</given-names></name><name><surname>Alvarado</surname><given-names>SP</given-names></name><name><surname>Jackson</surname><given-names>PS</given-names></name><name><surname>Pellegrini</surname><given-names>JW</given-names></name><name><surname>Chen</surname><given-names>HSV</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Jensen</surname><given-names>FE</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>1993</year><volume>19</volume></citation></ref><ref id="R263"><label>263</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stieg</surname><given-names>PE</given-names></name><name><surname>Sathi</surname><given-names>S</given-names></name><name><surname>Warach</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>DA</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group><article-title>Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat</article-title><source>Eur. J. Pharmacol</source><year>1999</year><volume>375</volume><fpage>115</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">10443569</pub-id></citation></ref><ref id="R264"><label>264</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sukhotina</surname><given-names>IA</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice</article-title><source>Psychopharmacology (Berl)</source><year>2000</year><volume>149</volume><fpage>345</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">10867961</pub-id></citation></ref><ref id="R265"><label>265</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sukhotina</surname><given-names>IA</given-names></name><name><surname>Zvrtau</surname><given-names>E</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>AY</given-names></name></person-group><article-title>Caffeine withdrawal syndrome in social interaction test in mice: Effects of NMDA receptor channel blockers, memantine and neramexane</article-title><source>Behav. Pharmacol</source><year>2004</year><volume>15</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">15187578</pub-id></citation></ref><ref id="R266"><label>266</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Dickenson</surname><given-names>AH</given-names></name></person-group><article-title>Differential pharmacological modulation of the spontaneous stimulus-independent activity in the rat spinal cord following peripheral nerve injury</article-title><source>Exp. Neurol</source><year>2006</year><volume>198</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16336968</pub-id></citation></ref><ref id="R267"><label>267</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Matthews</surname><given-names>EA</given-names></name><name><surname>Dickenson</surname><given-names>AH</given-names></name></person-group><article-title>Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy</article-title><source>Pain</source><year>2001</year><volume>91</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">11240082</pub-id></citation></ref><ref id="R268"><label>268</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swerdlow</surname><given-names>NR</given-names></name><name><surname>Falah-Tafti</surname><given-names>M</given-names></name><name><surname>Goins</surname><given-names>JC</given-names></name><name><surname>Crain</surname><given-names>SK</given-names></name><name><surname>Auerbach</surname><given-names>PP</given-names></name><name><surname>Shoemaker</surname><given-names>JM</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>2003</year><volume>29</volume></citation></ref><ref id="R269"><label>269</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>JH</given-names></name><name><surname>Arcuino</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><article-title>Glutamate release promotes growth of malignant gliomas</article-title><source>Nat. Med</source><year>2001</year><volume>7</volume><fpage>1010</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">11533703</pub-id></citation></ref><ref id="R270"><label>270</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Talalaenko</surname><given-names>AN</given-names></name><name><surname>Gordienko</surname><given-names>DV</given-names></name><name><surname>Pankrat'ev</surname><given-names>DV</given-names></name><name><surname>Zinkovich</surname><given-names>II</given-names></name><name><surname>Krivobok</surname><given-names>GK</given-names></name></person-group><article-title>The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats</article-title><source>Bull. Exp. Biol. Med</source><year>2001</year><volume>131</volume><fpage>38</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11329078</pub-id></citation></ref><ref id="R271"><label>271</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Graham</surname><given-names>SM</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Gergel</surname><given-names>I</given-names></name></person-group><article-title>Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil a randomized controlled trial</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>317</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">14734594</pub-id></citation></ref><ref id="R272"><label>272</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>R</given-names></name><name><surname>Chakravarthy</surname><given-names>B</given-names></name><name><surname>Hewitt</surname><given-names>K</given-names></name><name><surname>Tauskela</surname><given-names>J</given-names></name><name><surname>Morley</surname><given-names>P</given-names></name><name><surname>Atkinson</surname><given-names>T</given-names></name><name><surname>Durkin</surname><given-names>JP</given-names></name></person-group><article-title>Transient NMDA receptor inactivation provides long-term protection to cultured cortical neurons from a variety of death signals</article-title><source>J. Neurosci</source><year>2000</year><volume>20</volume><fpage>7183</fpage><lpage>7192</lpage><pub-id pub-id-type="pmid">11007874</pub-id></citation></ref><ref id="R273"><label>273</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tzschentke</surname><given-names>TM</given-names></name><name><surname>Schmidt</surname><given-names>WJ</given-names></name></person-group><article-title>Memantine does not substantially affect brain stimulation reward: comparison with MK-801</article-title><source>Brain Res</source><year>1999</year><volume>845</volume><fpage>192</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10536198</pub-id></citation></ref><ref id="R274"><label>274</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tzschentke</surname><given-names>TM</given-names></name><name><surname>Schmidt</surname><given-names>WJ</given-names></name></person-group><article-title>Effects of the non-competitive NMDA-receptor antagonist memantine on morphine- and cocaine-induced potentiation of lateral hypothalamic brain stimulation reward</article-title><source>Psychopharmacology (Berl)</source><year>2000</year><volume>149</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">10823402</pub-id></citation></ref><ref id="R275"><label>275</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Unger</surname><given-names>C</given-names></name><name><surname>Svedberg</surname><given-names>MM</given-names></name><name><surname>Yu</surname><given-names>WF</given-names></name><name><surname>Hedberg</surname><given-names>MM</given-names></name><name><surname>Nordberg</surname><given-names>A</given-names></name></person-group><article-title>Effect of subchronic treatment of memantine, galantamine and nicotine in the brain of APPswe transgenic mice</article-title><source>J. Pharmacol. Exp. Ther</source><year>2006</year><volume>317</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16354790</pub-id></citation></ref><ref id="R276"><label>276</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valencia-Alfonso</surname><given-names>CE</given-names></name><name><surname>Lerma-Diaz</surname><given-names>JM</given-names></name><name><surname>Sandoval Salazar</surname><given-names>C</given-names></name><name><surname>Villase or-Cabrera</surname><given-names>T</given-names></name><name><surname>Luquin</surname><given-names>SF-VA</given-names></name><name><surname>Garcia-Estrada</surname><given-names>J</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>2004</year><volume>30</volume></citation></ref><ref id="R277"><label>277</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Dam</surname><given-names>D</given-names></name><name><surname>Abramowski</surname><given-names>D</given-names></name><name><surname>Staufenbiel</surname><given-names>M</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name></person-group><article-title>Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model</article-title><source>Psychopharmacology (Berl)</source><year>2005</year><volume>180</volume><fpage>177</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15654502</pub-id></citation></ref><ref id="R278"><label>278</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Dam</surname><given-names>D</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name></person-group><article-title>Cognitive evaluation of disease-modifying efficacy of Galantamine and Memantine in the APP23 model</article-title><source>Eur. Neuropsychopharmacol</source><year>2006</year><volume>16</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">16095884</pub-id></citation></ref><ref id="R279"><label>279</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villetti</surname><given-names>G</given-names></name><name><surname>Bergamaschi</surname><given-names>M</given-names></name><name><surname>Bassani</surname><given-names>F</given-names></name><name><surname>Bolzoni</surname><given-names>PT</given-names></name><name><surname>Maiorino</surname><given-names>M</given-names></name><name><surname>Pietra</surname><given-names>C</given-names></name><name><surname>Rondelli</surname><given-names>I</given-names></name><name><surname>Chamiot-Clerc</surname><given-names>P</given-names></name><name><surname>Simonato</surname><given-names>M</given-names></name><name><surname>Barbieri</surname><given-names>M</given-names></name></person-group><article-title>Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain</article-title><source>J. Pharmacol. Exp. Ther</source><year>2003</year><volume>306</volume><fpage>804</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">12750440</pub-id></citation></ref><ref id="R280"><label>280</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volbracht</surname><given-names>C</given-names></name><name><surname>van Beek</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Blomgren</surname><given-names>K</given-names></name><name><surname>Leist</surname><given-names>M</given-names></name></person-group><article-title>Neuroprotective properties of memantine in different <italic>in vitro</italic> and <italic>in vivo</italic> models of excitotoxicity</article-title><source>Eur. J. Neurosci</source><year>2006</year><volume>23</volume><fpage>2611</fpage><lpage>2622</lpage><pub-id pub-id-type="pmid">16817864</pub-id></citation></ref><ref id="R281"><label>281</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vorwerk</surname><given-names>CK</given-names></name><name><surname>Zurakowski</surname><given-names>D</given-names></name><name><surname>McDermott</surname><given-names>LM</given-names></name><name><surname>Mawrin</surname><given-names>C</given-names></name><name><surname>Dreyer</surname><given-names>EB</given-names></name></person-group><article-title>Effects of axonal injury on ganglion cell survival and glutamate homeostasis</article-title><source>Brain Res. Bull</source><year>2004</year><volume>62</volume><fpage>485</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15036562</pub-id></citation></ref><ref id="R282"><label>282</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vosburg</surname><given-names>SK</given-names></name><name><surname>Hart</surname><given-names>CL</given-names></name><name><surname>Haney</surname><given-names>M</given-names></name><name><surname>Foltin</surname><given-names>RW</given-names></name></person-group><article-title>An evaluation of the reinforcing effects of memantine in cocaine-dependent humans</article-title><source>Drug Alcohol Depend</source><year>2005</year><volume>79</volume><fpage>257</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16002035</pub-id></citation></ref><ref id="R283"><label>283</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name></person-group><article-title>Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model</article-title><source>Eur. J. Neurosci</source><year>2005</year><volume>22</volume><fpage>2376</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16262676</pub-id></citation></ref><ref id="R284"><label>284</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XM</given-names></name><name><surname>Bausch</surname><given-names>SB</given-names></name></person-group><article-title>Effects of distinct classes of N-methyl-D-aspartate receptor antagonists on seizures, axonal sprouting and neuronal loss <italic>in vitro</italic>: suppression by NR2B-selective antagonists</article-title><source>Neuropharmacology</source><year>2004</year><volume>47</volume><fpage>1008</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15555635</pub-id></citation></ref><ref id="R285"><label>285</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YF</given-names></name><name><surname>Stieg</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>J</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group><article-title>Memantine, a clinically tolerated nmda antagonist, decreases infarct size in spontaneously hypertensive rats when administered two hours post ischemic-reperfusion cerebral injury</article-title><source>Neurology</source><year>1995</year><volume>45</volume><fpage>526P</fpage></citation></ref><ref id="R286"><label>286</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>F</given-names></name><name><surname>Castellino</surname><given-names>FJ</given-names></name><name><surname>Prorok</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name></person-group><article-title>Conantokins and variants derived from cone snail venom inhibit naloxone-induced withdrawal jumping in morphine-dependent mice</article-title><source>Neurosci. Lett</source><year>2006</year><volume>405</volume><fpage>137</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16859831</pub-id></citation></ref><ref id="R287"><label>287</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiland</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name><name><surname>Leonard</surname><given-names>S</given-names></name></person-group><article-title>Neuronal nicotinic acetylcholine receptors: from the gene to the disease</article-title><source>Behav. Brain Res</source><year>2000</year><volume>113</volume><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">10942031</pub-id></citation></ref><ref id="R288"><label>288</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenk</surname><given-names>GL</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Mobley</surname><given-names>SL</given-names></name></person-group><article-title>MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis</article-title><source>Eur. J. Pharmacol. Env. Tox. Pharmacol</source><year>1995</year><volume>293</volume><fpage>267</fpage><lpage>270</lpage></citation></ref><ref id="R289"><label>289</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenk</surname><given-names>GL</given-names></name><name><surname>McGann-Gramling</surname><given-names>K</given-names></name><name><surname>Hauss-Wegrzyniak</surname><given-names>B</given-names></name></person-group><article-title>The presence of the app(swe) mutation in mice does not increase the vulnerability of cholinergic basal forebrain neurons to neuroinflammation</article-title><source>Neuroscience</source><year>2004</year><volume>125</volume><fpage>769</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">15099690</pub-id></citation></ref><ref id="R290"><label>290</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenk</surname><given-names>GL</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Potential role of NMDA receptors as executors of neurodegeneration resulting from diverse insults focus on memantine</article-title><source>Behav. Pharmacol</source><year>2006</year><volume>17</volume><fpage>411</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">16940762</pub-id></citation></ref><ref id="R291"><label>291</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenk</surname><given-names>GL</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name><name><surname>Moebius</surname><given-names>HJ</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use</article-title><source>Life Sci</source><year>2000</year><volume>66</volume><fpage>1079</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">10737358</pub-id></citation></ref><ref id="R292"><label>292</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenk</surname><given-names>GL</given-names></name><name><surname>Willard</surname><given-names>LB</given-names></name></person-group><article-title>The neural mechanisms underlying cholinergic cell death within the basal forebrain</article-title><source>Int. J. Dev. Neurosci</source><year>1998</year><volume>16</volume><fpage>729</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">10198820</pub-id></citation></ref><ref id="R293"><label>293</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westenberg</surname><given-names>HG</given-names></name></person-group><article-title>Pharmacology of antidepressants: selectivity or multiplicity?</article-title><source>J. Clin. Psychiatry discussion 46-8</source><year>1999</year><volume>60 </volume><issue> 17</issue><supplement>Suppl.</supplement><fpage>4</fpage><lpage>8</lpage></citation></ref><ref id="R294"><label>294</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilde</surname><given-names>MI</given-names></name><name><surname>Markham</surname><given-names>A</given-names></name></person-group><article-title>Ondansetron.A review of its pharmacology and preliminary clinical findings in novel applications</article-title><source>Drugs</source><year>1996</year><volume>52</volume><fpage>773</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">9118822</pub-id></citation></ref><ref id="R295"><label>295</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>JL</given-names></name><name><surname>Harvey</surname><given-names>SA</given-names></name><name><surname>Balster</surname><given-names>RL</given-names></name><name><surname>Nicholson</surname><given-names>KL</given-names></name></person-group><article-title>Affinity and specificity of N-methyl- D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats</article-title><source>Psychopharmacology (Berl)</source><year>2003</year><volume>165</volume><fpage>378</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">12459931</pub-id></citation></ref><ref id="R296"><label>296</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willard</surname><given-names>LB</given-names></name><name><surname>Hauss-Wegrzyniak</surname><given-names>B</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Wenk</surname><given-names>GL</given-names></name></person-group><article-title>The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition</article-title><source>Exp. Brain Res</source><year>2000</year><volume>134</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11026726</pub-id></citation></ref><ref id="R297"><label>297</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Poritis</surname><given-names>N</given-names></name></person-group><article-title>Memantine in severe dementia: results of the M-BEST study (benefit and efficacy in severly demented patients during treatment with memantine)</article-title><source>Int. J. Geriatr. Psychiatry</source><year>1999</year><volume>14</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">10885864</pub-id></citation></ref><ref id="R298"><label>298</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>WoldeMussie</surname><given-names>E</given-names></name><name><surname>Yoles</surname><given-names>E</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Ruiz</surname><given-names>G</given-names></name><name><surname>Wheeler</surname><given-names>LA</given-names></name></person-group><article-title>Neuroprotective effect of memantine in different retinal injury models in rats</article-title><source>J. Glaucoma</source><year>2002</year><volume>11</volume><fpage>474</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12483089</pub-id></citation></ref><ref id="R299"><label>299</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wollmuth</surname><given-names>LP</given-names></name><name><surname>Kuner</surname><given-names>T</given-names></name><name><surname>Sakmann</surname><given-names>B</given-names></name></person-group><article-title>Adjacent asparagines in the NR2-subunit of the NMDA receptor channel control the voltage-dependent block by extracellular Mg2+</article-title><source>J. Physiol</source><year>1998</year><volume>506</volume><fpage>13</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">9481670</pub-id></citation></ref><ref id="R300"><label>300</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wollmuth</surname><given-names>LP</given-names></name><name><surname>Kuner</surname><given-names>T</given-names></name><name><surname>Seeburg</surname><given-names>PH</given-names></name><name><surname>Sakmann</surname><given-names>B</given-names></name></person-group><article-title>Differential contribution of the NR1- and NR2A-subunits to the selectivity filter of recombinant NMDA receptor channels</article-title><source>J. Physiol. (Lond)</source><year>1996</year><volume>491</volume><fpage>779</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">8815211</pub-id></citation></ref><ref id="R301"><label>301</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Takayanagi</surname><given-names>M</given-names></name><name><surname>Kamei</surname><given-names>H</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Dohniwa</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Ohhara</surname><given-names>T</given-names></name><name><surname>Takauma</surname><given-names>K</given-names></name><name><surname>Nabeshima</surname><given-names>T</given-names></name></person-group><article-title>Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats</article-title><source>Behav. Brain Res</source><year>2005</year><volume>162</volume><fpage>191</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15904984</pub-id></citation></ref><ref id="R302"><label>302</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagorodnyuk</surname><given-names>VP</given-names></name><name><surname>Chen</surname><given-names>BN</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Brookes</surname><given-names>SJ</given-names></name></person-group><article-title>Mechanotransduction by intraganglionic laminar endings of vagal tension receptors in the guinea pig oesophagus</article-title><source>J. Physiol</source><year>2003</year><volume>553</volume><fpage>575</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">14500769</pub-id></citation></ref><ref id="R303"><label>303</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagorodnyuk</surname><given-names>VP</given-names></name><name><surname>Lynn</surname><given-names>P</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Brookes</surname><given-names>SJH</given-names></name></person-group><article-title>Mechanisms of mechanotransduction by specialized low-threshold mechanoreceptors in the guinea pig rectum</article-title><source>Am. J. Physiol</source><year>2005</year><volume>289</volume><fpage>G397</fpage><lpage>G406</lpage></citation></ref><ref id="R304"><label>304</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zajaczkowski</surname><given-names>W</given-names></name><name><surname>Frankiewicz</surname><given-names>T</given-names></name><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP</article-title><source>Neuropharmacology</source><year>1997</year><volume>36</volume><fpage>961</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">9257940</pub-id></citation></ref><ref id="R305"><label>305</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zakharova</surname><given-names>E</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>A</given-names></name></person-group><article-title>Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats</article-title><source>Psychopharmacology</source><year>2005</year><volume>179</volume><fpage>128</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">15682308</pub-id></citation></ref><ref id="R306"><label>306</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zakharova</surname><given-names>E</given-names></name><name><surname>Malyshkin</surname><given-names>A</given-names></name><name><surname>Kashkin</surname><given-names>V</given-names></name><name><surname>Neznanova</surname><given-names>O</given-names></name><name><surname>Sukhotina</surname><given-names>I</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Bespalov</surname><given-names>A</given-names></name></person-group><article-title>The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats</article-title><source>Behav. Pharmacol</source><year>2004</year><volume>15</volume><fpage>273</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">15252277</pub-id></citation></ref><ref id="R307"><label>307</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zarate CA</surname><given-names>Jr</given-names></name><name><surname>Singh</surname><given-names>JB</given-names></name><name><surname>Quiroz</surname><given-names>JA</given-names></name><name><surname>De Jesus</surname><given-names>G</given-names></name><name><surname>Denicoff</surname><given-names>KK</given-names></name><name><surname>Luckenbaugh</surname><given-names>DA</given-names></name><name><surname>Manji</surname><given-names>HK</given-names></name><name><surname>Charney</surname><given-names>DS</given-names></name></person-group><article-title>A double-blind, placebo-controlled study of memantine in the treatment of major depression</article-title><source>Am. J. Psychiatry</source><year>2006</year><volume>163</volume><fpage>153</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16390905</pub-id></citation></ref><ref id="R308"><label>308</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>GH</given-names></name><name><surname>Min</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Back</surname><given-names>SK</given-names></name><name><surname>Yoon</surname><given-names>SJ</given-names></name><name><surname>Yoon</surname><given-names>YW</given-names></name><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Na</surname><given-names>HS</given-names></name><name><surname>Hong</surname><given-names>SK</given-names></name><name><surname>Han</surname><given-names>HC</given-names></name></person-group><article-title>Intraarticular pretreatment with ketamine and memantine could prevent arthritic pain relevance to the decrease of spinal c-fos expression in rats</article-title><source>Anesth. Analg</source><year>2004</year><volume>99</volume><fpage>152</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15281522</pub-id></citation></ref><ref id="R309"><label>309</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Marszalec</surname><given-names>W</given-names></name><name><surname>Yeh</surname><given-names>JZ</given-names></name><name><surname>Narahashi</surname><given-names>T</given-names></name></person-group><source>Soc. Neurosci. Abst</source><year>2005</year><volume>31</volume></citation></ref><ref id="R310"><label>310</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zoladz</surname><given-names>PR</given-names></name><name><surname>Campbell</surname><given-names>AM</given-names></name><name><surname>Park</surname><given-names>CR</given-names></name><name><surname>Schaefer</surname><given-names>D</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Diamond</surname><given-names>DM</given-names></name></person-group><article-title>Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane</article-title><source>Pharmacol. Biochem. Behav</source><year>2006</year><volume>85</volume><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">17045636</pub-id></citation></ref></ref-list></back></article>